|
G |
CCND1 |
cyclin D1 |
decreases expression |
EXP |
brazilein results in decreased expression of CCND1 mRNA; brazilein results in decreased expression of CCND1 protein |
CTD |
PMID:23948132 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CTNNB1 |
catenin beta 1 |
decreases expression |
EXP |
brazilein results in decreased expression of CTNNB1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
decreases expression |
EXP |
brazilein results in decreased expression of GSK3B protein modified form |
CTD |
PMID:23948132 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
EXP |
brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein promotes the reaction [Wortmannin results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein results in decreased expression of and results in decreased activity of MMP2 protein; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; Wortmannin promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein] brazilein results in decreased expression of MMP2 mRNA |
CTD |
PMID:23707804 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
EXP |
brazilein results in decreased expression of and results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:23707804 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
EXP |
brazilein results in decreased expression of RELA protein |
CTD |
PMID:23707804 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
|
G |
MME |
membrane metalloendopeptidase |
decreases activity |
EXP |
candoxatrilat results in decreased activity of MME protein |
CTD |
PMID:18084312 |
|
NCBI chr 3:155,024,202...155,183,729
Ensembl chr 3:155,024,124...155,183,704
|
|
G |
MMEL1 |
membrane metalloendopeptidase like 1 |
decreases activity |
EXP |
candoxatrilat results in decreased activity of MMEL1 protein |
CTD |
PMID:18084312 |
|
NCBI chr 1:2,590,639...2,633,016
Ensembl chr 1:2,590,639...2,633,016
|
|
G |
NPPA |
natriuretic peptide A |
multiple interactions |
ISO |
candoxatrilat inhibits the reaction [Carbon Tetrachloride results in decreased secretion of NPPA protein] |
CTD |
PMID:16449355 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
EXP |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
EXP |
fluvastatin results in decreased activity of ABCB11 protein fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] |
CTD |
PMID:15901796 PMID:20829430 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects transport multiple interactions |
ISO EXP |
ABCC2 protein affects the transport of fluvastatin ABCC2 protein binds to and results in increased uptake of fluvastatin analog; fluvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; fluvastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] |
CTD |
PMID:16026004 PMID:23562342 PMID:24909372 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
APOB |
apolipoprotein B |
multiple interactions |
EXP |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; fluvastatin promotes the reaction [[Valsartan co-treated with benazepril] results in decreased expression of APOB protein] |
CTD |
PMID:19773416 PMID:20671225 |
|
NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073
|
|
G |
APOE |
apolipoprotein E |
multiple interactions increases expression |
EXP |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin fluvastatin results in increased expression of APOE protein |
CTD |
PMID:8017468 PMID:19773416 |
|
NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
|
|
G |
ARHGAP29 |
Rho GTPase activating protein 29 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGAP29 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:94,168,905...94,314,592
Ensembl chr 1:94,148,988...94,275,068
|
|
G |
ARHGEF12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGEF12 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr11:120,336,413...120,489,937
Ensembl chr11:120,336,413...120,489,937
|
|
G |
ARHGEF3 |
Rho guanine nucleotide exchange factor 3 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGEF3 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 3:56,727,420...57,079,268
Ensembl chr 3:56,727,418...57,079,329
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]] |
CTD |
PMID:35465754 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCAP29 |
B cell receptor associated protein 29 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BCAP29 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 7:107,580,007...107,623,317
Ensembl chr 7:107,580,246...107,629,170
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L11 |
BCL2 like 11 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
BUB1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BUB1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 2:110,637,528...110,678,063
Ensembl chr 2:110,637,528...110,678,063
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of CASP1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP ISO |
fluvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Mevalonic Acid inhibits the reaction [fluvastatin results in increased cleavage of and results in increased activity of CASP3 protein] Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]] |
CTD |
PMID:24964743 PMID:35465754 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions |
EXP |
fluvastatin results in increased activity of CASP8 protein Mevalonic Acid inhibits the reaction [fluvastatin results in increased activity of CASP8 protein] |
CTD |
PMID:24964743 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CAT |
catalase |
increases expression multiple interactions |
EXP ISO |
fluvastatin results in increased expression of CAT protein Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]] |
CTD |
PMID:24964743 PMID:35465754 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of CCL2 mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CDK2AP2 |
cyclin dependent kinase 2 associated protein 2 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of CDK2AP2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr11:67,506,497...67,508,162
Ensembl chr11:67,506,497...67,508,649
|
|
G |
CETP |
cholesteryl ester transfer protein |
multiple interactions |
EXP |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr16:56,961,950...56,983,845
Ensembl chr16:56,961,923...56,983,845
|
|
G |
CKS2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of CKS2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 9:89,311,195...89,316,703
Ensembl chr 9:89,311,195...89,316,703
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases expression |
EXP |
fluvastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions |
EXP |
fluvastatin inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] |
CTD |
PMID:16081671 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions decreases activity |
EXP |
[fluvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; fluvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam] fluvastatin results in decreased activity of CYP3A4 protein |
CTD |
PMID:16029222 PMID:24204015 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DDB2 |
damage specific DNA binding protein 2 |
decreases expression multiple interactions |
EXP |
fluvastatin results in decreased expression of DDB2 mRNA; fluvastatin results in decreased expression of DDB2 protein [fluvastatin results in decreased expression of DDB2] which results in increased expression of SOD2 mRNA; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of DDB2 mRNA]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of DDB2 protein] |
CTD |
PMID:24964743 |
|
NCBI chr11:47,214,454...47,239,217
Ensembl chr11:47,214,465...47,239,217
|
|
G |
EDNRA |
endothelin receptor type A |
decreases expression |
ISO |
fluvastatin results in decreased expression of EDNRA mRNA |
CTD |
PMID:28951255 |
|
NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954
|
|
G |
EMP3 |
epithelial membrane protein 3 (MAM blood group) |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of EMP3 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr19:48,325,552...48,330,553
Ensembl chr19:48,321,509...48,330,553
|
|
G |
ERCC5 |
ERCC excision repair 5, endonuclease |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ERCC5 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr13:102,846,032...102,875,995
Ensembl chr13:102,845,831...102,875,995
|
|
G |
ERG |
ETS transcription factor ERG |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ERG mRNA |
CTD |
PMID:16996129 |
|
NCBI chr21:38,367,261...38,661,783
Ensembl chr21:38,380,027...38,661,780
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions decreases expression |
EXP |
Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]]; geranylgeraniol inhibits the reaction [Fluvastatin results in decreased expression of F3 protein]; Mevalonic Acid inhibits the reaction [Fluvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Fluvastatin results in decreased expression of F3 protein] Fluvastatin results in decreased expression of F3 mRNA; Fluvastatin results in decreased expression of F3 protein |
CTD |
PMID:9081680 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FDFT1 |
farnesyl-diphosphate farnesyltransferase 1 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of FDFT1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395
|
|
G |
FNTA |
farnesyltransferase, CAAX box, subunit alpha |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of FNTA mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:43,056,323...43,085,785
Ensembl chr 8:43,034,194...43,085,788
|
|
G |
FOXO1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
Fluvastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]] |
CTD |
PMID:35465754 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
[Fluvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]] |
CTD |
PMID:35465754 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GADD45B |
growth arrest and DNA damage inducible beta |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of GADD45B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr19:2,476,127...2,478,257
Ensembl chr19:2,476,122...2,478,259
|
|
G |
GSR |
glutathione-disulfide reductase |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
HLA-DQA1 |
major histocompatibility complex, class II, DQ alpha 1 |
affects expression |
EXP |
fluvastatin affects the expression of HLA-DQA1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:32,637,406...32,655,272
Ensembl chr 6:32,628,179...32,647,062
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases activity |
EXP |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin fluvastatin results in decreased activity of HMGCR protein |
CTD |
PMID:8593127 PMID:19773416 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HSD17B1 |
hydroxysteroid 17-beta dehydrogenase 1 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr17:42,552,923...42,555,214
Ensembl chr17:42,552,922...42,555,214
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IGF1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IGFBP5 |
insulin like growth factor binding protein 5 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549
|
|
G |
IL10RA |
interleukin 10 receptor subunit alpha |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IL10RA mRNA |
CTD |
PMID:16996129 |
|
NCBI chr11:117,986,394...118,003,037
Ensembl chr11:117,986,370...118,003,037
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096
|
|
G |
IL1B |
interleukin 1 beta |
decreases expression |
ISO |
fluvastatin results in decreased expression of IL1B mRNA |
CTD |
PMID:28951255 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2RG |
interleukin 2 receptor subunit gamma |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IL2RG mRNA |
CTD |
PMID:16996129 |
|
NCBI chr X:71,107,404...71,111,577
Ensembl chr X:71,107,404...71,112,108
|
|
G |
IRF4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Fluvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr 6:391,752...411,443
Ensembl chr 6:391,739...411,443
|
|
G |
KAT2B |
lysine acetyltransferase 2B |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 3:20,040,446...20,154,404
Ensembl chr 3:20,040,446...20,154,404
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions increases activity |
EXP |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; fluvastatin promotes the reaction [Cholesterol, LDL binds to LDLR protein]; fluvastatin promotes the reaction [Indomethacin promotes the reaction [Cholesterol, LDL binds to LDLR protein]] fluvastatin results in increased activity of LDLR protein |
CTD |
PMID:8593127 PMID:10395027 PMID:19773416 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]] |
CTD |
PMID:35465754 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LIPC |
lipase C, hepatic type |
multiple interactions |
EXP |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
|
|
G |
LMNA |
lamin A/C |
decreases farnesylation |
EXP |
fluvastatin results in decreased farnesylation of LMNA protein |
CTD |
PMID:16996129 |
|
NCBI chr 1:156,082,573...156,140,081
Ensembl chr 1:156,082,573...156,140,081
|
|
G |
LPL |
lipoprotein lipase |
multiple interactions |
EXP |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
LZTS1 |
leucine zipper tumor suppressor 1 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of LZTS1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:20,246,165...20,303,963
Ensembl chr 8:20,246,165...20,303,963
|
|
G |
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
EXP |
fluvastatin results in decreased expression of MCL1 protein |
CTD |
PMID:16996129 |
|
NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738
|
|
G |
MED23 |
mediator complex subunit 23 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of MED23 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 6:131,573,966...131,628,313
Ensembl chr 6:131,573,966...131,628,242
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
EXP |
Amitrole inhibits the reaction [fluvastatin results in decreased expression of MMP2 mRNA] |
CTD |
PMID:24964743 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
EXP |
fluvastatin results in decreased expression of MMP9 mRNA Amitrole inhibits the reaction [fluvastatin results in decreased expression of MMP9 mRNA] |
CTD |
PMID:24964743 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPHOSPH8 |
M-phase phosphoprotein 8 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of MPHOSPH8 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr13:19,633,659...19,673,441
Ensembl chr13:19,633,659...19,673,441
|
|
G |
MSTN |
myostatin |
increases expression |
ISO |
Fluvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:190,055,700...190,062,729
Ensembl chr 2:190,055,700...190,062,729
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
NDC80 |
NDC80 kinetochore complex component |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of NDC80 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr18:2,571,557...2,616,635
Ensembl chr18:2,571,557...2,616,635
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108
|
|
G |
NOS2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
fluvastatin results in increased expression of NOS2 mRNA; fluvastatin results in increased expression of NOS2 protein [[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [fluvastatin results in increased abundance of Nitric Oxide]; Mevalonic Acid inhibits the reaction [fluvastatin results in increased expression of NOS2 protein] |
CTD |
PMID:24964743 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
[fluvastatin co-treated with Valsartan] results in increased expression of NOS3 mRNA |
CTD |
PMID:28951255 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NPHS1 |
NPHS1 adhesion molecule, nephrin |
increases expression multiple interactions |
ISO |
fluvastatin increases expression of Nphs1 protein in kidney Fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 mRNA] |
CTD RGD |
PMID:16452496 PMID:19188342 |
RGD:38596324 |
NCBI chr19:35,862,915...35,869,357
Ensembl chr19:35,825,964...35,869,287
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity multiple interactions |
EXP |
fluvastatin results in increased activity of NR1I2 protein [Fluvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Fluvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Fluvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:15802384 PMID:24204015 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP ISO |
fluvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
OPTN |
optineurin |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of OPTN mRNA |
CTD |
PMID:16996129 |
|
NCBI chr10:13,100,082...13,138,308
Ensembl chr10:13,099,449...13,138,308
|
|
G |
PALS1 |
protein associated with LIN7 1, MAGUK p55 family member |
multiple interactions |
EXP |
[Zoledronic Acid co-treated with Fluvastatin] results in increased expression of PALS1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr14:67,241,435...67,336,061
Ensembl chr14:67,240,713...67,336,061
|
|
G |
PAPPA2 |
pappalysin 2 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of PAPPA2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:176,463,175...176,845,601
Ensembl chr 1:176,463,171...176,845,601
|
|
G |
PCSK9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
EXP |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr 1:55,039,548...55,064,852
Ensembl chr 1:55,039,447...55,064,852
|
|
G |
PON1 |
paraoxonase 1 |
multiple interactions decreases activity |
ISO |
fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] fluvastatin results in decreased activity of PON1 protein |
CTD |
PMID:14668577 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
fluvastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]] |
CTD |
PMID:11779144 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPP1R12A |
protein phosphatase 1 regulatory subunit 12A |
multiple interactions |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of PPP1R12A protein modified form] |
CTD |
PMID:16452496 |
|
NCBI chr12:79,773,563...79,935,460
Ensembl chr12:79,773,563...79,935,460
|
|
G |
PPP1R15A |
protein phosphatase 1 regulatory subunit 15A |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of PPP1R15A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr19:48,872,421...48,876,058
Ensembl chr19:48,872,212...48,876,059
|
|
G |
PRDX3 |
peroxiredoxin 3 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of PRDX3 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr10:119,167,720...119,178,812
Ensembl chr10:119,167,720...119,178,812
|
|
G |
PROCR |
protein C receptor |
increases expression |
EXP |
fluvastatin results in increased expression of PROCR protein |
CTD |
PMID:16142594 |
|
NCBI chr20:35,171,096...35,216,259
Ensembl chr20:35,172,072...35,216,240
|
|
G |
PTGIS |
prostaglandin I2 synthase |
increases expression |
EXP |
Fluvastatin increases expression of PTGIS mRNA in umbilical vein endothelial cells |
RGD |
PMID:21213109 |
RGD:401901154 |
NCBI chr20:49,503,874...49,568,137
Ensembl chr20:49,503,874...49,568,137
|
|
G |
RAB27B |
RAB27B, member RAS oncogene family |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB27B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr18:54,717,857...54,895,516
Ensembl chr18:54,717,860...54,895,516
|
|
G |
RAB32 |
RAB32, member RAS oncogene family |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB32 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 6:146,543,833...146,554,953
Ensembl chr 6:146,543,833...146,554,953
|
|
G |
RAB5B |
RAB5B, member RAS oncogene family |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB5B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr12:55,973,949...55,996,683
Ensembl chr12:55,973,913...55,996,683
|
|
G |
RABGAP1L |
RAB GTPase activating protein 1 like |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RABGAP1L mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:174,159,520...174,995,308
Ensembl chr 1:174,159,410...174,995,308
|
|
G |
RAP1A |
RAP1A, member of RAS oncogene family |
decreases prenylation |
EXP |
fluvastatin results in decreased prenylation of RAP1A protein |
CTD |
PMID:16996129 |
|
NCBI chr 1:111,542,009...111,716,691
Ensembl chr 1:111,542,218...111,716,691
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
EXP |
fluvastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16996129 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
REL |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]] |
CTD |
PMID:9081680 |
|
NCBI chr 2:60,881,574...60,931,612
Ensembl chr 2:60,881,491...60,931,612
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]] |
CTD |
PMID:9081680 |
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RGS11 |
regulator of G protein signaling 11 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RGS11 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr16:268,307...275,944
Ensembl chr16:268,301...275,980
|
|
G |
RHOA |
ras homolog family member A |
multiple interactions |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of RHOA protein] |
CTD |
PMID:16452496 |
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
RHOB |
ras homolog family member B |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RHOB mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440
|
|
G |
RIMS2 |
regulating synaptic membrane exocytosis 2 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RIMS2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:103,500,610...104,256,094
Ensembl chr 8:103,500,610...104,254,430
|
|
G |
RIN2 |
Ras and Rab interactor 2 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RIN2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr20:19,757,599...20,002,456
Ensembl chr20:19,757,606...20,002,457
|
|
G |
RXRA |
retinoid X receptor alpha |
multiple interactions |
EXP |
fluvastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]] |
CTD |
PMID:11779144 |
|
NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585
|
|
G |
SGK1 |
serum/glucocorticoid regulated kinase 1 |
affects expression |
ISO |
fluvastatin affects the expression of SGK1 mRNA; fluvastatin affects the expression of SGK1 protein |
CTD |
PMID:16696316 |
|
NCBI chr 6:134,169,256...134,318,112
Ensembl chr 6:134,169,248...134,318,112
|
|
G |
SGK2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
EXP |
[fluvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr20:43,559,027...43,585,627
Ensembl chr20:43,558,968...43,588,237
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
decreases activity |
EXP |
fluvastatin results in decreased activity of SLC15A1 protein |
CTD |
PMID:15846457 |
|
NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
affects import increases uptake multiple interactions |
EXP |
SLCO1B1 protein affects the import of fluvastatin SLCO1B1 protein results in increased uptake of Fluvastatin [biochanin A results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [isoliquiritigenin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [kaempferol results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [licochalcone A results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; [sinensetin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Fluvastatin]; SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Fluvastatin |
CTD |
PMID:16046661 PMID:23564645 PMID:32259555 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
affects import |
EXP |
SLCO1B3 protein affects the import of fluvastatin |
CTD |
PMID:16046661 |
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
G |
SLCO2B1 |
solute carrier organic anion transporter family member 2B1 |
affects import |
EXP |
SLCO2B1 protein affects the import of fluvastatin |
CTD |
PMID:16046661 |
|
NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO EXP |
[fluvastatin co-treated with Doxorubicin] results in increased expression of SOD2 protein fluvastatin results in increased expression of SOD2 mRNA; fluvastatin results in increased expression of SOD2 protein [Fluvastatin results in decreased expression of DDB2] which results in increased expression of SOD2 mRNA; Mevalonic Acid inhibits the reaction [Fluvastatin results in increased expression of SOD2 protein] |
CTD |
PMID:19147586 PMID:24964743 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOS2 |
SOS Ras/Rho guanine nucleotide exchange factor 2 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of SOS2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr14:50,117,130...50,231,882
Ensembl chr14:50,117,130...50,231,578
|
|
G |
SPIN2A |
spindlin family member 2A |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of SPIN2A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr X:57,134,265...57,147,180
Ensembl chr X:57,134,530...57,137,523
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SPP1 mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
STK17A |
serine/threonine kinase 17a |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of STK17A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 7:43,583,108...43,627,379
Ensembl chr 7:43,582,758...43,650,713
|
|
G |
TFPI |
tissue factor pathway inhibitor |
increases expression |
EXP |
fluvastatin results in increased expression of TFPI protein |
CTD |
PMID:16142594 |
|
NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
|
|
G |
TFRC |
transferrin receptor |
multiple interactions decreases expression |
EXP |
[[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; Amitrole inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of TFRC mRNA]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [fluvastatin results in decreased expression of TFRC protein] fluvastatin results in decreased expression of TFRC mRNA; fluvastatin results in decreased expression of TFRC protein |
CTD |
PMID:24964743 |
|
NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
affects expression multiple interactions |
ISO |
fluvastatin affects the expression of TGFB1 protein Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]] |
CTD |
PMID:16696316 PMID:35465754 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TNFRSF10A |
TNF receptor superfamily member 10a |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:23,190,452...23,225,102
Ensembl chr 8:23,190,452...23,225,102
|
|
G |
TP53INP1 |
tumor protein p53 inducible nuclear protein 1 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of TP53INP1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:94,925,972...94,949,378
Ensembl chr 8:94,925,972...94,949,378
|
|
G |
VIM |
vimentin |
multiple interactions |
ISO |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of VIM mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
G |
WNT11 |
Wnt family member 11 |
multiple interactions |
EXP |
[zoledronic acid co-treated with fluvastatin] results in increased expression of WNT11 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr11:76,186,325...76,210,761
Ensembl chr11:76,186,325...76,210,736
|
|
|
G |
IL13 |
interleukin 13 |
multiple interactions |
ISO |
ilomastat inhibits the reaction [Mustard Gas results in increased expression of IL13 protein] |
CTD |
PMID:18852015 |
|
NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MMP1 protein]; ilomastat inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MMP1 mRNA] |
CTD |
PMID:18837084 |
|
NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TIMP1 mRNA]; ilomastat affects the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TIMP1 protein] |
CTD |
PMID:18837084 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
increases expression decreases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of ABCA1 mRNA lovastatin decreases expression of ABCA1 mRNA in HepG2 cells [Dietary Fats co-treated with Lovastatin] affects the expression of ABCA1 mRNA Lovastatin results in decreased expression of ABCA1 mRNA |
CTD RGD |
PMID:19260826 PMID:29852127 PMID:27765770 |
RGD:18936994 |
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases transport decreases activity multiple interactions |
EXP |
ABCB1 protein results in increased transport of Lovastatin; ABCB1 protein results in increased transport of Lovastatin analog Lovastatin analog results in decreased activity of ABCB1 protein Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] |
CTD |
PMID:15616150 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
EXP |
Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Lovastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 PMID:24014644 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 (ABCC1 blood group) |
decreases activity multiple interactions |
ISO |
Lovastatin results in decreased activity of ABCC1 protein [Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA] |
CTD |
PMID:18056276 PMID:22712078 |
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression decreases activity |
EXP ISO |
ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Lovastatin results in increased expression of ABCC2 mRNA Lovastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]; Lovastatin promotes the reaction [Cisplatin results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:15616150 PMID:23562342 PMID:26739623 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of ABCG5 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ABCG5 mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
affects expression |
ISO |
Lovastatin affects the expression of ABCG8 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACACA mRNA |
CTD |
PMID:29852127 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACOX1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACOX1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr17:75,941,507...75,979,166
Ensembl chr17:75,941,507...75,979,177
|
|
G |
ACSS2 |
acyl-CoA synthetase short chain family member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACSS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr20:34,874,989...34,927,959
Ensembl chr20:34,872,146...34,927,962
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
EXP |
Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Lovastatin results in decreased expression of ACTA2 protein |
CTD |
PMID:22129737 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339
|
|
G |
ACTB |
actin beta |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of ACTB mRNA Lovastatin results in increased expression of ACTB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
|
|
G |
ACTR3 |
actin related protein 3 |
increases expression |
ISO |
Lovastatin results in increased expression of ACTR3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:113,889,934...113,962,596
Ensembl chr 2:113,890,063...113,962,596
|
|
G |
ADAM10 |
ADAM metallopeptidase domain 10 |
increases expression multiple interactions |
ISO EXP |
Lovastatin results in increased expression of ADAM10 protein [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein |
CTD |
PMID:29341888 |
|
NCBI chr15:58,588,809...58,749,707
Ensembl chr15:58,588,809...58,749,791
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of ADIPOQ mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ADIPOQ mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AHCY |
adenosylhomocysteinase |
decreases expression |
ISO |
Lovastatin results in decreased expression of AHCY mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:34,231,981...34,311,836
Ensembl chr20:34,280,268...34,311,802
|
|
G |
AKAP7 |
A-kinase anchoring protein 7 |
decreases response to substance |
EXP |
AKAP7 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 6:131,125,627...131,283,532
Ensembl chr 6:131,135,467...131,283,535
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
EXP ISO |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of AKT1 protein] Lovastatin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16425225 PMID:17472962 PMID:19760159 PMID:20578043 PMID:35734936 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALOX15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased activity of ALOX15 protein] |
CTD |
PMID:35734936 |
|
NCBI chr17:4,630,919...4,641,678
Ensembl chr17:4,630,919...4,642,294
|
|
G |
ANK2 |
ankyrin 2 |
decreases response to substance |
EXP |
ANK2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 4:112,705,622...113,383,736
Ensembl chr 4:112,818,032...113,384,221
|
|
G |
ANXA4 |
annexin A4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ANXA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
|
|
G |
ANXA5 |
annexin A5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:121,667,946...121,696,980
Ensembl chr 4:121,667,946...121,696,995
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions |
EXP |
[Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein |
CTD |
PMID:12633795 PMID:17319473 |
|
NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
|
|
G |
APOB |
apolipoprotein B |
multiple interactions decreases secretion |
EXP |
[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein Lovastatin results in decreased secretion of APOB protein |
CTD |
PMID:11728391 PMID:12633795 |
|
NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073
|
|
G |
APOE |
apolipoprotein E |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of APOE mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of APOE mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions increases cleavage increases secretion |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; TAPI-2 inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; U 0126 inhibits the reaction [Lovastatin results in increased secretion of APP protein] Lovastatin results in increased cleavage of APP protein [APP protein co-treated with Lovastatin] results in increased secretion of APP protein; [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein; [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein; [Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein; [Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[APP protein co-treated with Lovastatin] results in increased secretion of APP protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased secretion of APP protein; Lovastatin results in increased secretion of APP protein modified form |
CTD |
PMID:19741129 PMID:29341888 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
ARHGDIA |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Lovastatin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,721...81,871,378
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATM protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102
|
|
G |
ATR |
ATR serine/threonine kinase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATR protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 3:142,449,235...142,578,733
Ensembl chr 3:142,449,007...142,578,733
|
|
G |
BACE1 |
beta-secretase 1 |
decreases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased expression of BACE1 protein [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein |
CTD |
PMID:29341888 |
|
NCBI chr11:117,285,698...117,316,256
Ensembl chr11:117,285,232...117,316,259
|
|
G |
BACE2 |
beta-secretase 2 |
multiple interactions increases expression |
EXP ISO |
[Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein Lovastatin results in increased expression of BACE2 protein |
CTD |
PMID:29341888 |
|
NCBI chr21:41,168,160...41,282,530
Ensembl chr21:41,167,801...41,282,530
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions affects localization |
EXP ISO |
Lovastatin results in increased expression of BAX protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BAX protein]; Lovastatin promotes the reaction [Cisplatin results in increased expression of BAX mRNA] Lovastatin affects the localization of BAX protein |
CTD |
PMID:10473109 PMID:15180944 PMID:26739623 PMID:35734936 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCAR1 |
BCAR1 scaffold protein, Cas family member |
increases cleavage multiple interactions |
ISO |
Lovastatin results in increased cleavage of BCAR1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of BCAR1 protein] |
CTD |
PMID:16367743 |
|
NCBI chr16:75,228,181...75,268,007
Ensembl chr16:75,228,181...75,268,053
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
decreases expression multiple interactions |
EXP ISO |
Lovastatin results in decreased expression of BCL2 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:10473109 PMID:11178870 PMID:12094262 PMID:35734936 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
decreases expression multiple interactions |
ISO |
Lovastatin results in decreased expression of BCL2L1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:11178870 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BCL2L11 |
BCL2 like 11 |
multiple interactions increases expression |
EXP ISO |
pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein] |
CTD |
PMID:18766339 PMID:35734936 |
|
NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444
|
|
G |
BDNF |
brain derived neurotrophic factor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein] |
CTD |
PMID:24718106 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
multiple interactions decreases expression |
EXP |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein] |
CTD |
PMID:17472962 PMID:18815881 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BRCA2 |
BRCA2 DNA repair associated |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr13:32,315,508...32,400,268
Ensembl chr13:32,315,086...32,400,268
|
|
G |
C1QBP |
complement C1q binding protein |
increases expression |
ISO |
Lovastatin results in increased expression of C1QBP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:5,432,777...5,439,155
Ensembl chr17:5,432,777...5,448,830
|
|
G |
CALR |
calreticulin |
increases expression |
ISO |
Lovastatin results in increased expression of CALR mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489
|
|
G |
CAMK2B |
calcium/calmodulin dependent protein kinase II beta |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr 7:44,217,154...44,326,013
Ensembl chr 7:44,210,019...44,334,577
|
|
G |
CASP2 |
caspase 2 |
increases activity multiple interactions |
EXP ISO |
Lovastatin results in increased activity of CASP2 protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] |
CTD |
PMID:12933658 PMID:16234849 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases cleavage increases activity decreases expression |
EXP ISO |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] Lovastatin analog results in increased cleavage of CASP3 protein Lovastatin results in increased activity of CASP3 protein Lovastatin results in decreased expression of CASP3 mRNA Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein]; Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:11720884 PMID:12933658 PMID:15180944 PMID:16367743 PMID:18034278 PMID:18766339 PMID:20493250 PMID:26863638 PMID:35734936 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP6 |
caspase 6 |
increases activity |
EXP |
Lovastatin results in increased activity of CASP6 protein |
CTD |
PMID:11720884 |
|
NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583
|
|
G |
CASP8 |
caspase 8 |
increases activity |
EXP ISO |
Lovastatin results in increased activity of CASP8 protein |
CTD |
PMID:15180944 PMID:15705602 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
Lovastatin results in increased activity of CASP9 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of CASP9 protein] |
CTD |
PMID:12933658 PMID:15180944 PMID:15705602 PMID:35734936 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein] |
CTD |
PMID:35734936 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCN2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCND1 |
cyclin D1 |
decreases expression increases expression |
EXP ISO |
Lovastatin results in decreased expression of CCND1 protein Lovastatin results in increased expression of CCND1 mRNA; Lovastatin results in increased expression of CCND1 protein |
CTD |
PMID:18034278 PMID:20578043 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND3 |
cyclin D3 |
decreases expression |
EXP |
Lovastatin results in decreased expression of CCND3 protein |
CTD |
PMID:10502407 |
|
NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357
|
|
G |
CCT5 |
chaperonin containing TCP1 subunit 5 |
increases expression |
ISO |
Lovastatin results in increased expression of CCT5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:10,249,921...10,266,412
Ensembl chr 5:10,249,929...10,266,389
|
|
G |
CCT6A |
chaperonin containing TCP1 subunit 6A |
increases expression |
ISO |
Lovastatin results in increased expression of CCT6A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:56,051,765...56,063,989
Ensembl chr 7:56,051,685...56,063,989
|
|
G |
CCT8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CCT8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr21:29,056,326...29,073,648
Ensembl chr21:29,055,805...29,073,797
|
|
G |
CD40 |
CD40 molecule |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
decreases expression |
EXP |
Lovastatin results in decreased expression of CD44 mRNA; Lovastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CDC42 |
cell division cycle 42 |
increases expression decreases expression |
EXP ISO |
Lovastatin results in increased expression of CDC42 protein Lovastatin results in decreased expression of CDC42 mRNA |
CTD |
PMID:18766339 PMID:20493250 |
|
NCBI chr 1:22,052,709...22,101,360
Ensembl chr 1:22,052,627...22,101,360
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
decreases activity |
EXP |
Lovastatin results in decreased activity of CDK2 protein |
CTD |
PMID:10502407 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CDK4 mRNA; Lovastatin results in decreased expression of CDK4 protein |
CTD |
PMID:20578043 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDK5 |
cyclin dependent kinase 5 |
decreases cleavage |
ISO |
Lovastatin results in decreased cleavage of CDK5 protein |
CTD |
PMID:19741129 |
|
NCBI chr 7:151,053,815...151,057,897
Ensembl chr 7:151,053,815...151,057,897
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of CDKN1A protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] |
CTD |
PMID:18034278 PMID:22712078 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
increases expression |
ISO EXP |
Lovastatin results in increased expression of CDKN1B mRNA; Lovastatin results in increased expression of CDKN1B protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 PMID:18034278 PMID:20578043 |
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDKN3 |
cyclin dependent kinase inhibitor 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CDKN3 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr14:54,397,007...54,420,218
Ensembl chr14:54,396,849...54,420,218
|
|
G |
CENPF |
centromere protein F |
increases expression multiple interactions |
EXP |
Lovastatin results in increased expression of CENPF protein Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein] |
CTD |
PMID:12467231 |
|
NCBI chr 1:214,603,195...214,664,571
Ensembl chr 1:214,603,185...214,664,574
|
|
G |
CFL1 |
cofilin 1 |
decreases phosphorylation |
ISO |
Lovastatin results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20578043 |
|
NCBI chr11:65,854,673...65,858,180
Ensembl chr11:65,823,022...65,862,026
|
|
G |
CHEK1 |
checkpoint kinase 1 |
multiple interactions |
EXP ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK1 protein modified form] |
CTD |
PMID:17088865 PMID:21356574 PMID:26739623 |
|
NCBI chr11:125,625,136...125,681,124
Ensembl chr11:125,625,163...125,676,255
|
|
G |
CHEK2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422
|
|
G |
CHRNA7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases expression |
EXP ISO |
[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein] U 0126 inhibits the reaction [Lovastatin results in increased expression of CHRNA7 protein] Lovastatin results in increased expression of CHRNA7 mRNA; Lovastatin results in increased expression of CHRNA7 protein |
CTD |
PMID:29341888 |
|
NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018
|
|
G |
CLIC1 |
chloride intracellular channel 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CLIC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:31,730,581...31,737,318
Ensembl chr 6:31,730,581...31,739,763
|
|
G |
COX5A |
cytochrome c oxidase subunit 5A |
increases expression |
ISO |
Lovastatin results in increased expression of COX5A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:74,919,791...74,938,073
Ensembl chr15:74,919,791...74,938,083
|
|
G |
CP |
ceruloplasmin |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CP protein] |
CTD |
PMID:35734936 |
|
NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CRK |
CRK proto-oncogene, adaptor protein |
increases expression |
ISO |
Lovastatin results in increased expression of CRK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:1,420,693...1,456,232
Ensembl chr17:1,420,689...1,463,162
|
|
G |
CRP |
C-reactive protein |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CRP protein] |
CTD |
PMID:35734936 |
|
NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589
|
|
G |
CTNNB1 |
catenin beta 1 |
decreases degradation increases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased degradation of CTNNB1 protein Lovastatin results in increased expression of CTNNB1 mRNA Lovastatin affects the localization of and results in increased expression of CTNNB1 protein |
CTD |
PMID:17234346 PMID:19741129 PMID:24742230 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CYP1A1 mRNA]; Lovastatin results in increased expression of and results in increased activity of CYP1A1 protein Lovastatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:1311272 PMID:22712078 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
Lovastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases activity |
EXP |
Lovastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions increases expression |
EXP |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Lovastatin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:12505310 PMID:17041008 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DCTN2 |
dynactin subunit 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of DCTN2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:57,530,051...57,547,192
Ensembl chr12:57,529,633...57,547,224
|
|
G |
DDT |
D-dopachrome tautomerase |
decreases expression |
ISO |
Lovastatin results in decreased expression of DDT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr22:23,971,370...23,980,504
Ensembl chr22:23,970,542...23,980,525
|
|
G |
DLG3 |
discs large MAGUK scaffold protein 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein] |
CTD |
PMID:24718106 |
|
NCBI chr X:70,444,835...70,505,490
Ensembl chr X:70,444,835...70,505,490
|
|
G |
DLST |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Lovastatin results in decreased expression of DLST mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:74,881,916...74,903,743
Ensembl chr14:74,881,891...74,903,743
|
|
G |
DOCK7 |
dedicator of cytokinesis 7 |
increases expression |
ISO |
Lovastatin results in increased expression of DOCK7 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:62,454,726...62,688,386
Ensembl chr 1:62,454,298...62,688,386
|
|
G |
DPYSL2 |
dihydropyrimidinase like 2 |
increases expression |
ISO |
Lovastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:26,514,031...26,658,175
Ensembl chr 8:26,514,031...26,658,178
|
|
G |
DSTN |
destrin, actin depolymerizing factor |
decreases expression |
ISO |
Lovastatin results in decreased expression of DSTN mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:17,570,075...17,609,919
Ensembl chr20:17,570,075...17,609,919
|
|
G |
EAF2 |
ELL associated factor 2 |
decreases response to substance |
EXP |
EAF2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 3:121,835,209...121,886,526
Ensembl chr 3:121,835,183...121,886,526
|
|
G |
EEF2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of EEF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:3,976,056...3,985,463
Ensembl chr19:3,976,056...3,985,463
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF3I |
eukaryotic translation initiation factor 3 subunit I |
decreases expression |
ISO |
Lovastatin results in decreased expression of EIF3I mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:32,222,407...32,236,170
Ensembl chr 1:32,221,077...32,245,397
|
|
G |
ERCC1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of ERCC1 mRNA Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA] |
CTD |
PMID:26739623 |
|
NCBI chr19:45,407,334...45,451,547
Ensembl chr19:45,407,334...45,478,828
|
|
G |
ERCC5 |
ERCC excision repair 5, endonuclease |
multiple interactions increases expression |
ISO |
Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC5 mRNA] Lovastatin results in increased expression of ERCC5 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr13:102,846,032...102,875,995
Ensembl chr13:102,845,831...102,875,995
|
|
G |
ERCC6 |
ERCC excision repair 6, chromatin remodeling factor |
increases expression |
ISO |
Lovastatin results in increased expression of ERCC6 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr10:49,434,881...49,539,538
Ensembl chr10:49,454,168...49,539,538
|
|
G |
ERP29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ERP29 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:112,013,426...112,023,449
Ensembl chr12:112,013,348...112,023,449
|
|
G |
FADS2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FADS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr11:61,816,203...61,867,354
Ensembl chr11:61,792,980...61,867,354
|
|
G |
FAS |
Fas cell surface death receptor |
multiple interactions |
EXP ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of FAS protein] |
CTD |
PMID:17088865 PMID:35734936 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASLG |
Fas ligand |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA] |
CTD |
PMID:17088865 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FASN |
fatty acid synthase |
increases expression |
EXP |
Lovastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FBXO32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]; Lovastatin promotes the reaction [Fenofibrate results in increased expression of FBXO32 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein] Lovastatin results in increased expression of FBXO32 mRNA; Lovastatin results in increased expression of FBXO32 protein |
CTD |
PMID:19406843 PMID:33408297 |
|
NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206
|
|
G |
FDFT1 |
farnesyl-diphosphate farnesyltransferase 1 |
increases activity |
EXP |
Lovastatin results in increased activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395
|
|
G |
FDPS |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FDPS mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666
|
|
G |
FLOT1 |
flotillin 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr 6:30,727,709...30,742,687
Ensembl chr 6:30,727,709...30,742,732
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions decreases expression |
ISO |
Lovastatin affects the expression of FOS protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FOS mRNA] Lovastatin results in decreased expression of FOS |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSB |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased expression of FOSB protein] |
CTD |
PMID:18434508 |
|
NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179
|
|
G |
FOXO1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
ISO |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of FOXO1 protein] Lovastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 PMID:33408297 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FSCN1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of FSCN1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:5,592,816...5,606,655
Ensembl chr 7:5,592,816...5,606,655
|
|
G |
G3BP1 |
G3BP stress granule assembly factor 1 |
increases expression |
ISO |
Lovastatin results in increased expression of G3BP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:151,771,954...151,812,785
Ensembl chr 5:151,771,045...151,812,911
|
|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of G6PD mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
GALE |
UDP-galactose-4-epimerase |
decreases expression |
ISO |
Lovastatin results in decreased expression of GALE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:23,795,599...23,800,754
Ensembl chr 1:23,795,599...23,800,781
|
|
G |
GAP43 |
growth associated protein 43 |
increases expression |
ISO EXP |
Lovastatin results in increased expression of GAP43 protein |
CTD |
PMID:20694854 |
|
NCBI chr 3:115,623,510...115,721,483
Ensembl chr 3:115,623,510...115,721,490
|
|
G |
GDI2 |
GDP dissociation inhibitor 2 |
increases expression |
ISO |
Lovastatin results in increased expression of GDI2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:5,765,223...5,813,434
Ensembl chr10:5,765,223...5,842,132
|
|
G |
GK |
glycerol kinase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of GK mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:30,653,423...30,731,462
Ensembl chr X:30,653,359...30,731,462
|
|
G |
GMPS |
guanine monophosphate synthase |
increases expression |
ISO |
Lovastatin results in increased expression of GMPS mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:155,869,430...155,944,020
Ensembl chr 3:155,870,650...155,944,020
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; Lovastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:29852127 PMID:30853469 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GRIN2B |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr12:13,537,337...13,982,134
Ensembl chr12:13,437,942...13,982,002
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
decreases phosphorylation increases phosphorylation |
EXP ISO |
Lovastatin results in decreased phosphorylation of GSK3B protein Lovastatin results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17234346 PMID:19741129 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions |
EXP ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21356574 PMID:22712078 PMID:26739623 PMID:28710503 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HDAC1 |
histone deacetylase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HDAC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:32,292,083...32,333,626
Ensembl chr 1:32,292,083...32,333,635
|
|
G |
HINT1 |
histidine triad nucleotide binding protein 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HINT1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:131,159,027...131,165,256
Ensembl chr 5:131,155,383...131,224,468
|
|
G |
HLA-DRB3 |
major histocompatibility complex, class II, DR beta 3 |
affects expression |
EXP |
Lovastatin affects the expression of HLA-DRB3 mRNA |
CTD |
PMID:25811541 |
|
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions affects expression decreases activity increases expression |
EXP ISO |
[Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate; [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate; Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate] [Dietary Fats co-treated with Lovastatin] affects the expression of HMGCR mRNA Lovastatin affects the expression of HMGCR mRNA Lovastatin results in increased expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:17208200 PMID:19260826 PMID:19699819 PMID:19856009 PMID:27208389 PMID:29852127 More...
|
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of HMOX1 protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:20594940 PMID:21910007 PMID:28710503 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNRNPAB |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
ISO |
Lovastatin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:178,204,533...178,211,163
Ensembl chr 5:178,204,533...178,211,163
|
|
G |
HNRNPDL |
heterogeneous nuclear ribonucleoprotein D like |
decreases expression |
ISO |
Lovastatin results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:82,422,564...82,430,462
Ensembl chr 4:82,422,565...82,430,462
|
|
G |
HNRNPF |
heterogeneous nuclear ribonucleoprotein F |
increases expression |
ISO |
Lovastatin results in increased expression of HNRNPF mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:43,385,618...43,409,186
Ensembl chr10:43,385,617...43,409,186
|
|
G |
HNRNPK |
heterogeneous nuclear ribonucleoprotein K |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of HNRNPK mRNA Lovastatin results in increased expression of HNRNPK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:83,968,083...83,980,615
Ensembl chr 9:83,968,083...83,980,631
|
|
G |
HRAS |
HRas proto-oncogene, GTPase |
decreases prenylation multiple interactions |
EXP |
Lovastatin results in decreased prenylation of HRAS protein Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein |
CTD |
PMID:16156861 PMID:19360310 |
|
NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321
|
|
G |
HSP90AB1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:44,246,194...44,253,883
Ensembl chr 6:44,246,166...44,253,888
|
|
G |
HSPA8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
Lovastatin results in increased expression of HSPA8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HSPD1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGF1 |
insulin like growth factor 1 |
decreases response to substance |
ISO |
IGF1 protein results in decreased susceptibility to Lovastatin |
CTD |
PMID:9525472 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
multiple interactions |
ISO |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:19741129 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] |
CTD |
PMID:21430599 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] |
CTD |
PMID:18809656 PMID:21430599 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein] |
CTD |
PMID:28710503 PMID:35734936 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INS |
insulin |
multiple interactions |
ISO |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]; Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
INSIG1 |
insulin induced gene 1 |
increases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of INSIG1 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of INSIG1 mRNA |
CTD |
PMID:19260826 PMID:29852127 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
INSIG2 |
insulin induced gene 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:118,088,471...118,110,997
Ensembl chr 2:118,088,452...118,110,997
|
|
G |
INSR |
insulin receptor |
multiple interactions |
ISO |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414
|
|
G |
IPO5 |
importin 5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of IPO5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:97,953,675...98,024,296
Ensembl chr13:97,953,658...98,024,296
|
|
G |
IRF4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr 6:391,752...411,443
Ensembl chr 6:391,739...411,443
|
|
G |
IRS1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
|
|
G |
IRS2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr13:109,752,695...109,786,583
Ensembl chr13:109,752,695...109,786,583
|
|
G |
ISYNA1 |
inositol-3-phosphate synthase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of ISYNA1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:18,434,388...18,438,133
Ensembl chr19:18,434,388...18,438,167
|
|
G |
ITGB1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:12405293 |
|
NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions decreases expression |
ISO |
Lovastatin affects the expression of JUN protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of JUN mRNA] Lovastatin results in decreased expression of JUN |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
EXP |
Lovastatin affects the activity of KCNH2 protein |
CTD |
PMID:16278312 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KRAS |
KRAS proto-oncogene, GTPase |
decreases prenylation increases expression affects localization increases activity |
EXP ISO |
Lovastatin results in decreased prenylation of KRAS protein Lovastatin results in increased expression of KRAS protein Lovastatin affects the localization of KRAS protein Lovastatin results in increased activity of KRAS protein |
CTD |
PMID:12106604 PMID:12907238 PMID:16156861 PMID:17005160 |
|
NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936
|
|
G |
KRT18 |
keratin 18 |
decreases expression |
ISO |
Lovastatin results in decreased expression of KRT18 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906
|
|
G |
LASP1 |
LIM and SH3 protein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of LASP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:38,870,058...38,921,770
Ensembl chr17:38,869,859...38,921,770
|
|
G |
LCN2 |
lipocalin 2 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions increases activity increases expression |
EXP ISO |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of LDLR mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA] Lovastatin results in increased activity of LDLR protein |
CTD |
PMID:8593127 PMID:11728391 PMID:12524230 PMID:20578043 PMID:29852127 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LEF1 |
lymphoid enhancer binding factor 1 |
affects localization |
EXP |
Lovastatin affects the localization of LEF1 protein |
CTD |
PMID:17234346 |
|
NCBI chr 4:108,047,548...108,168,932
Ensembl chr 4:108,047,545...108,168,956
|
|
G |
LIPC |
lipase C, hepatic type |
affects expression |
ISO |
Lovastatin affects the expression of LIPC mRNA |
CTD |
PMID:27208389 |
|
NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
|
|
G |
LMNB1 |
lamin B1 |
decreases farnesylation increases degradation affects localization |
EXP |
Lovastatin results in decreased farnesylation of LMNB1 protein Lovastatin results in increased degradation of LMNB1 protein Lovastatin affects the localization of LMNB1 protein |
CTD |
PMID:10203554 PMID:11720884 |
|
NCBI chr 5:126,776,623...126,837,020
Ensembl chr 5:126,776,623...126,837,020
|
|
G |
LPA |
lipoprotein(a) |
multiple interactions |
EXP |
[Lovastatin co-treated with Niacin] results in decreased expression of LPA protein; [Niacin co-treated with Lovastatin] results in decreased expression of LPA protein |
CTD |
PMID:12633795 PMID:17319473 |
|
NCBI chr 6:160,531,482...160,664,275
Ensembl chr 6:160,531,482...160,664,275
|
|
G |
LPIN2 |
lipin 2 |
decreases response to substance |
EXP |
LPIN2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr18:2,916,994...3,013,144
Ensembl chr18:2,885,296...3,013,144
|
|
G |
LPL |
lipoprotein lipase |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of LPL mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of LPL mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
LRP5 |
LDL receptor related protein 5 |
increases expression |
ISO |
Lovastatin results in increased expression of LRP5 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr11:68,298,412...68,449,275
Ensembl chr11:68,312,591...68,449,275
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation decreases activity decreases phosphorylation |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK1 protein] Lovastatin results in decreased activity of MAPK1 protein [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12213976 PMID:16952276 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 More...
|
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions increases phosphorylation decreases activity decreases phosphorylation |
EXP ISO |
[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased phosphorylation of MAPK3 protein Lovastatin results in decreased activity of MAPK3 protein Lovastatin results in decreased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16952276 PMID:18434508 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 More...
|
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK9 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MBP |
myelin basic protein |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683
|
|
G |
MFN2 |
mitofusin 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 1:11,980,444...12,013,508
Ensembl chr 1:11,980,181...12,015,211
|
|
G |
MIR133B |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 6:52,148,923...52,149,041
Ensembl chr 6:52,148,923...52,149,041
|
|
G |
MIR206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 6:52,144,349...52,144,434
Ensembl chr 6:52,144,349...52,144,434
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
decreases expression |
EXP |
Lovastatin results in decreased expression of MMP2 protein |
CTD |
PMID:19360310 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
Lovastatin results in decreased expression of MMP9 protein |
CTD |
PMID:19360310 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MPO protein] |
CTD |
PMID:35734936 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MSTN |
myostatin |
increases expression |
ISO |
Lovastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:190,055,700...190,062,729
Ensembl chr 2:190,055,700...190,062,729
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Doxorubicin inhibits the reaction [Lovastatin results in increased expression of NFE2L2 mRNA]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NMRAL1 |
NmrA like redox sensor 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NMRAL1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:4,461,694...4,476,337
Ensembl chr16:4,461,691...4,495,763
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein] |
CTD |
PMID:18809656 PMID:35734936 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPPA |
natriuretic peptide A |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NQO1 mRNA |
CTD |
PMID:1311272 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
multiple interactions |
EXP |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NRAS |
NRAS proto-oncogene, GTPase |
decreases prenylation |
EXP |
Lovastatin results in decreased prenylation of NRAS protein |
CTD |
PMID:16156861 |
|
NCBI chr 1:114,704,469...114,716,771
Ensembl chr 1:114,704,469...114,716,771
|
|
G |
NUCB1 |
nucleobindin 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NUCB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:48,900,312...48,923,372
Ensembl chr19:48,900,050...48,923,473
|
|
G |
OAT |
ornithine aminotransferase |
decreases expression |
ISO |
Lovastatin results in decreased expression of OAT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:124,397,303...124,418,923
Ensembl chr10:124,397,303...124,418,976
|
|
G |
OSM |
oncostatin M |
multiple interactions |
EXP |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] |
CTD |
PMID:12524230 |
|
NCBI chr22:30,262,829...30,266,851
Ensembl chr22:30,262,829...30,266,851
|
|
G |
PA2G4 |
proliferation-associated 2G4 |
increases expression |
ISO |
Lovastatin results in increased expression of PA2G4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:56,104,559...56,113,910
Ensembl chr12:56,104,537...56,113,910
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage |
EXP |
Lovastatin analog results in increased cleavage of PARP1 protein |
CTD |
PMID:26863638 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PARVB |
parvin beta |
decreases response to substance |
EXP |
PARVB SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr22:43,999,211...44,172,939
Ensembl chr22:43,999,211...44,172,939
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of PCK1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PDGFRA |
platelet derived growth factor receptor alpha |
decreases expression |
ISO |
Lovastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:20578043 |
|
NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of PDIA3 mRNA Lovastatin results in increased expression of PDIA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:43,746,438...43,773,278
Ensembl chr15:43,746,394...43,773,279
|
|
G |
PDIA4 |
protein disulfide isomerase family A member 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:149,003,051...149,028,505
Ensembl chr 7:149,003,062...149,028,662
|
|
G |
PGAM1 |
phosphoglycerate mutase 1 |
increases expression decreases expression |
ISO |
Lovastatin results in increased expression of PGAM1 mRNA Lovastatin results in decreased expression of PGAM1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:97,426,191...97,433,444
Ensembl chr10:97,426,191...97,433,444
|
|
G |
PKM |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PKM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:72,199,029...72,231,591
Ensembl chr15:72,199,029...72,231,819
|
|
G |
PLA2G4A |
phospholipase A2 group IVA |
increases expression |
ISO |
Lovastatin results in increased expression of PLA2G4A mRNA |
CTD |
PMID:20578043 |
|
NCBI chr 1:186,828,949...186,988,981
Ensembl chr 1:186,828,949...186,988,981
|
|
G |
PLAT |
plasminogen activator, tissue type |
multiple interactions increases secretion increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PLAT protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PLAT protein] Lovastatin results in increased secretion of PLAT protein |
CTD |
PMID:10412747 PMID:12405293 |
|
NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709
|
|
G |
PLAU |
plasminogen activator, urokinase |
decreases secretion |
ISO |
Lovastatin results in decreased secretion of PLAU protein |
CTD |
PMID:12405293 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
PON3 |
paraoxonase 3 |
increases hydrolysis increases metabolic processing multiple interactions |
EXP ISO |
PON3 protein results in increased hydrolysis of Lovastatin PON3 protein results in increased metabolism of Lovastatin 7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]; Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 PMID:15772423 |
|
NCBI chr 7:95,359,872...95,396,375
Ensembl chr 7:95,359,872...95,396,375
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions affects localization increases expression |
EXP ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; Lovastatin results in increased expression of and affects the localization of PPARG protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of PPARG mRNA; PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 PMID:26863638 PMID:29852127 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPP1CA |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Lovastatin results in decreased expression of PPP1CA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:67,398,183...67,401,858
Ensembl chr11:67,398,181...67,421,183
|
|
G |
PPP2R1A |
protein phosphatase 2 scaffold subunit Aalpha |
increases expression |
ISO |
Lovastatin results in increased expression of PPP2R1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:52,190,052...52,229,518
Ensembl chr19:52,170,936...52,229,518
|
|
G |
PRKCD |
protein kinase C delta |
multiple interactions increases cleavage |
ISO |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein] |
CTD |
PMID:16367743 |
|
NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
|
|
G |
PSMA3 |
proteasome 20S subunit alpha 3 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:58,244,843...58,272,004
Ensembl chr14:58,244,843...58,272,012
|
|
G |
PSMA6 |
proteasome 20S subunit alpha 6 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMA6 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:35,278,558...35,317,493
Ensembl chr14:35,278,633...35,317,493
|
|
G |
PSMC2 |
proteasome 26S subunit, ATPase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMC2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:103,347,524...103,369,395
Ensembl chr 7:103,328,570...103,370,346
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions increases expression |
EXP ISO |
Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; Lovastatin results in increased expression of and results in increased phosphorylation of PTEN protein; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions increases expression |
EXP ISO |
Lovastatin results in decreased expression of PTGS2 protein Mevalonic Acid affects the reaction [Lovastatin analog results in increased expression of PTGS2 protein] Lovastatin analog results in increased expression of PTGS2 mRNA; Lovastatin analog results in increased expression of PTGS2 protein Lovastatin results in increased expression of PTGS2 mRNA; Lovastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20578043 PMID:21910007 PMID:26863638 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
RAB1A |
RAB1A, member RAS oncogene family |
decreases expression |
ISO |
Lovastatin results in decreased expression of RAB1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:65,086,854...65,130,106
Ensembl chr 2:65,070,696...65,130,331
|
|
G |
RAC1 |
Rac family small GTPase 1 |
multiple interactions affects localization decreases activity increases expression |
EXP |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein] Lovastatin results in decreased activity of RAC1 protein Lovastatin results in increased expression of RAC1 protein |
CTD |
PMID:12933658 PMID:18766339 PMID:19360310 PMID:21356574 |
|
NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
|
|
G |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions decreases activity |
EXP |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] Lovastatin results in decreased activity of RAF1 protein |
CTD |
PMID:19360310 PMID:19760159 |
|
NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201
|
|
G |
RAP1A |
RAP1A, member of RAS oncogene family |
increases expression |
EXP |
Lovastatin results in increased expression of RAP1A protein |
CTD |
PMID:12467231 |
|
NCBI chr 1:111,542,009...111,716,691
Ensembl chr 1:111,542,218...111,716,691
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO EXP |
Lovastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RHOA |
ras homolog family member A |
multiple interactions decreases expression decreases prenylation affects localization |
EXP ISO |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein] Lovastatin results in decreased geranoylation of and affects the localization of RHOA protein Lovastatin results in decreased expression of RHOA mRNA Lovastatin results in decreased prenylation of RHOA protein Farnesol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein] |
CTD |
PMID:9398081 PMID:11178870 PMID:12405293 PMID:12933658 PMID:16156861 PMID:20493250 PMID:20578043 More...
|
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
RHOB |
ras homolog family member B |
decreases prenylation multiple interactions increases expression |
EXP ISO |
Lovastatin results in decreased prenylation of RHOB protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] Lovastatin results in increased expression of RHOB protein |
CTD |
PMID:12467231 PMID:16156861 PMID:16234849 |
|
NCBI chr 2:20,447,074...20,449,440
Ensembl chr 2:20,447,074...20,449,440
|
|
G |
RPL27 |
ribosomal protein L27 |
increases expression |
ISO |
Lovastatin results in increased expression of RPL27 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:42,998,273...43,002,959
Ensembl chr17:42,998,273...43,002,959
|
|
G |
RPL9 |
ribosomal protein L9 |
increases expression |
ISO |
Lovastatin results in increased expression of RPL9 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:39,454,124...39,458,922
Ensembl chr 4:39,452,587...39,458,931
|
|
G |
RPLP0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Lovastatin results in increased expression of RPLP0 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:120,196,699...120,201,111
Ensembl chr12:120,196,699...120,201,235
|
|
G |
RPSA |
ribosomal protein SA |
increases expression |
ISO |
Lovastatin results in increased expression of RPSA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:39,406,720...39,412,542
Ensembl chr 3:39,406,716...39,426,255
|
|
G |
RUVBL2 |
RuvB like AAA ATPase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:48,993,448...49,015,995
Ensembl chr19:48,993,562...49,015,970
|
|
G |
S100A8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
SAE1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of SAE1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:47,130,835...47,210,636
Ensembl chr19:47,113,274...47,210,636
|
|
G |
SCAP |
SREBF chaperone |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCAP mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 3:47,413,681...47,477,127
Ensembl chr 3:47,413,681...47,477,126
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
multiple interactions affects expression |
ISO |
[Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone] Lovastatin affects the expression of SCARB1 mRNA |
CTD |
PMID:20404351 PMID:27208389 |
|
NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
|
|
G |
SEPHS1 |
selenophosphate synthetase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of SEPHS1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:13,317,428...13,348,293
Ensembl chr10:13,317,428...13,348,298
|
|
G |
SLC31A1 |
solute carrier family 31 member 1 |
increases expression |
ISO |
Lovastatin results in increased expression of SLC31A1 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 9:113,221,544...113,264,492
Ensembl chr 9:113,221,544...113,264,492
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions decreases activity |
EXP |
Lovastatin inhibits the reaction [SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide] Lovastatin results in decreased activity of SLCO1B1 protein |
CTD |
PMID:15616150 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SOX10 |
SRY-box transcription factor 10 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr22:37,972,312...37,984,555
Ensembl chr22:37,970,686...37,987,422
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
ISO EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF1 mRNA Lovastatin results in increased expression of SREBF1 mRNA |
CTD |
PMID:29852127 PMID:32739440 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
increases localization multiple interactions |
EXP ISO |
Lovastatin results in increased localization of SREBF2 protein [Dietary Fats co-treated with Lovastatin] affects the expression of SREBF2 mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein] |
CTD |
PMID:11728391 PMID:20578043 PMID:29852127 |
|
NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306
|
|
G |
STEAP2 |
STEAP2 metalloreductase |
decreases response to substance |
EXP |
STEAP2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 7:90,211,740...90,243,408
Ensembl chr 7:90,167,590...90,238,137
|
|
G |
STIP1 |
stress induced phosphoprotein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of STIP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
|
|
G |
SYNGAP1 |
synaptic Ras GTPase activating protein 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 6:33,418,167...33,453,689
Ensembl chr 6:33,419,661...33,453,689
|
|
G |
TCP1 |
t-complex 1 |
increases expression |
ISO |
Lovastatin results in increased expression of TCP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:159,778,498...159,789,602
Ensembl chr 6:159,778,498...159,789,703
|
|
G |
TG |
thyroglobulin |
increases secretion |
EXP |
Lovastatin results in increased secretion of TG protein |
CTD |
PMID:12843138 |
|
NCBI chr 8:132,866,958...133,134,899
Ensembl chr 8:132,866,958...133,134,903
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species]; Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:22129737 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TH |
tyrosine hydroxylase |
increases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of TH protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein] |
CTD |
PMID:20694854 |
|
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
|
|
G |
THOP1 |
thimet oligopeptidase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of THOP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:2,785,503...2,815,807
Ensembl chr19:2,785,503...2,815,807
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein] |
CTD |
PMID:18809656 PMID:21430599 PMID:22712078 PMID:35734936 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
increases expression |
ISO |
Lovastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:24742230 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
increases response to substance |
EXP |
Lovastatin results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:17928957 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Lovastatin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TOP2A |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TOP2A mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr17:40,388,525...40,417,896
Ensembl chr17:40,388,525...40,417,896
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions increases expression |
EXP ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form] Lovastatin results in increased expression of TP53 mRNA |
CTD |
PMID:17088865 PMID:21199873 PMID:26739623 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TRIM63 |
tripartite motif containing 63 |
multiple interactions |
ISO |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of TRIM63 protein] |
CTD |
PMID:33408297 |
|
NCBI chr 1:26,051,301...26,067,630
Ensembl chr 1:26,051,301...26,068,436
|
|
G |
TTC7A |
tetratricopeptide repeat domain 7A |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FSN mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:46,915,866...47,076,123
Ensembl chr 2:46,915,869...47,076,137
|
|
G |
TUBA1A |
tubulin alpha 1a |
increases expression |
ISO |
Lovastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:49,184,795...49,189,080
Ensembl chr12:49,184,686...49,189,080
|
|
G |
TUBA1B |
tubulin alpha 1b |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of TUBA1B mRNA Lovastatin results in increased expression of TUBA1B mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:49,127,782...49,131,395
Ensembl chr12:49,127,782...49,131,397
|
|
G |
TUBB |
tubulin beta class I |
decreases expression |
ISO |
Lovastatin results in decreased expression of TUBB5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:30,720,352...30,725,422
Ensembl chr 6:30,717,435...30,725,538
|
|
G |
TUFM |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Lovastatin results in decreased expression of TUFM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:28,842,411...28,846,348
Ensembl chr16:28,842,411...28,846,348
|
|
G |
U2AF2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
ISO |
Lovastatin results in increased expression of U2AF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:55,655,035...55,674,716
Ensembl chr19:55,654,146...55,674,716
|
|
G |
UCP2 |
uncoupling protein 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of UCP2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843
|
|
G |
USP5 |
ubiquitin specific peptidase 5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of USP5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:6,852,150...6,866,632
Ensembl chr12:6,852,148...6,866,632
|
|
G |
VCP |
valosin containing protein |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of VCP mRNA Lovastatin results in increased expression of VCP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,053,928...35,072,668
|
|
G |
WEE1 |
WEE1 G2 checkpoint kinase |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of WEE1 mRNA] Lovastatin results in increased expression of WEE1 mRNA |
CTD |
PMID:22712078 |
|
NCBI chr11:9,573,670...9,589,985
Ensembl chr11:9,573,670...9,593,457
|
|
G |
XIAP |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
Lovastatin results in increased expression of XIAP mRNA |
CTD |
PMID:26739623 |
|
NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972
|
|
G |
XPA |
XPA, DNA damage recognition and repair factor |
increases expression |
ISO |
Lovastatin results in increased expression of XPA mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 9:97,654,398...97,697,340
Ensembl chr 9:97,674,909...97,697,340
|
|
G |
YWHAE |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon |
increases expression |
ISO |
Lovastatin results in increased expression of YWHAE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:1,344,275...1,400,222
Ensembl chr17:1,344,275...1,400,222
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
affects expression decreases expression multiple interactions |
ISO |
mevastatin affects the expression of ABCA1 mRNA Mevastatin (compactin) decreases expression of abca1 mRNA in rat peripheral fibroblasts Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]] |
CTD RGD |
PMID:16415093 PMID:17526932 PMID:17526932 |
RGD:2308820 |
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
BDNF |
brain derived neurotrophic factor |
multiple interactions |
ISO |
mevastatin inhibits the reaction [BDNF protein results in decreased activity of HU 211] |
CTD |
PMID:20554863 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
increases expression |
EXP |
mevastatin results in increased expression of BMP2 mRNA; mevastatin results in increased expression of BMP2 protein |
CTD |
PMID:10814523 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
CD40 |
CD40 molecule |
multiple interactions |
ISO |
mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
increases expression multiple interactions |
EXP |
mevastatin results in increased expression of CYP3A4 mRNA [mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:12235278 PMID:15466163 PMID:17041008 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions decreases expression |
ISO |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation |
ISO |
mevastatin results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16330322 |
|
NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516
|
|
G |
FOXO1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
mevastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
IDI1 |
isopentenyl-diphosphate delta isomerase 1 |
multiple interactions increases expression |
ISO |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr10:1,039,152...1,056,704
Ensembl chr10:1,039,152...1,049,119
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
ISO |
mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
EXP |
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IRF4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
mevastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr 6:391,752...411,443
Ensembl chr 6:391,739...411,443
|
|
G |
MSMO1 |
methylsterol monooxygenase 1 |
increases expression multiple interactions |
ISO |
mevastatin results in increased expression of MSMO1 mRNA EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164
|
|
G |
MSTN |
myostatin |
increases expression |
ISO |
mevastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:190,055,700...190,062,729
Ensembl chr 2:190,055,700...190,062,729
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
increases expression |
EXP |
Mevastatin increases expression of NR1H3 mRNA in mononuclear cells |
RGD |
PMID:16252156 |
RGD:401827902 |
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
multiple interactions |
EXP |
[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:12235278 PMID:17041008 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
RAC1 |
Rac family small GTPase 1 |
multiple interactions |
ISO |
mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein] |
CTD |
PMID:16734383 |
|
NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
|
|
G |
RHOA |
ras homolog family member A |
decreases lipidation multiple interactions |
EXP |
mevastatin results in decreased lipidation of RHOA protein Mevalonic Acid inhibits the reaction [mevastatin results in decreased lipidation of RHOA protein] |
CTD |
PMID:17322126 |
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
SELE |
selectin E |
multiple interactions |
EXP |
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
decreases expression increases cleavage multiple interactions |
ISO |
mevastatin results in decreased expression of SREBF1 protein mevastatin results in increased cleavage of SREBF1 protein EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein] |
CTD |
PMID:16330322 PMID:17526932 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
increases expression increases cleavage |
ISO |
mevastatin results in increased expression of SREBF2 protein mevastatin results in increased cleavage of SREBF2 protein |
CTD |
PMID:16330322 PMID:17526932 |
|
NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
XBP1 |
X-box binding protein 1 |
multiple interactions |
ISO |
Tunicamycin inhibits the reaction [mevastatin results in increased cleavage of XBP1 protein] |
CTD |
PMID:16330322 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
decreases activity |
EXP |
norverapamil results in decreased activity of CYP3A5 protein |
CTD |
PMID:15689501 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein] |
CTD |
PMID:15007106 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:15177934 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ECE1 |
endothelin converting enzyme 1 |
multiple interactions decreases activity |
ISO |
EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of ECE1 protein] phosphoramidon decreases activity of recombinant Ece1 protein in COS cells |
CTD RGD |
PMID:11145282 PMID:16280098 PMID:8034569 |
RGD:728596 |
NCBI chr 1:21,217,250...21,345,504
Ensembl chr 1:21,217,247...21,345,572
|
|
G |
EDN1 |
endothelin 1 |
decreases expression multiple interactions |
ISO |
phosphoramidon results in decreased expression of EDN1 protein EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein] |
CTD |
PMID:11145282 PMID:16280098 PMID:16391412 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EDNRA |
endothelin receptor type A |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein]; phosphoramidon inhibits the reaction [Phenylephrine results in increased expression of EDNRA protein] |
CTD |
PMID:15007106 |
|
NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954
|
|
G |
EDNRB |
endothelin receptor type B |
increases expression |
ISO |
phosphoramidon results in increased expression of EDNRB protein |
CTD |
PMID:15007106 |
|
NCBI chr13:77,895,481...77,975,527
Ensembl chr13:77,895,481...77,975,529
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:15177934 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [Morphine results in decreased expression of ICAM1 protein alternative form] |
CTD |
PMID:10070497 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
KEL |
Kell metallo-endopeptidase (Kell blood group) |
multiple interactions |
EXP |
KEL protein alternative form binds to and affects the metabolism of phosphoramidon |
CTD |
PMID:15769748 |
|
NCBI chr 7:142,941,114...142,962,363
Ensembl chr 7:142,941,114...142,962,363
|
|
G |
LEP |
leptin |
decreases expression |
ISO |
phosphoramidon results in decreased expression of LEP protein |
CTD |
PMID:16391412 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15177934 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15177934 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MME |
membrane metalloendopeptidase |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [Morphine results in increased activity of MME protein] |
CTD |
PMID:10070497 |
|
NCBI chr 3:155,024,202...155,183,729
Ensembl chr 3:155,024,124...155,183,704
|
|
G |
NTS |
neurotensin |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15177934 |
|
NCBI chr12:85,874,295...85,882,992
Ensembl chr12:85,874,295...85,882,992
|
|
G |
SELL |
selectin L |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [Morphine results in decreased expression of SELL protein alternative form] |
CTD |
PMID:10070497 |
|
NCBI chr 1:169,690,667...169,711,620
Ensembl chr 1:169,690,665...169,711,702
|
|
G |
TAC1 |
tachykinin precursor 1 |
multiple interactions |
ISO |
[TAC1 protein co-treated with phosphoramidon] results in increased uptake of Oxygen |
CTD |
PMID:9808699 |
|
NCBI chr 7:97,732,086...97,740,472
Ensembl chr 7:97,732,084...97,740,472
|
|
|
G |
MMP13 |
matrix metallopeptidase 13 |
decreases activity |
EXP |
prinomastat results in decreased activity of MMP13 protein |
CTD |
PMID:17267227 |
|
NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
decreases activity |
EXP |
prinomastat results in decreased activity of MMP2 protein |
CTD |
PMID:17267227 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP3 |
matrix metallopeptidase 3 |
decreases activity |
EXP |
prinomastat results in decreased activity of MMP3 protein |
CTD |
PMID:17267227 |
|
NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609
|
|
G |
MMP8 |
matrix metallopeptidase 8 |
decreases activity |
EXP |
prinomastat results in decreased activity of MMP8 protein |
CTD |
PMID:17267227 |
|
NCBI chr11:102,711,796...102,724,954
Ensembl chr11:102,711,796...102,727,050
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
prinomastat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
A2M |
alpha-2-macroglobulin |
decreases expression |
ISO |
Simvastatin results in decreased expression of A2M mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
EXP ISO |
Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein |
CTD |
PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 PMID:22120639 PMID:25055962 More...
|
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases transport affects response to substance multiple interactions decreases activity |
EXP |
ABCB1 protein results in increased transport of Simvastatin ABCB1 polymorphism affects the susceptibility to Simvastatin ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Simvastatin analog results in decreased activity of ABCB1 protein |
CTD |
PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression decreases activity |
EXP ISO |
Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Simvastatin results in decreased expression of ABCB11 mRNA Simvastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
increases expression decreases expression |
ISO |
Simvastatin results in increased expression of ABCB4 mRNA Simvastatin results in decreased expression of ABCB4 mRNA |
CTD |
PMID:21241519 PMID:27765674 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
multiple interactions decreases expression affects response to substance decreases activity |
ISO EXP |
ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Simvastatin results in decreased expression of ABCC2 mRNA ABCC2 polymorphism affects the susceptibility to Simvastatin Simvastatin analog results in decreased activity of ABCC2 protein |
CTD |
PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases nitrosation |
EXP |
artemisinin inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein] |
CTD |
PMID:18463201 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCG1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of ABCG1 mRNA |
CTD |
PMID:19383813 PMID:22120639 |
|
NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Simvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:21241519 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACAA2 |
acetyl-CoA acyltransferase 2 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of ACAA2 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:49,782,164...49,813,533
Ensembl chr18:49,782,164...49,813,953
|
|
G |
ACACB |
acetyl-CoA carboxylase beta |
increases expression |
ISO |
Simvastatin results in increased expression of ACACB mRNA |
CTD |
PMID:12056585 |
|
NCBI chr12:109,111,189...109,268,226
Ensembl chr12:109,116,587...109,268,226
|
|
G |
ACAN |
aggrecan |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr15:88,803,436...88,875,353
Ensembl chr15:88,803,436...88,875,353
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA] Simvastatin results in decreased expression of ACTA2 protein |
CTD |
PMID:15677772 PMID:15855201 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339
|
|
G |
ACTB |
actin beta |
increases expression |
ISO |
Simvastatin results in increased expression of ACTB mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
|
|
G |
ACTN4 |
actinin alpha 4 |
increases expression |
EXP |
Simvastatin results in increased expression of ACTN4 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr19:38,647,649...38,731,589
Ensembl chr19:38,647,649...38,731,589
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein] carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:17641834 PMID:29071762 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
ADORA2B |
adenosine A2b receptor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B protein] |
CTD |
PMID:33774062 |
|
NCBI chr17:15,850,362...15,975,746
Ensembl chr17:15,945,130...15,975,746
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein |
CTD |
PMID:19262002 |
|
NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904
|
|
G |
AFP |
alpha fetoprotein |
increases expression |
EXP |
Simvastatin results in increased expression of AFP mRNA |
CTD |
PMID:10365819 |
|
NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174
|
|
G |
AGER |
advanced glycosylation end-product specific receptor |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein] Simvastatin results in decreased expression of AGER protein |
CTD |
PMID:17038636 |
|
NCBI chr 6:32,180,969...32,184,253
Ensembl chr 6:32,180,968...32,184,322
|
|
G |
AGT |
angiotensinogen |
multiple interactions decreases expression |
EXP ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]] Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA] Simvastatin results in decreased expression of AGT mRNA |
CTD |
PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 PMID:22306966 More...
|
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AGTR1 |
angiotensin II receptor type 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of AGTR1 mRNA |
CTD |
PMID:17513949 PMID:18475152 |
|
NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008
|
|
G |
AKR1C1 |
aldo-keto reductase family 1 member C1 |
increases expression |
EXP |
Simvastatin results in increased expression of AKR1C1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:4,963,415...4,983,283
Ensembl chr10:4,963,253...4,983,283
|
|
G |
AKR1C3 |
aldo-keto reductase family 1 member C3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686
|
|
G |
AKR1D1 |
aldo-keto reductase family 1 member D1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
decreases expression decreases phosphorylation increases phosphorylation multiple interactions decreases activity |
EXP ISO |
Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein Simvastatin results in decreased phosphorylation of AKT1 protein Simvastatin results in increased phosphorylation of AKT1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein] Simvastatin results in decreased activity of AKT1 protein Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 PMID:18047562 PMID:19299917 PMID:20060890 PMID:20464445 PMID:20562903 PMID:20594940 PMID:21059805 PMID:22082490 PMID:22144680 PMID:25412314 PMID:27734117 PMID:33034787 More...
|
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
ALDH3A1 |
aldehyde dehydrogenase 3 family member A1 |
increases expression |
EXP |
Simvastatin results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:19,737,984...19,748,298
Ensembl chr17:19,737,984...19,748,943
|
|
G |
ALK |
ALK receptor tyrosine kinase |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 2:29,192,774...29,921,586
Ensembl chr 2:29,192,774...29,921,586
|
|
G |
ALOX5AP |
arachidonate 5-lipoxygenase activating protein |
increases expression |
EXP |
Simvastatin results in increased expression of ALOX5AP mRNA |
CTD |
PMID:17183729 |
|
NCBI chr13:30,713,485...30,764,426
Ensembl chr13:30,713,478...30,764,426
|
|
G |
ALPI |
alkaline phosphatase, intestinal |
increases expression |
ISO |
Simvastatin results in increased expression of ALPI mRNA |
CTD |
PMID:14973129 |
|
NCBI chr 2:232,456,153...232,460,753
Ensembl chr 2:232,456,125...232,460,753
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
increases expression multiple interactions affects expression |
ISO EXP |
Simvastatin results in increased expression of ALPL mRNA Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA] |
CTD |
PMID:20417880 PMID:28975700 |
|
NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410
|
|
G |
ANGPT1 |
angiopoietin 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein |
CTD |
PMID:18544044 |
|
NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055
|
|
G |
ANGPT2 |
angiopoietin 2 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein] |
CTD |
PMID:20821229 |
|
NCBI chr 8:6,499,632...6,563,245
Ensembl chr 8:6,499,632...6,563,409
|
|
G |
ANGPTL3 |
angiopoietin like 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:62,597,520...62,606,313
Ensembl chr 1:62,597,520...62,606,313
|
|
G |
ANGPTL4 |
angiopoietin like 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370
|
|
G |
ANKRA2 |
ankyrin repeat family A member 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ANKRA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:73,552,190...73,565,639
Ensembl chr 5:73,552,190...73,565,667
|
|
G |
ANPEP |
alanyl aminopeptidase, membrane |
increases expression |
ISO |
Simvastatin results in increased expression of ANPEP mRNA |
CTD |
PMID:19262002 |
|
NCBI chr15:89,784,895...89,814,852
Ensembl chr15:89,784,895...89,815,401
|
|
G |
ANXA1 |
annexin A1 |
increases expression |
ISO |
Simvastatin results in increased expression of ANXA1 protein |
CTD |
PMID:14973129 |
|
NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,393
|
|
G |
ANXA3 |
annexin A3 |
decreases expression |
EXP ISO |
Simvastatin results in decreased expression of ANXA3 mRNA Simvastatin results in decreased expression of ANXA3 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr 4:78,551,770...78,610,447
Ensembl chr 4:78,551,747...78,610,451
|
|
G |
AOC1 |
amine oxidase copper containing 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 7:150,852,120...150,861,504
Ensembl chr 7:150,824,627...150,861,504
|
|
G |
APMAP |
adipocyte plasma membrane associated protein |
decreases expression |
ISO |
Simvastatin results in decreased expression of APMAP protein |
CTD |
PMID:20217863 |
|
NCBI chr20:24,962,925...24,992,751
Ensembl chr20:24,962,925...24,992,751
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions decreases expression increases expression |
ISO EXP |
MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein] Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA] |
CTD |
PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 PMID:18420099 PMID:18540024 PMID:20152243 PMID:21241519 PMID:25055962 More...
|
|
NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
|
|
G |
APOA2 |
apolipoprotein A2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:161,222,292...161,223,628
Ensembl chr 1:161,222,292...161,223,631
|
|
G |
APOA4 |
apolipoprotein A4 |
multiple interactions decreases expression increases expression |
ISO |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein] Simvastatin results in increased expression of APOA4 protein |
CTD |
PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962 |
|
NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304
|
|
G |
APOB |
apolipoprotein B |
multiple interactions decreases expression decreases secretion affects response to substance |
EXP ISO |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] Simvastatin results in decreased expression of APOB protein Simvastatin results in decreased secretion of APOB protein Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein] APOB polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 PMID:11728391 PMID:12633795 PMID:12901521 PMID:15184351 PMID:18471454 PMID:18702965 PMID:20413733 More...
|
|
NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073
|
|
G |
APOC1 |
apolipoprotein C1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOC1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr19:44,914,325...44,919,346
Ensembl chr19:44,914,247...44,919,349
|
|
G |
APOC3 |
apolipoprotein C3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOC3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr11:116,829,907...116,833,072
Ensembl chr11:116,829,706...116,833,072
|
|
G |
APOE |
apolipoprotein E |
decreases expression affects response to substance multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein APOE polymorphism affects the susceptibility to Simvastatin Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein] APOE affects the susceptibility to Simvastatin |
CTD |
PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 PMID:18270459 PMID:19461118 PMID:25055962 More...
|
|
NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
|
|
G |
APOF |
apolipoprotein F |
decreases expression |
ISO |
Simvastatin results in decreased expression of APOF mRNA |
CTD |
PMID:25055962 |
|
NCBI chr12:56,360,568...56,362,857
Ensembl chr12:56,360,568...56,362,857
|
|
G |
APOM |
apolipoprotein M |
decreases expression increases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of APOM mRNA Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein] |
CTD |
PMID:21729290 PMID:22160096 |
|
NCBI chr 6:31,652,404...31,658,210
Ensembl chr 6:31,652,416...31,658,210
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions decreases activity |
EXP ISO |
oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein] |
CTD |
PMID:17241114 PMID:28734741 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
ARHGAP29 |
Rho GTPase activating protein 29 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ARHGAP29 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:94,168,905...94,314,592
Ensembl chr 1:94,148,988...94,275,068
|
|
G |
ARHGAP4 |
Rho GTPase activating protein 4 |
increases expression |
EXP |
Simvastatin results in increased expression of ARHGAP4 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr X:153,907,378...153,926,264
Ensembl chr X:153,907,367...153,934,999
|
|
G |
ARHGEF2 |
Rho/Rac guanine nucleotide exchange factor 2 |
increases expression |
EXP |
Simvastatin results in increased expression of ARHGEF2 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 1:155,946,854...155,979,617
Ensembl chr 1:155,946,851...156,007,070
|
|
G |
ASS1 |
argininosuccinate synthase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ASS1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274
|
|
G |
ATF2 |
activating transcription factor 2 |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of ATF2 protein |
CTD |
PMID:15488325 |
|
NCBI chr 2:175,072,259...175,168,203
Ensembl chr 2:175,072,250...175,168,382
|
|
G |
ATF3 |
activating transcription factor 3 |
increases expression |
EXP |
Simvastatin results in increased expression of ATF3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
|
|
G |
ATF6 |
activating transcription factor 6 |
increases expression |
ISO |
Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein |
CTD |
PMID:18807172 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions |
EXP |
Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein |
CTD |
PMID:20499237 |
|
NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,222,823...108,369,102
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein |
CTD |
PMID:15916736 |
|
NCBI chr12:110,280,616...110,351,093
Ensembl chr12:110,280,756...110,351,093
|
|
G |
ATP6V1E1 |
ATPase H+ transporting V1 subunit E1 |
increases expression |
ISO |
Simvastatin results in increased expression of ATP6V1E1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr22:17,592,136...17,628,822
Ensembl chr22:17,592,136...17,628,749
|
|
G |
AURKA |
aurora kinase A |
decreases expression |
EXP |
Simvastatin results in decreased expression of AURKA mRNA |
CTD |
PMID:17428261 |
|
NCBI chr20:56,369,390...56,392,215
Ensembl chr20:56,369,389...56,392,337
|
|
G |
AXIN2 |
axin 2 |
affects expression |
ISO |
Simvastatin affects the expression of AXIN2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648
|
|
G |
AXL |
AXL receptor tyrosine kinase |
decreases expression |
EXP |
Simvastatin results in decreased expression of AXL mRNA |
CTD |
PMID:17428261 |
|
NCBI chr19:41,219,223...41,261,766
Ensembl chr19:41,219,223...41,261,766
|
|
G |
BAD |
BCL2 associated agonist of cell death |
multiple interactions decreases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] |
CTD |
PMID:12438947 PMID:27734117 |
|
NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
affects localization increases expression |
EXP ISO |
Simvastatin affects the localization of BAX protein Simvastatin results in increased expression of BAX protein Simvastatin results in increased expression of BAX mRNA Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein |
CTD |
PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBC3 |
BCL2 binding component 3 |
multiple interactions increases expression affects localization |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein] Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein Simvastatin affects the localization of BBC3 protein |
CTD |
PMID:17428261 PMID:20045437 PMID:21199873 PMID:37956312 |
|
NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression increases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in decreased expression of BCL2 protein Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein |
CTD |
PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 PMID:20369390 PMID:21729534 PMID:25300705 More...
|
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] Simvastatin results in decreased expression of BCL2L1 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:20060890 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BDNF |
brain derived neurotrophic factor |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of BDNF Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA] |
CTD |
PMID:18047562 PMID:20851742 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions increases secretion |
EXP ISO |
Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA] [Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP Simvastatin results in increased secretion of BGLAP protein |
CTD |
PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 PMID:19216230 PMID:19249597 PMID:19292885 PMID:20381859 PMID:20417880 PMID:20564244 PMID:21431270 PMID:22058016 More...
|
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
BHLHA15 |
basic helix-loop-helix family member a15 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 7:98,211,439...98,215,457
Ensembl chr 7:98,211,439...98,215,457
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] Simvastatin results in decreased expression of BIRC2 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:19343037 |
|
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
BIRC3 |
baculoviral IAP repeat containing 3 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] |
CTD |
PMID:17277159 PMID:19343037 |
|
NCBI chr11:102,317,484...102,339,403
Ensembl chr11:102,317,484...102,339,403
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
multiple interactions decreases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein] Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17277159 PMID:20464445 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BMP1 |
bone morphogenetic protein 1 |
increases expression |
ISO |
Simvastatin results in increased expression of BMP1 mRNA |
CTD |
PMID:12963647 |
|
NCBI chr 8:22,165,372...22,212,326
Ensembl chr 8:22,165,140...22,212,326
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
increases secretion increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased secretion of BMP2 protein Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA] Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] |
CTD |
PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 PMID:18310456 PMID:18628692 PMID:19292885 PMID:19912653 PMID:20024970 PMID:20381859 PMID:20417880 PMID:20687301 More...
|
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
BMPR2 |
bone morphogenetic protein receptor type 2 |
affects expression increases stability increases expression |
EXP |
Simvastatin affects the expression of BMPR2 mRNA Simvastatin results in increased stability of BMPR2 mRNA Simvastatin results in increased expression of BMPR2 protein |
CTD |
PMID:16297860 |
|
NCBI chr 2:202,376,327...202,567,749
Ensembl chr 2:202,376,327...202,567,751
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Simvastatin results in increased expression of BNIP3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
C5AR1 |
complement C5a receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr19:47,307,477...47,322,066
Ensembl chr19:47,290,023...47,322,066
|
|
G |
CACNA1C |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein] Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein |
CTD |
PMID:19791473 |
|
NCBI chr12:1,970,780...2,697,950
Ensembl chr12:1,970,772...2,697,950
|
|
G |
CACNA1H |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein] Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein |
CTD |
PMID:19791473 |
|
NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169
|
|
G |
CALB1 |
calbindin 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 8:90,058,608...90,082,879
Ensembl chr 8:90,058,608...90,095,475
|
|
G |
CALB2 |
calbindin 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CALB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr16:71,358,723...71,390,433
Ensembl chr16:71,358,713...71,390,436
|
|
G |
CALD1 |
caldesmon 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein |
CTD |
PMID:14630613 |
|
NCBI chr 7:134,745,467...134,970,729
Ensembl chr 7:134,744,252...134,970,729
|
|
G |
CALML3 |
calmodulin like 3 |
increases expression |
EXP |
Simvastatin results in increased expression of CALML3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:5,524,961...5,526,771
Ensembl chr10:5,524,961...5,526,771
|
|
G |
CAPN1 |
calpain 1 |
increases expression |
EXP |
Simvastatin results in increased expression of CAPN1 mRNA |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006
|
|
G |
CAPZA1 |
capping actin protein of muscle Z-line subunit alpha 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CAPZA1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 1:112,619,832...112,671,616
Ensembl chr 1:112,619,805...112,671,616
|
|
G |
CAPZA2 |
capping actin protein of muscle Z-line subunit alpha 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CAPZA2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 7:116,862,587...116,922,049
Ensembl chr 7:116,811,070...116,922,049
|
|
G |
CASP1 |
caspase 1 |
decreases activity multiple interactions |
ISO |
Simvastatin results in decreased activity of CASP1 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein] |
CTD |
PMID:16054375 PMID:30408459 PMID:35762198 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
multiple interactions |
EXP |
Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein |
CTD |
PMID:19253821 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases cleavage increases activity decreases activity increases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein Simvastatin results in increased cleavage of CASP3 protein Simvastatin results in decreased activity of CASP3 protein Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein] [Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein] |
CTD |
PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 PMID:15949312 PMID:16054375 PMID:16325779 PMID:16470222 PMID:16698853 PMID:17241114 PMID:17428261 PMID:17928392 PMID:18004065 PMID:18031796 PMID:18521906 PMID:18826357 PMID:19253821 PMID:19343037 PMID:20045437 PMID:20403180 PMID:20427495 PMID:20464445 PMID:20883752 PMID:21651924 PMID:21729534 PMID:21968084 PMID:22022327 PMID:25300705 PMID:26773838 PMID:27734117 PMID:29071762 PMID:35762198 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP6 |
caspase 6 |
multiple interactions |
EXP |
Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein |
CTD |
PMID:19253821 |
|
NCBI chr 4:109,664,388...109,709,767
Ensembl chr 4:109,688,622...109,703,583
|
|
G |
CASP7 |
caspase 7 |
multiple interactions increases activity |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:19253821 PMID:20045437 PMID:20427495 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions increases cleavage |
EXP ISO |
Simvastatin results in increased activity of CASP8 protein Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein Simvastatin results in increased cleavage of CASP8 protein Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein] |
CTD |
PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases activity decreases activity increases cleavage |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 PMID:20045437 PMID:21910007 More...
|
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
decreases expression multiple interactions increases activity |
ISO EXP |
Simvastatin results in decreased expression of CAT mRNA carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein] Simvastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CAV1 |
caveolin 1 |
multiple interactions decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA] Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein] Simvastatin results in decreased expression of CAV1 protein Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] |
CTD |
PMID:16698853 PMID:18224302 PMID:19816600 |
|
NCBI chr 7:116,525,009...116,561,185
Ensembl chr 7:116,524,994...116,561,179
|
|
G |
CAV2 |
caveolin 2 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein] |
CTD |
PMID:16698853 |
|
NCBI chr 7:116,499,738...116,508,541
Ensembl chr 7:116,287,380...116,508,541
|
|
G |
CBS |
cystathionine beta-synthase |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] |
CTD |
PMID:18224302 |
|
NCBI chr21:43,053,191...43,076,873
Ensembl chr21:43,053,191...43,076,943
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression affects expression decreases response to substance |
EXP ISO |
[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein Simvastatin affects the expression of CCL2 mRNA Simvastatin results in decreased susceptibility to CCL2 protein |
CTD |
PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 PMID:15855201 PMID:16321392 PMID:16414398 PMID:16443229 PMID:16781696 PMID:17449418 PMID:18309148 PMID:19225232 PMID:19262002 PMID:21268089 PMID:22305382 More...
|
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL20 |
C-C motif chemokine ligand 20 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CCL20 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA] Simvastatin results in decreased expression of CCL3 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCL4 |
C-C motif chemokine ligand 4 |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
increases expression decreases expression |
EXP ISO |
Simvastatin results in increased expression of CCL5 mRNA Simvastatin results in decreased expression of CCL5 protein Simvastatin results in decreased expression of CCL5 mRNA |
CTD |
PMID:17112859 PMID:17183729 PMID:17449418 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCN1 |
cellular communication network factor 1 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA] Simvastatin results in decreased expression of CCN1 mRNA |
CTD |
PMID:17428261 PMID:20191585 |
|
NCBI chr 1:85,580,761...85,583,950
Ensembl chr 1:85,580,761...85,584,589
|
|
G |
CCN2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 PMID:19659652 More...
|
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCNA2 |
cyclin A2 |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of CCNA2 mRNA Simvastatin results in decreased expression of CCNA2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein] |
CTD |
PMID:17428261 PMID:26577051 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein] Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein |
CTD |
PMID:17277159 PMID:17428261 PMID:20878096 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNE1 |
cyclin E1 |
multiple interactions decreases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein] |
CTD |
PMID:26577051 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CCR1 |
C-C motif chemokine receptor 1 |
multiple interactions decreases expression |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA] Simvastatin results in decreased expression of CCR1 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr 3:46,201,711...46,208,313
Ensembl chr 3:46,201,711...46,208,313
|
|
G |
CCR2 |
C-C motif chemokine receptor 2 |
multiple interactions decreases expression |
EXP ISO |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA] Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein |
CTD |
PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418 |
|
NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,864...46,360,940
|
|
G |
CCR4 |
C-C motif chemokine receptor 4 |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr 3:32,951,644...32,956,349
Ensembl chr 3:32,951,644...32,956,349
|
|
G |
CCR5 |
C-C motif chemokine receptor 5 |
multiple interactions decreases expression |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA] Simvastatin results in decreased expression of CCR5 protein Simvastatin results in decreased expression of CCR5 mRNA |
CTD |
PMID:16321392 PMID:17112859 PMID:17449418 |
|
NCBI chr 3:46,370,142...46,376,206
Ensembl chr 3:46,370,946...46,376,206
|
|
G |
CD14 |
CD14 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD14 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:140,631,732...140,633,701
Ensembl chr 5:140,631,728...140,633,700
|
|
G |
CD151 |
CD151 molecule (Raph blood group) |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD151 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr11:832,952...838,831
Ensembl chr11:832,887...839,831
|
|
G |
CD24 |
CD24 molecule |
increases expression |
EXP |
Simvastatin results in increased expression of CD24 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 6:106,969,831...106,976,855
Ensembl chr 6:106,969,831...106,975,627
|
|
G |
CD27 |
CD27 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD27 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr12:6,443,892...6,451,713
Ensembl chr12:6,444,955...6,451,718
|
|
G |
CD2AP |
CD2 associated protein |
increases expression |
EXP |
Simvastatin results in increased expression of CD2AP mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 6:47,477,789...47,627,263
Ensembl chr 6:47,477,789...47,627,263
|
|
G |
CD40 |
CD40 molecule |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of CD40 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]] |
CTD |
PMID:16387846 PMID:17169357 PMID:17507688 |
|
NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863
|
|
G |
CD40LG |
CD40 ligand |
decreases expression multiple interactions increases expression |
ISO EXP |
Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA] Simvastatin results in increased expression of CD40LG protein |
CTD |
PMID:17169357 PMID:18269829 PMID:21330348 |
|
NCBI chr X:136,648,158...136,660,390
Ensembl chr X:136,648,158...136,660,390
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter] Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CD80 |
CD80 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD80 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614
|
|
G |
CD83 |
CD83 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr 6:14,117,256...14,136,918
Ensembl chr 6:14,117,256...14,136,918
|
|
G |
CD86 |
CD86 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139
|
|
G |
CDC25B |
cell division cycle 25B |
affects expression |
EXP |
Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein |
CTD |
PMID:19110722 |
|
NCBI chr20:3,786,951...3,806,115
Ensembl chr20:3,786,772...3,806,121
|
|
G |
CDC42 |
cell division cycle 42 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CDC42 protein |
CTD |
PMID:17169357 |
|
NCBI chr 1:22,052,709...22,101,360
Ensembl chr 1:22,052,627...22,101,360
|
|
G |
CDC45 |
cell division cycle 45 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CDC45 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr22:19,479,466...19,520,612
Ensembl chr22:19,479,457...19,520,612
|
|
G |
CDC6 |
cell division cycle 6 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CDC6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:40,287,879...40,304,657
Ensembl chr17:40,287,879...40,304,657
|
|
G |
CDH5 |
cadherin 5 |
increases expression |
ISO |
Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein |
CTD |
PMID:19109527 |
|
NCBI chr16:66,366,691...66,404,784
Ensembl chr16:66,366,690...66,404,784
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein] |
CTD |
PMID:17428261 PMID:20878096 PMID:26577051 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
multiple interactions decreases expression decreases activity |
EXP ISO |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in decreased expression of CDK2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein] Simvastatin results in decreased activity of CDK2 protein |
CTD |
PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
decreases expression decreases activity |
EXP ISO |
Simvastatin results in decreased expression of CDK4 protein Simvastatin results in decreased activity of CDK4 protein |
CTD |
PMID:18804536 PMID:20878096 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDK5 |
cyclin dependent kinase 5 |
increases expression |
EXP |
Simvastatin results in increased expression of CDK5 |
CTD |
PMID:19461118 |
|
NCBI chr 7:151,053,815...151,057,897
Ensembl chr 7:151,053,815...151,057,897
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP ISO |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 PMID:18804536 More...
|
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
multiple interactions increases expression |
EXP ISO |
[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 PMID:20878096 More...
|
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDKN1C |
cyclin dependent kinase inhibitor 1C |
increases expression |
EXP |
Simvastatin results in increased expression of CDKN1C mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:2,883,218...2,885,775
Ensembl chr11:2,883,213...2,885,775
|
|
G |
CDKN2A |
cyclin dependent kinase inhibitor 2A |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN2A protein |
CTD |
PMID:18804536 |
|
NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,752...21,995,301
|
|
G |
CDKN2D |
cyclin dependent kinase inhibitor 2D |
increases expression |
EXP |
Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein |
CTD |
PMID:20878096 |
|
NCBI chr19:10,566,460...10,568,979
Ensembl chr19:10,566,460...10,569,059
|
|
G |
CDT1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CDT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr16:88,803,789...88,809,258
Ensembl chr16:88,803,789...88,809,258
|
|
G |
CEBPZ |
CCAAT enhancer binding protein zeta |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr 2:37,201,612...37,231,596
Ensembl chr 2:37,201,612...37,231,596
|
|
G |
CES1 |
carboxylesterase 1 |
multiple interactions |
ISO EXP |
Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 protein] Simvastatin inhibits the reaction [CES1 protein results in increased hydrolysis of remdesivir] |
CTD |
PMID:33383043 PMID:34774545 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CETP |
cholesteryl ester transfer protein |
affects response to substance decreases expression multiple interactions |
EXP |
CETP polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased expression of CETP protein [CETP polymorphism affects the susceptibility to Simvastatin] which affects the abundance of Cholesterol, HDL; [CETP polymorphism affects the susceptibility to Simvastatin] which affects the abundance of Triglycerides |
CTD |
PMID:10519734 PMID:16038892 PMID:17931083 |
|
NCBI chr16:56,961,950...56,983,845
Ensembl chr16:56,961,923...56,983,845
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
multiple interactions increases expression decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein] Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form |
CTD |
PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007 |
|
NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
|
|
G |
CFTR |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR protein] |
CTD |
PMID:33774062 |
|
NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
|
|
G |
CHAT |
choline O-acetyltransferase |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr10:49,609,095...49,667,942
Ensembl chr10:49,609,095...49,667,942
|
|
G |
CHRM5 |
cholinergic receptor muscarinic 5 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr15:33,968,497...34,067,458
Ensembl chr15:33,968,497...34,067,458
|
|
G |
CHUK |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein] Simvastatin results in increased expression of CHUK mRNA |
CTD |
PMID:18463201 PMID:19262002 |
|
NCBI chr10:100,186,319...100,229,596
Ensembl chr10:100,188,300...100,229,596
|
|
G |
CIITA |
class II major histocompatibility complex transactivator |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein] |
CTD |
PMID:11219190 |
|
NCBI chr16:10,866,206...10,943,021
Ensembl chr16:10,866,222...10,943,021
|
|
G |
CKM |
creatine kinase, M-type |
multiple interactions increases secretion decreases expression |
EXP ISO |
[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein] Simvastatin results in decreased expression of CKM protein |
CTD |
PMID:8611662 PMID:19252767 PMID:29071762 PMID:35762198 |
|
NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875
|
|
G |
CLCN3 |
chloride voltage-gated channel 3 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein] Simvastatin results in decreased expression of CLCN3 protein |
CTD |
PMID:20644009 |
|
NCBI chr 4:169,620,578...169,723,673
Ensembl chr 4:169,612,633...169,723,673
|
|
G |
CLDN18 |
claudin 18 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 protein] |
CTD |
PMID:33774062 |
|
NCBI chr 3:137,998,816...138,033,649
Ensembl chr 3:137,998,735...138,033,655
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 protein] |
CTD |
PMID:33774062 |
|
NCBI chr 7:73,830,996...73,832,690
Ensembl chr 7:73,799,542...73,832,690
|
|
G |
COL11A1 |
collagen type XI alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL11A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872
|
|
G |
COL12A1 |
collagen type XII alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL12A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 6:75,084,326...75,206,053
Ensembl chr 6:75,084,326...75,206,267
|
|
G |
COL13A1 |
collagen type XIII alpha 1 chain |
decreases response to substance |
EXP |
COL13A1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr10:69,801,906...69,959,144
Ensembl chr10:69,801,880...69,964,275
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions increases expression decreases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] Simvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 PMID:20417880 More...
|
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
multiple interactions increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
COL3A1 |
collagen type III alpha 1 chain |
increases expression decreases expression |
EXP ISO |
Simvastatin results in increased expression of COL3A1 mRNA Simvastatin results in decreased expression of COL3A1 mRNA |
CTD |
PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729 |
|
NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
|
|
G |
COL4A1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Simvastatin results in decreased expression of COL4A1 mRNA |
CTD |
PMID:10412775 |
|
NCBI chr13:110,148,963...110,307,157
Ensembl chr13:110,148,963...110,307,157
|
|
G |
COL5A1 |
collagen type V alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL5A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 9:134,641,803...134,844,843
Ensembl chr 9:134,641,803...134,844,843
|
|
G |
COL6A2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL6A2 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr21:46,098,112...46,132,848
Ensembl chr21:46,098,112...46,132,848
|
|
G |
COL7A1 |
collagen type VII alpha 1 chain |
increases expression |
EXP |
Simvastatin results in increased expression of COL7A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:48,564,073...48,595,329
Ensembl chr 3:48,564,073...48,595,329
|
|
G |
CORO1A |
coronin 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of CORO1A protein |
CTD |
PMID:20217863 |
|
NCBI chr16:30,183,602...30,189,076
Ensembl chr16:30,182,827...30,189,076
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CRP |
C-reactive protein |
decreases expression multiple interactions |
EXP |
Simvastatin results in decreased expression of CRP protein [Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] |
CTD |
PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 PMID:20152243 More...
|
|
NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589
|
|
G |
CSN1S2AP |
casein alpha s2 like A, pseudogene |
increases expression |
ISO |
Simvastatin results in increased expression of CSN1S2A mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:70,067,386...70,085,273
Ensembl chr 4:70,067,386...70,085,290 Ensembl chr 4:70,067,386...70,085,290
|
|
G |
CSPG4 |
chondroitin sulfate proteoglycan 4 |
increases expression |
ISO |
Simvastatin results in increased expression of CSPG4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr15:75,674,322...75,713,466
Ensembl chr15:75,674,322...75,712,848
|
|
G |
CTF1 |
cardiotrophin 1 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr16:30,895,846...30,903,560
Ensembl chr16:30,896,614...30,903,547
|
|
G |
CTLA4 |
cytotoxic T-lymphocyte associated protein 4 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CTLA4 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 2:203,867,771...203,873,965
Ensembl chr 2:203,853,888...203,873,965
|
|
G |
CTNNAL1 |
catenin alpha like 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 9:108,942,577...109,013,499
Ensembl chr 9:108,942,569...109,013,522
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein] Simvastatin results in increased expression of CTNNB1 protein Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein] |
CTD |
PMID:18004065 PMID:22058016 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CTSL |
cathepsin L |
increases expression |
ISO |
Simvastatin results in increased expression of CTSL mRNA |
CTD |
PMID:19001041 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
CTSS |
cathepsin S |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein] |
CTD |
PMID:20835264 |
|
NCBI chr 1:150,730,188...150,765,778
Ensembl chr 1:150,730,079...150,765,957
|
|
G |
CTTN |
cortactin |
affects localization multiple interactions |
EXP |
Simvastatin affects the localization of CTTN protein Simvastatin affects the reaction [F2 affects the localization of CTTN protein] |
CTD |
PMID:14630613 |
|
NCBI chr11:70,398,529...70,436,575
Ensembl chr11:70,398,404...70,436,584
|
|
G |
CX3CR1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:18359719 |
|
NCBI chr 3:39,263,494...39,292,966
Ensembl chr 3:39,263,495...39,281,735
|
|
G |
CXCL1 |
C-X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein] Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein |
CTD |
PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
Simvastatin results in increased expression of CXCL12 |
CTD |
PMID:19591934 |
|
NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493
|
|
G |
CXCL16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL16 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
|
|
G |
CXCL2 |
C-X-C motif chemokine ligand 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions decreases expression decreases secretion |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL8 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CXCL8 protein Simvastatin results in decreased expression of CXCL8 mRNA; Simvastatin results in decreased expression of CXCL8 protein Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA] Simvastatin results in decreased secretion of CXCL8 protein |
CTD |
PMID:12117737 PMID:16387846 PMID:16511915 PMID:17178392 PMID:18203325 PMID:20065508 More...
|
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CXCR2 |
C-X-C motif chemokine receptor 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCR2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:218,125,294...218,137,251
Ensembl chr 2:218,125,289...218,137,251
|
|
G |
CXCR4 |
C-X-C motif chemokine receptor 4 |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of CXCR4 mRNA Simvastatin results in increased expression of CXCR4 |
CTD |
PMID:16414398 PMID:19591934 |
|
NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177
|
|
G |
CYBA |
cytochrome b-245 alpha chain |
affects response to substance |
EXP |
CYBA gene SNP affects the susceptibility to Simvastatin |
CTD |
PMID:15936011 |
|
NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein] |
CTD |
PMID:30513525 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646
|
|
G |
CYP11B1 |
cytochrome P450 family 11 subfamily B member 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846
|
|
G |
CYP11B2 |
cytochrome P450 family 11 subfamily B member 2 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CYP17A1 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP17A1 mRNA; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; resveratrol promotes the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; Simvastatin promotes the reaction [resveratrol results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:21918126 PMID:24524197 PMID:25055962 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
Simvastatin results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
Simvastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP27A1 |
cytochrome P450 family 27 subfamily A member 1 |
multiple interactions |
ISO |
Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases expression |
EXP |
Simvastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
decreases activity |
EXP |
Simvastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions |
EXP |
Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin] |
CTD |
PMID:22594507 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
affects response to substance |
EXP |
CYP2D6 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:11753271 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP39A1 |
cytochrome P450 family 39 subfamily A member 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CYP39A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 6:46,549,580...46,652,818
Ensembl chr 6:46,549,580...46,652,830
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
affects metabolic processing decreases expression multiple interactions decreases activity increases metabolic processing affects response to substance increases expression |
EXP ISO |
CYP3A4 protein affects the metabolism of Simvastatin Simvastatin results in decreased expression of CYP3A4 mRNA; Simvastatin results in decreased expression of CYP3A4 protein Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] CYP3A4 protein results in increased metabolism of Simvastatin CYP3A4 polymorphism affects the susceptibility to Simvastatin Simvastatin results in increased expression of CYP3A4 mRNA [Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; telaprevir inhibits the reaction [CYP3A4 protein results in increased metabolism of Simvastatin] |
CTD |
PMID:12505310 PMID:15650881 PMID:16011971 PMID:17041008 PMID:19802823 PMID:24204015 PMID:24927617 PMID:30086269 More...
|
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
affects response to substance |
EXP |
CYP3A5 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:17192506 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP3A51P |
cytochrome P450 family 3 subfamily A member 51, pseudogene |
affects response to substance |
EXP |
CYP3A51P gene polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:20519697 |
|
NCBI chr 7:99,685,024...99,700,120
Ensembl chr 7:99,685,145...99,700,034
|
|
G |
CYP46A1 |
cytochrome P450 family 46 subfamily A member 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CYP46A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr14:99,684,298...99,727,301
Ensembl chr14:99,684,298...99,727,301
|
|
G |
CYP51A1 |
cytochrome P450 family 51 subfamily A member 1 |
increases expression |
ISO |
Simvastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:92,112,153...92,134,803
Ensembl chr 7:92,084,987...92,134,803
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
DBF4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
EXP |
Simvastatin results in decreased expression of DBF4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:87,876,493...87,909,553
Ensembl chr 7:87,876,216...87,909,553
|
|
G |
DBP |
D-box binding PAR bZIP transcription factor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of DBP mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr19:48,630,030...48,637,379
Ensembl chr19:48,630,030...48,637,379
|
|
G |
DCX |
doublecortin |
increases expression |
ISO |
Simvastatin results in increased expression of DCX |
CTD |
PMID:18544044 |
|
NCBI chr X:111,293,779...111,412,192
Ensembl chr X:111,293,779...111,412,429
|
|
G |
DDAH1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of DDAH1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:85,318,485...85,578,200
Ensembl chr 1:85,318,481...85,578,363
|
|
G |
DGAT1 |
diacylglycerol O-acyltransferase 1 |
increases expression increases activity |
ISO |
Simvastatin results in increased expression of DGAT1 mRNA Simvastatin results in increased activity of DGAT1 protein |
CTD |
PMID:12056585 |
|
NCBI chr 8:144,314,584...144,326,852
Ensembl chr 8:144,314,584...144,326,910
|
|
G |
DHCR24 |
24-dehydrocholesterol reductase |
increases expression |
EXP ISO |
Simvastatin results in increased expression of DHCR24 Simvastatin results in increased expression of DHCR24 mRNA Simvastatin results in increased expression of DHCR24 mRNA; Simvastatin results in increased expression of DHCR24 protein |
CTD |
PMID:21987590 PMID:25055962 |
|
NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195
|
|
G |
DHCR7 |
7-dehydrocholesterol reductase |
affects response to substance affects expression multiple interactions |
EXP ISO |
DHCR7 mutant form affects the susceptibility to Simvastatin Simvastatin affects the expression of DHCR7 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of DHCR7 mRNA Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol] Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA]; Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol] |
CTD |
PMID:15896653 PMID:16446309 PMID:19365639 PMID:25055962 PMID:28975700 |
|
NCBI chr11:71,434,411...71,448,393
Ensembl chr11:71,428,193...71,452,868
|
|
G |
DIABLO |
diablo IAP-binding mitochondrial protein |
affects localization multiple interactions |
EXP |
Simvastatin affects the localization of DIABLO protein DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:20045437 |
|
NCBI chr12:122,207,662...122,227,456
Ensembl chr12:122,207,668...122,226,062
|
|
G |
DKK1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] |
CTD |
PMID:22058016 |
|
NCBI chr10:52,314,281...52,317,657
Ensembl chr10:52,314,281...52,318,042
|
|
G |
DLL4 |
delta like canonical Notch ligand 4 |
increases expression |
ISO |
Simvastatin results in increased expression of DLL4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr15:40,929,340...40,939,073
Ensembl chr15:40,929,340...40,939,073
|
|
G |
DNM1L |
dynamin 1 like |
affects localization increases expression |
EXP |
Simvastatin affects the localization of DNM1L protein Simvastatin results in increased expression of DNM1L protein |
CTD |
PMID:20045437 |
|
NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650
|
|
G |
DRD1 |
dopamine receptor D1 |
multiple interactions increases expression |
ISO |
SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein] Simvastatin results in increased expression of DRD1 mRNA; Simvastatin results in increased expression of DRD1 protein |
CTD |
PMID:15711596 |
|
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
|
|
G |
DRD2 |
dopamine receptor D2 |
increases expression |
ISO |
Simvastatin results in increased expression of DRD2 mRNA; Simvastatin results in increased expression of DRD2 protein |
CTD |
PMID:15711596 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
DSPP |
dentin sialophosphoprotein |
increases expression |
EXP |
Simvastatin results in increased expression of DSPP mRNA |
CTD |
PMID:19249597 |
|
NCBI chr 4:87,608,529...87,616,873
Ensembl chr 4:87,608,529...87,616,873
|
|
G |
DUSP1 |
dual specificity phosphatase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of DUSP1 mRNA; Simvastatin results in decreased expression of DUSP1 protein |
CTD |
PMID:21080865 |
|
NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195
|
|
G |
E2F1 |
E2F transcription factor 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of E2F1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
EAF2 |
ELL associated factor 2 |
decreases response to substance |
EXP |
EAF2 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr 3:121,835,209...121,886,526
Ensembl chr 3:121,835,183...121,886,526
|
|
G |
EDN1 |
endothelin 1 |
decreases secretion decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased secretion of EDN1 protein Simvastatin results in decreased expression of EDN1 mRNA Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 protein]; Simvastatin results in increased expression of and results in increased secretion of EDN1 protein Simvastatin results in decreased expression of EDN1 mRNA; Simvastatin results in decreased expression of EDN1 protein Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA] |
CTD |
PMID:16375908 PMID:18390205 PMID:19099753 PMID:20369390 PMID:20644009 PMID:21844074 PMID:22022327 More...
|
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EDNRA |
endothelin receptor type A |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDNRA mRNA] |
CTD |
PMID:19505368 PMID:22022327 |
|
NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20359552 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EGR1 |
early growth response 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of EGR1 protein |
CTD |
PMID:12818400 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation multiple interactions |
ISO |
Simvastatin results in decreased phosphorylation of EIF4EBP1 protein IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22144680 PMID:27734117 |
|
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
|
|
G |
ENO1 |
enolase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ENO1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190
|
|
G |
ENTPD1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 |
|
NCBI chr10:95,694,186...95,877,266
Ensembl chr10:95,711,779...95,877,266
|
|
G |
EPHA3 |
EPH receptor A3 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA3 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 3:89,107,621...89,482,134
Ensembl chr 3:89,107,621...89,482,134
|
|
G |
EPHA8 |
EPH receptor A8 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA8 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 1:22,563,489...22,603,595
Ensembl chr 1:22,563,489...22,603,595
|
|
G |
EPO |
erythropoietin |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700
|
|
G |
EPOR |
erythropoietin receptor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPOR protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr19:11,377,207...11,384,314
Ensembl chr19:11,377,207...11,384,342
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions decreases activity |
EXP |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]; Simvastatin affects the reaction [F2 affects the localization of CTTN protein]; Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 PMID:14630613 |
|
NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions decreases activity decreases expression affects response to substance increases expression |
EXP ISO |
geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of F3]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] Simvastatin results in decreased activity of F3 protein F3 polymorphism affects the susceptibility to Simvastatin Simvastatin results in increased expression of F3 mRNA; Simvastatin results in increased expression of F3 protein Simvastatin results in decreased expression of F3; Simvastatin results in decreased expression of F3 mRNA; Simvastatin results in decreased expression of F3 protein |
CTD |
PMID:9081680 PMID:10830219 PMID:12753293 PMID:12818400 PMID:15824212 PMID:17513194 PMID:18031796 PMID:18841289 PMID:19027114 More...
|
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FASN |
fatty acid synthase |
increases expression |
EXP ISO |
Simvastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 PMID:12056585 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FBXO32 |
F-box protein 32 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of FBXO32 mRNA; Simvastatin results in increased expression of FBXO32 protein FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA] |
CTD |
PMID:19001041 PMID:25300705 PMID:27734117 PMID:33034787 |
|
NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206
|
|
G |
FDFT1 |
farnesyl-diphosphate farnesyltransferase 1 |
increases expression multiple interactions increases activity |
ISO EXP |
Simvastatin results in increased expression of FDFT1 protein Simvastatin results in increased expression of FDFT1 mRNA resveratrol inhibits the reaction [Simvastatin results in increased expression of FDFT1 mRNA] Simvastatin results in increased activity of FDFT1 protein |
CTD |
PMID:8517861 PMID:12518039 PMID:23386644 |
|
NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395
|
|
G |
FDPS |
farnesyl diphosphate synthase |
increases expression multiple interactions |
EXP |
Simvastatin results in increased expression of FDPS mRNA resveratrol inhibits the reaction [Simvastatin results in increased expression of FDPS mRNA] |
CTD |
PMID:23386644 |
|
NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666
|
|
G |
FGF19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
|
|
G |
FGF2 |
fibroblast growth factor 2 |
increases expression |
EXP |
Simvastatin results in increased expression of FGF2 |
CTD |
PMID:20381859 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FKBP1A |
FKBP prolyl isomerase 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of FKBP1A mRNA |
CTD |
PMID:16414398 |
|
NCBI chr20:1,368,978...1,393,054
Ensembl chr20:1,368,977...1,393,164
|
|
G |
FKBP4 |
FKBP prolyl isomerase 4 |
increases expression |
ISO |
Simvastatin results in increased expression of FKBP4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr12:2,794,970...2,805,423
Ensembl chr12:2,794,970...2,805,423
|
|
G |
FLOT1 |
flotillin 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr 6:30,727,709...30,742,687
Ensembl chr 6:30,727,709...30,742,732
|
|
G |
FLT1 |
fms related receptor tyrosine kinase 1 |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of FLT1 mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of FLT1 protein] Simvastatin results in increased expression of FLT1 mRNA |
CTD |
PMID:19109527 PMID:20821229 |
|
NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145
|
|
G |
FN1 |
fibronectin 1 |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of FN1 mRNA Simvastatin results in increased expression of FN1 mRNA |
CTD |
PMID:10412775 PMID:15855201 PMID:16274305 PMID:16414398 |
|
NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression decreases localization |
EXP ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of FOS mRNA] Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA] FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FOS protein] Simvastatin results in decreased localization of FOS protein |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:16005304 PMID:19100119 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FOSB |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179
|
|
G |
FOSL1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Simvastatin results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
|
|
G |
FOSL2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 2:28,392,858...28,417,317
Ensembl chr 2:28,392,448...28,417,317
|
|
G |
FOXO1 |
forkhead box O1 |
affects localization decreases phosphorylation multiple interactions decreases localization increases phosphorylation |
ISO EXP |
Simvastatin affects the localization of FOXO1 protein Simvastatin results in decreased phosphorylation of FOXO1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of FOXO1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein] Simvastatin results in decreased localization of FOXO1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased localization of FOXO1 protein] Simvastatin results in increased phosphorylation of FOXO1 protein |
CTD |
PMID:12438947 PMID:18826357 PMID:19001041 PMID:33034787 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions affects localization decreases phosphorylation decreases expression increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [Simvastatin results in increased phosphorylation of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein] Simvastatin results in decreased phosphorylation of FOXO3 protein Simvastatin results in decreased expression of FOXO3 protein |
CTD |
PMID:19001041 PMID:20883752 PMID:27734117 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
FOXP3 |
forkhead box P3 |
increases expression decreases expression affects methylation multiple interactions |
EXP ISO |
Simvastatin results in increased expression of FOXP3 Simvastatin results in decreased expression of FOXP3 mRNA Simvastatin affects the methylation of FOXP3 promoter IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of FOXP3] |
CTD |
PMID:20408897 PMID:20491794 PMID:22305382 |
|
NCBI chr X:49,250,438...49,264,710
Ensembl chr X:49,250,438...49,264,800
|
|
G |
FST |
follistatin |
multiple interactions |
ISO |
FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:33034787 |
|
NCBI chr 5:53,480,629...53,487,134
Ensembl chr 5:53,480,626...53,487,134
|
|
G |
FZD2 |
frizzled class receptor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of FZD2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr17:44,557,484...44,561,262
Ensembl chr17:44,557,484...44,561,262
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
GAPDH |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
ISO |
Simvastatin results in decreased expression of GAPDH mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:6,534,517...6,538,371
Ensembl chr12:6,534,512...6,538,374
|
|
G |
GATA6 |
GATA binding protein 6 |
increases expression |
ISO |
Simvastatin results in increased expression of GATA6 mRNA; Simvastatin results in increased expression of GATA6 protein |
CTD |
PMID:19842842 |
|
NCBI chr18:22,169,589...22,202,528
Ensembl chr18:22,169,589...22,202,528
|
|
G |
GDI2 |
GDP dissociation inhibitor 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of GDI2 protein |
CTD |
PMID:20217863 |
|
NCBI chr10:5,765,223...5,813,434
Ensembl chr10:5,765,223...5,842,132
|
|
G |
GDNF |
glial cell derived neurotrophic factor |
increases expression |
ISO |
Simvastatin results in increased expression of GDNF |
CTD |
PMID:20851742 |
|
NCBI chr 5:37,812,677...37,840,041
Ensembl chr 5:37,812,677...37,840,041
|
|
G |
GFRA1 |
GDNF family receptor alpha 1 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr10:116,056,925...116,274,705
Ensembl chr10:116,056,925...116,276,803
|
|
G |
GJA1 |
gap junction protein alpha 1 |
multiple interactions |
ISO |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Simvastatin affects the localization of and results in decreased phosphorylation of GJA1 protein |
CTD |
PMID:23978459 |
|
NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727
|
|
G |
GJB2 |
gap junction protein beta 2 |
increases expression |
EXP |
Simvastatin results in increased expression of GJB2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:20,187,470...20,192,938
Ensembl chr13:20,187,463...20,192,938
|
|
G |
GLB1 |
galactosidase beta 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Coal Ash results in increased expression of GLB1 protein] |
CTD |
PMID:26773838 |
|
NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of GPX1 mRNA Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20883752 PMID:28734741 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GPX2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Simvastatin results in increased expression of GPX2 mRNA |
CTD |
PMID:18787804 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of GSK3B Simvastatin results in increased expression of GSK3B protein modified form Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:18004065 PMID:18047562 PMID:19461118 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
H2AX |
H2A.X variant histone |
increases phosphorylation |
EXP |
Simvastatin results in increased phosphorylation of H2AX protein |
CTD |
PMID:20499237 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HES5 |
hes family bHLH transcription factor 5 |
increases expression |
ISO |
Simvastatin results in increased expression of HES5 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 1:2,528,745...2,530,263
Ensembl chr 1:2,528,745...2,530,263
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression decreases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of HIF1A protein Simvastatin results in decreased expression of HIF1A mRNA HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA] |
CTD |
PMID:18356691 PMID:21844074 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HLA-DMA |
major histocompatibility complex, class II, DM alpha |
decreases expression |
ISO |
Simvastatin results in decreased expression of RT1-DMA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 6:32,948,618...32,953,097
Ensembl chr 6:32,948,613...32,969,094
|
|
G |
HLA-DQB1 |
major histocompatibility complex, class II, DQ beta 1 |
affects expression |
EXP |
Simvastatin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:32,659,467...32,666,657
Ensembl chr 6:32,659,467...32,668,383
|
|
G |
HLA-DRA |
major histocompatibility complex, class II, DR alpha |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein] |
CTD |
PMID:11219190 |
|
NCBI chr 6:32,439,887...32,445,046
Ensembl chr 6:32,439,878...32,445,046
|
|
G |
HLA-E |
major histocompatibility complex, class I, E |
affects expression |
EXP |
Simvastatin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:30,489,509...30,494,194
Ensembl chr 6:30,489,509...30,494,194
|
|
G |
HLA-F |
major histocompatibility complex, class I, F |
affects expression |
EXP |
Simvastatin affects the expression of HLA-F mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:29,723,434...29,738,532
Ensembl chr 6:29,722,775...29,738,528
|
|
G |
HMGB1 |
high mobility group box 1 |
multiple interactions |
ISO EXP |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholecalciferol] results in increased expression of HMGB1 mRNA] [Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein] |
CTD |
PMID:20519084 PMID:25412314 |
|
NCBI chr13:30,456,704...30,617,597
Ensembl chr13:30,456,704...30,617,597
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance decreases activity increases expression increases activity multiple interactions affects response to substance |
EXP ISO |
HMGCR exon alternative form results in decreased susceptibility to Simvastatin Simvastatin results in decreased activity of HMGCR protein Simvastatin results in increased expression of HMGCR mRNA; Simvastatin results in increased expression of HMGCR protein Simvastatin results in increased activity of HMGCR protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin results in increased expression of and results in decreased activity of HMGCR protein; Simvastatin results in increased expression of and results in increased activity of HMGCR protein Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] [HMGCR intron polymorphism affects the expression of HMGCR exon alternative form] which results in decreased susceptibility to Simvastatin; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; [Simvastatin co-treated with Ezetimibe] results in increased expression of HMGCR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; Resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA]; Simvastatin results in increased expression of and results in increased activity of HMGCR protein HMGCR intron polymorphism affects the susceptibility to Simvastatin; HMGCR polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:1627634 PMID:8517861 PMID:8593127 PMID:9512650 PMID:10357840 PMID:12056585 PMID:12477733 PMID:12518039 PMID:16282522 PMID:17870053 PMID:17980884 PMID:18332269 PMID:18559695 PMID:19383813 PMID:20413733 PMID:21257924 PMID:21907337 PMID:22120639 PMID:23386644 PMID:24524197 PMID:24613879 PMID:25055962 PMID:28975700 PMID:29969672 More...
|
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases response to substance increases expression increases activity decreases expression increases stability |
ISO EXP |
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]] HMOX1 gene mutant form results in increased susceptibility to Simvastatin Simvastatin results in increased expression of HMOX1 mRNA; Simvastatin results in increased expression of HMOX1 protein Simvastatin results in increased activity of HMOX1 protein Simvastatin results in decreased expression of HMOX1 mRNA Simvastatin results in increased stability of HMOX1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased stability of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; tin protoporphyrin IX inhibits the reaction [Simvastatin results in increased expression of HMOX1 protein] |
CTD |
PMID:16375908 PMID:16414398 PMID:16628357 PMID:17928392 PMID:18073186 PMID:18787804 PMID:20368269 PMID:20594940 PMID:21844074 PMID:21910007 PMID:21925249 PMID:21968084 PMID:30513525 More...
|
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNF1A |
HNF1 homeobox A |
increases expression |
ISO |
Simvastatin results in increased expression of HNF1A mRNA |
CTD |
PMID:22160096 |
|
NCBI chr12:120,978,543...121,002,512
Ensembl chr12:120,978,543...121,002,512
|
|
G |
HRAS |
HRas proto-oncogene, GTPase |
multiple interactions decreases activity |
EXP ISO |
Farnesol inhibits the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of HRAS protein]; Simvastatin results in decreased prenylation of and results in decreased localization of HRAS protein Simvastatin results in decreased activity of HRAS |
CTD |
PMID:11914545 PMID:12477733 PMID:18625914 PMID:19360310 |
|
NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with resveratrol] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:24524197 |
|
NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054
|
|
G |
HSF1 |
heat shock transcription factor 1 |
affects localization |
EXP |
Simvastatin affects the localization of HSF1 protein |
CTD |
PMID:16375908 |
|
NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720
|
|
G |
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
Simvastatin results in increased expression of HSP90AA1 protein |
CTD |
PMID:16375908 |
|
NCBI chr14:102,080,742...102,139,749
Ensembl chr14:102,080,742...102,139,699
|
|
G |
HSPA4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
EXP |
Simvastatin results in increased expression of HSPA4 protein |
CTD |
PMID:16375908 |
|
NCBI chr 5:133,052,013...133,106,449
Ensembl chr 5:133,052,013...133,106,449
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Simvastatin results in increased expression of HSPA5 mRNA; Simvastatin results in increased expression of HSPA5 protein |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
HSPA8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
ISO |
Simvastatin results in decreased expression of HSPA8 protein |
CTD |
PMID:20217863 |
|
NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230
|
|
G |
HTRA2 |
HtrA serine peptidase 2 |
affects localization |
EXP |
Simvastatin affects the localization of HTRA2 protein |
CTD |
PMID:20045437 |
|
NCBI chr 2:74,529,405...74,533,556
Ensembl chr 2:74,529,596...74,533,350
|
|
G |
IBSP |
integrin binding sialoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of IBSP mRNA |
CTD |
PMID:20417880 |
|
NCBI chr 4:87,799,554...87,812,435
Ensembl chr 4:87,799,554...87,812,435
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
EXP ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Simvastatin affects the expression of and affects the secretion of ICAM1 protein; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of ICAM1 protein modified form] Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein; Simvastatin results in decreased expression of ICAM1 protein modified form |
CTD |
PMID:10946302 PMID:12615677 PMID:14602771 PMID:15234187 PMID:16054375 PMID:16193989 PMID:17277159 PMID:19166837 PMID:20863785 PMID:21764683 PMID:21874229 PMID:21994025 More...
|
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
ID1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ID1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,605,283...31,606,515
|
|
G |
IDI1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr10:1,039,152...1,056,704
Ensembl chr10:1,039,152...1,049,119
|
|
G |
IDO1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
EXP |
Simvastatin results in increased expression of IDO1 |
CTD |
PMID:20491794 |
|
NCBI chr 8:39,913,891...39,928,790
Ensembl chr 8:39,902,275...39,928,790
|
|
G |
IFNG |
interferon gamma |
multiple interactions increases secretion increases expression |
EXP ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] Simvastatin results in increased secretion of IFNG protein Simvastatin results in increased expression of IFNG mRNA |
CTD |
PMID:11219190 PMID:16321392 PMID:17507688 PMID:18453621 PMID:19589242 PMID:19886038 PMID:21268089 More...
|
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein] |
CTD |
PMID:17327694 PMID:27734117 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
decreases expression multiple interactions increases expression |
EXP ISO |
Simvastatin results in decreased expression of IGF1R; Simvastatin results in decreased expression of IGF1R mRNA; Simvastatin results in decreased expression of IGF1R protein [Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] Simvastatin results in increased expression of IGF1R protein alternative form |
CTD |
PMID:17158816 PMID:17327694 PMID:18489904 PMID:27734117 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
IGFBP6 |
insulin like growth factor binding protein 6 |
increases expression |
EXP |
Simvastatin results in increased expression of IGFBP6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr12:53,097,667...53,102,340
Ensembl chr12:53,097,436...53,102,345
|
|
G |
IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions increases phosphorylation decreases expression |
EXP |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of IKBKB protein] Simvastatin results in decreased expression of IKBKB mRNA |
CTD |
PMID:17277159 PMID:18463201 |
|
NCBI chr 8:42,271,302...42,332,460
Ensembl chr 8:42,271,302...42,332,460
|
|
G |
IL10 |
interleukin 10 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of IL10 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein] Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] Simvastatin results in increased expression of IL10 mRNA; Simvastatin results in increased expression of IL10 protein |
CTD |
PMID:15883752 PMID:20491794 PMID:21925249 PMID:33774062 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12B |
interleukin 12B |
multiple interactions increases expression |
ISO |
FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B protein]; Simvastatin promotes the reaction [Pam(3)CSK(4) peptide results in increased expression of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein] |
CTD |
PMID:15187114 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
IL13 |
interleukin 13 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL13 mRNA; Simvastatin results in decreased expression of IL13 protein |
CTD |
PMID:17169357 |
|
NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110
|
|
G |
IL16 |
interleukin 16 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of IL16 mRNA |
CTD |
PMID:15665042 |
|
NCBI chr15:81,182,712...81,314,058
Ensembl chr15:81,159,575...81,314,058
|
|
G |
IL17A |
interleukin 17A |
multiple interactions decreases secretion decreases expression |
EXP |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL17A mRNA] |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
|
|
G |
IL17F |
interleukin 17F |
decreases secretion |
EXP |
Simvastatin results in decreased secretion of IL17F protein |
CTD |
PMID:21856936 |
|
NCBI chr 6:52,236,681...52,245,689
Ensembl chr 6:52,236,681...52,245,689
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL18 protein] |
CTD |
PMID:18660453 PMID:27377765 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]] |
CTD |
PMID:15705589 PMID:15728660 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions decreases secretion decreases expression |
ISO EXP |
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B mRNA]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] Simvastatin results in decreased secretion of IL1B protein Simvastatin results in decreased expression of IL1B mRNA; Simvastatin results in decreased expression of IL1B protein farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:10946302 PMID:12829860 PMID:15883752 PMID:16054375 PMID:17075836 PMID:18047562 PMID:18309148 PMID:18791746 PMID:19166837 PMID:19574840 PMID:20126887 PMID:20191585 PMID:21910007 PMID:22305382 PMID:27377765 PMID:30408459 PMID:31260663 PMID:33774062 PMID:35762198 More...
|
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL1R2 |
interleukin 1 receptor type 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL1R2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:101,991,960...102,028,544
Ensembl chr 2:101,991,960...102,028,544
|
|
G |
IL1RL1 |
interleukin 1 receptor like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:102,311,563...102,352,356
Ensembl chr 2:102,311,502...102,352,037
|
|
G |
IL2 |
interleukin 2 |
multiple interactions |
ISO |
IL2 affects the reaction [Simvastatin results in increased expression of FOXP3] |
CTD |
PMID:20408897 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL20RB |
interleukin 20 receptor subunit beta |
increases expression |
EXP |
Simvastatin results in increased expression of IL20RB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:136,957,983...137,011,085
Ensembl chr 3:136,946,230...137,011,085
|
|
G |
IL21 |
interleukin 21 |
decreases expression decreases secretion |
EXP |
Simvastatin results in decreased expression of IL21 mRNA Simvastatin results in decreased secretion of IL21 protein |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 4:122,610,108...122,621,066
Ensembl chr 4:122,610,108...122,621,066
|
|
G |
IL22 |
interleukin 22 |
decreases secretion |
EXP |
Simvastatin results in decreased secretion of IL22 protein |
CTD |
PMID:21856936 |
|
NCBI chr12:68,248,242...68,253,604
Ensembl chr12:68,248,242...68,253,604
|
|
G |
IL23A |
interleukin 23 subunit alpha |
decreases expression |
EXP ISO |
Simvastatin results in decreased expression of IL23A mRNA |
CTD |
PMID:18453621 PMID:22305382 |
|
NCBI chr12:56,338,884...56,340,410
Ensembl chr12:56,334,174...56,340,410
|
|
G |
IL25 |
interleukin 25 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL25 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr14:23,372,809...23,376,403
Ensembl chr14:23,372,809...23,376,403
|
|
G |
IL27 |
interleukin 27 |
increases expression increases secretion multiple interactions |
EXP |
Simvastatin results in increased expression of IL27 mRNA Simvastatin results in increased secretion of IL27 protein IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] |
CTD |
PMID:18453621 |
|
NCBI chr16:28,499,362...28,506,834
Ensembl chr16:28,499,362...28,512,051
|
|
G |
IL2RA |
interleukin 2 receptor subunit alpha |
affects expression decreases expression |
EXP |
Simvastatin affects the expression of IL2RA protein Simvastatin results in decreased expression of IL2RA mRNA |
CTD |
PMID:16387846 PMID:18453621 |
|
NCBI chr10:6,010,689...6,062,367
Ensembl chr10:6,010,689...6,062,370
|
|
G |
IL4 |
interleukin 4 |
multiple interactions decreases expression increases secretion increases expression |
EXP ISO |
IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] Simvastatin results in decreased expression of IL4 mRNA; Simvastatin results in decreased expression of IL4 protein Simvastatin results in increased secretion of IL4 protein Simvastatin results in increased expression of IL4 mRNA |
CTD |
PMID:17169357 PMID:18453621 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL4R |
interleukin 4 receptor |
decreases expression |
EXP ISO |
Simvastatin results in decreased expression of IL4R mRNA Simvastatin results in decreased expression of IL4RA mRNA |
CTD |
PMID:16414398 PMID:18453621 |
|
NCBI chr16:27,313,756...27,364,778
Ensembl chr16:27,313,668...27,364,778
|
|
G |
IL6 |
interleukin 6 |
multiple interactions affects secretion decreases secretion decreases expression increases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL6 mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Simvastatin results in decreased expression of and results in decreased secretion of IL6 protein Simvastatin affects the secretion of IL6 protein Simvastatin results in decreased secretion of IL6 protein Simvastatin results in decreased expression of IL6 mRNA; Simvastatin results in decreased expression of IL6 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Simvastatin results in increased expression of IL6 mRNA Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] |
CTD |
PMID:12117737 PMID:15665042 PMID:15883752 PMID:16387846 PMID:16424782 PMID:16511915 PMID:17075836 PMID:17641834 PMID:17729120 PMID:18203325 PMID:18453621 PMID:18504409 PMID:19001041 PMID:19166837 PMID:20065508 PMID:20126887 PMID:21994025 PMID:22305382 More...
|
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INHA |
inhibin subunit alpha |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INHA mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 2:219,572,310...219,575,711
Ensembl chr 2:219,569,162...219,575,711
|
|
G |
INSIG2 |
insulin induced gene 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 2:118,088,471...118,110,997
Ensembl chr 2:118,088,452...118,110,997
|
|
G |
INSL3 |
insulin like 3 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr19:17,816,512...17,821,519
Ensembl chr19:17,816,512...17,821,574
|
|
G |
IRF1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 5:132,481,609...132,490,773
Ensembl chr 5:132,440,440...132,508,719
|
|
G |
IRF4 |
interferon regulatory factor 4 |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of IRF4 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein] Simvastatin results in decreased expression of IRF4 mRNA; Simvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:21856936 PMID:33034787 |
|
NCBI chr 6:391,752...411,443
Ensembl chr 6:391,739...411,443
|
|
G |
IRS1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
|
|
G |
ITGAL |
integrin subunit alpha L |
affects binding decreases expression multiple interactions |
EXP |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin results in decreased expression of ITGAL mRNA Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL] |
CTD |
PMID:12615677 PMID:15041742 PMID:16828882 |
|
NCBI chr16:30,472,742...30,523,185
Ensembl chr16:30,472,658...30,523,567
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions decreases expression |
ISO |
Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] Simvastatin results in decreased expression of ITGAM mRNA Simvastatin results in decreased expression of ITGAM mRNA; Simvastatin results in decreased expression of ITGAM protein |
CTD |
PMID:16414398 PMID:21330348 PMID:21441352 |
|
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
ITGB1 |
integrin subunit beta 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ITGB1 mRNA; Simvastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:17428261 PMID:21874229 |
|
NCBI chr10:32,900,318...32,958,230
Ensembl chr10:32,887,273...33,005,792
|
|
G |
ITGB2 |
integrin subunit beta 2 |
affects binding decreases expression multiple interactions |
EXP ISO |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin results in decreased expression of ITGB2 mRNA Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2] Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] |
CTD |
PMID:12615677 PMID:15041742 PMID:21330348 |
|
NCBI chr21:44,885,953...44,928,815
Ensembl chr21:44,885,953...44,931,989
|
|
G |
ITGB3BP |
integrin subunit beta 3 binding protein |
decreases expression |
EXP |
Simvastatin results in decreased expression of ITGB3BP mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:63,440,770...63,529,187
Ensembl chr 1:63,440,770...63,593,721
|
|
G |
ITGB4 |
integrin subunit beta 4 |
affects expression increases expression |
EXP |
Simvastatin affects the expression of ITGB4 mRNA; Simvastatin affects the expression of ITGB4 protein Simvastatin results in increased expression of ITGB4 mRNA; Simvastatin results in increased expression of ITGB4 protein |
CTD |
PMID:14630613 PMID:19110722 |
|
NCBI chr17:75,721,459...75,757,818
Ensembl chr17:75,721,328...75,757,818
|
|
G |
ITGBL1 |
integrin subunit beta like 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:101,452,675...101,720,856
Ensembl chr13:101,452,593...101,720,856
|
|
G |
JAK1 |
Janus kinase 1 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein] |
CTD |
PMID:16534557 |
|
NCBI chr 1:64,833,229...65,067,746
Ensembl chr 1:64,833,223...65,067,754
|
|
G |
JAK2 |
Janus kinase 2 |
multiple interactions decreases phosphorylation decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein] Simvastatin results in decreased phosphorylation of JAK2 protein Simvastatin results in decreased expression of JAK2 mRNA |
CTD |
PMID:16414398 PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression increases phosphorylation decreases localization |
EXP ISO |
pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein] Simvastatin results in decreased expression of JUN mRNA Simvastatin results in decreased localization of JUN protein JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of JUN protein] |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:15488325 PMID:17125918 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
JUNB |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr19:12,791,486...12,793,315
Ensembl chr19:12,791,486...12,793,315
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases localization multiple interactions decreases activity |
ISO |
Simvastatin results in decreased localization of KCNH2 protein Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:21525004 PMID:30086269 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KDR |
kinase insert domain receptor |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of KDR mRNA; Simvastatin results in increased expression of KDR protein Simvastatin inhibits the reaction [Streptozocin results in increased expression of KDR mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of KDR protein] |
CTD |
PMID:15572054 PMID:19109527 PMID:20821229 |
|
NCBI chr 4:55,078,481...55,125,595
Ensembl chr 4:55,078,481...55,125,595
|
|
G |
KIR2DS2 |
killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of KIR2DS2 mRNA |
CTD |
PMID:18192897 |
|
|
|
G |
KIT |
KIT proto-oncogene, receptor tyrosine kinase |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of KIT mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,267...54,740,783
|
|
G |
KLF10 |
KLF transcription factor 10 |
multiple interactions |
EXP |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA] |
CTD |
PMID:19225232 |
|
NCBI chr 8:102,648,784...102,655,725
Ensembl chr 8:102,648,784...102,655,725
|
|
G |
KLF16 |
KLF transcription factor 16 |
increases expression |
ISO |
Simvastatin results in increased expression of KLF16 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr19:1,852,399...1,876,536
Ensembl chr19:1,852,399...1,863,579
|
|
G |
KLF2 |
KLF transcription factor 2 |
increases expression decreases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of KLF2 mRNA Simvastatin results in decreased expression of KLF2 mRNA Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of KLF2 mRNA] |
CTD |
PMID:17428261 PMID:20493886 PMID:20737288 PMID:22305382 |
|
NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685
|
|
G |
KLF6 |
KLF transcription factor 6 |
increases expression |
EXP |
Simvastatin results in increased expression of KLF6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
KLRF1 |
killer cell lectin like receptor F1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of KLRF1 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr12:9,800,052...9,845,005
Ensembl chr12:9,827,481...9,845,007
|
|
G |
KRAS |
KRAS proto-oncogene, GTPase |
decreases prenylation |
EXP |
Simvastatin results in decreased prenylation of KRAS protein |
CTD |
PMID:8063617 |
|
NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936
|
|
G |
KRT13 |
keratin 13 |
increases expression |
EXP |
Simvastatin results in increased expression of KRT13 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:41,500,981...41,505,612
Ensembl chr17:41,500,981...41,505,705
|
|
G |
KRT15 |
keratin 15 |
increases expression |
EXP |
Simvastatin results in increased expression of KRT15 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:41,513,745...41,518,890
Ensembl chr17:41,513,745...41,522,529
|
|
G |
KRT17 |
keratin 17 |
increases expression |
EXP |
Simvastatin results in increased expression of KRT17 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:41,619,442...41,624,575
Ensembl chr17:41,619,442...41,624,842
|
|
G |
LBH |
LBH regulator of WNT signaling pathway |
increases expression |
ISO |
Simvastatin results in increased expression of LBH mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 2:30,231,534...30,260,028
Ensembl chr 2:30,231,534...30,323,730
|
|
G |
LBP |
lipopolysaccharide binding protein |
decreases expression |
ISO |
Simvastatin results in decreased expression of LBP mRNA |
CTD |
PMID:16414398 |
|
NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
|
|
G |
LCAT |
lecithin-cholesterol acyltransferase |
increases activity decreases expression |
ISO |
Simvastatin results in increased activity of LCAT protein Simvastatin results in decreased expression of LCAT mRNA |
CTD |
PMID:21241519 PMID:25055962 |
|
NCBI chr16:67,939,750...67,944,120
Ensembl chr16:67,939,750...67,944,131
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions increases expression increases activity affects response to substance |
EXP ISO |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Simvastatin co-treated with Ezetimibe] results in increased expression of LDLR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] Simvastatin results in increased expression of LDLR mRNA; Simvastatin results in increased expression of LDLR protein Simvastatin results in increased activity of LDLR protein Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin; LDLR mutant form affects the susceptibility to Simvastatin |
CTD |
PMID:1627634 PMID:8457250 PMID:8593127 PMID:9633944 PMID:10208479 PMID:10357840 PMID:11181283 PMID:11600564 PMID:11728391 PMID:11849659 PMID:17980884 PMID:18640378 PMID:19383813 PMID:20018177 PMID:20413733 PMID:22120639 More...
|
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LEF1 |
lymphoid enhancer binding factor 1 |
increases expression |
ISO |
Simvastatin results in increased expression of LEF1 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr 4:108,047,548...108,168,932
Ensembl chr 4:108,047,545...108,168,956
|
|
G |
LEP |
leptin |
multiple interactions decreases secretion decreases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; GGTI 298 inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; GGTI 298 inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA] Simvastatin inhibits the reaction [Poloxamer results in increased secretion of LEP protein] Simvastatin results in decreased expression of LEP mRNA; Simvastatin results in decreased expression of LEP mRNA alternative form |
CTD |
PMID:19254925 PMID:29071762 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LEPR |
leptin receptor |
affects response to substance |
EXP |
LEPR polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:14625131 PMID:18854995 |
|
NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of LHB protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of LHB protein] |
CTD |
PMID:17105841 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
multiple interactions |
EXP |
[Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]] |
CTD |
PMID:19225232 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
LITAF |
lipopolysaccharide induced TNF factor |
decreases expression |
ISO |
Simvastatin results in decreased expression of LITAF mRNA |
CTD |
PMID:16414398 |
|
NCBI chr16:11,547,722...11,640,317
Ensembl chr16:11,547,722...11,636,381
|
|
G |
LOX |
lysyl oxidase |
decreases expression |
ISO |
Simvastatin results in decreased expression of LOX mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:122,063,195...122,078,259
Ensembl chr 5:122,063,195...122,078,413
|
|
G |
LPA |
lipoprotein(a) |
multiple interactions |
EXP |
[Niacin co-treated with Simvastatin] results in decreased expression of LPA protein |
CTD |
PMID:18471454 |
|
NCBI chr 6:160,531,482...160,664,275
Ensembl chr 6:160,531,482...160,664,275
|
|
G |
LPL |
lipoprotein lipase |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of LPL Simvastatin results in increased expression of LPL protein |
CTD |
PMID:2009092 PMID:19216230 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
LRP6 |
LDL receptor related protein 6 |
decreases expression |
ISO |
Simvastatin results in decreased expression of LRP6 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr12:12,116,025...12,267,044
Ensembl chr12:12,116,025...12,267,044
|
|
G |
LRRC2 |
leucine rich repeat containing 2 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of LRRC2 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 3:46,515,385...46,566,302
Ensembl chr 3:46,515,385...46,606,948
|
|
G |
LTB |
lymphotoxin beta |
decreases expression |
EXP |
Simvastatin results in decreased expression of LTB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 6:31,580,558...31,582,425
Ensembl chr 6:31,580,525...31,582,522
|
|
G |
MAD2L1 |
mitotic arrest deficient 2 like 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:120,055,623...120,066,848
Ensembl chr 4:120,055,623...120,066,858
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of MAP1LC3B protein [Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form; Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:23817226 PMID:25412314 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAP3K14 |
mitogen-activated protein kinase kinase kinase 14 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MAP3K14 mRNA |
CTD |
PMID:17277159 |
|
NCBI chr17:45,263,119...45,317,020
Ensembl chr17:45,263,119...45,317,029
|
|
G |
MAP3K7 |
mitogen-activated protein kinase kinase kinase 7 |
multiple interactions |
EXP |
Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein] |
CTD |
PMID:17277159 |
|
NCBI chr 6:90,513,579...90,587,072
Ensembl chr 6:90,513,573...90,587,086
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation decreases activity |
EXP ISO |
[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein Simvastatin results in decreased phosphorylation of MAPK1 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK1 protein Simvastatin results in increased phosphorylation of MAPK1 protein Simvastatin results in decreased activity of MAPK1 protein |
CTD |
PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 PMID:18310456 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19383813 PMID:20359552 PMID:20417880 PMID:20464445 PMID:20594940 PMID:21080865 PMID:21910007 PMID:30513525 More...
|
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions decreases expression |
ISO |
Simvastatin results in increased phosphorylation of and results in increased activity of MAPK14 protein Simvastatin results in decreased expression of MAPK14 mRNA |
CTD |
PMID:16414398 PMID:17928392 |
|
NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,782...36,111,236
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation decreases activity |
EXP ISO |
[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK3 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein Simvastatin results in decreased phosphorylation of MAPK3 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK3 protein Simvastatin results in increased phosphorylation of MAPK3 protein Simvastatin results in decreased activity of MAPK3 protein |
CTD |
PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 PMID:18310456 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19383813 PMID:20359552 PMID:20417880 PMID:20464445 PMID:20594940 PMID:21080865 PMID:21910007 PMID:30513525 More...
|
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions increases activity |
ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein] Simvastatin results in increased activity of MAPK8 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:15187114 PMID:18047562 PMID:18310456 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
increases activity |
ISO |
Simvastatin results in increased activity of MAPK9 protein |
CTD |
PMID:15187114 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MAPT |
microtubule associated protein tau |
affects expression |
EXP |
Simvastatin affects the expression of MAPT |
CTD |
PMID:19461118 |
|
NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334
|
|
G |
MB |
myoglobin |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Poloxamer results in increased secretion of MB protein] |
CTD |
PMID:29071762 |
|
NCBI chr22:35,606,764...35,623,354
Ensembl chr22:35,606,764...35,637,951
|
|
G |
MCM4 |
minichromosome maintenance complex component 4 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MCM4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:47,960,941...47,978,160
Ensembl chr 8:47,960,185...47,978,160
|
|
G |
MDH1 |
malate dehydrogenase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MDH1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 2:63,588,963...63,607,197
Ensembl chr 2:63,588,609...63,607,197
|
|
G |
MDM2 |
MDM2 proto-oncogene |
increases phosphorylation multiple interactions |
EXP |
Simvastatin results in increased phosphorylation of MDM2 protein Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]] |
CTD |
PMID:15625077 |
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
MERTK |
MER proto-oncogene, tyrosine kinase |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of MERTK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 2:111,898,607...112,029,561
Ensembl chr 2:111,898,607...112,029,561
|
|
G |
MIR221 |
microRNA 221 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MIR221 |
CTD |
PMID:25517390 |
|
NCBI chr X:45,746,157...45,746,266
Ensembl chr X:45,746,157...45,746,266
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MKI67 protein |
CTD |
PMID:26577051 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
multiple interactions increases expression decreases secretion decreases expression |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein] Simvastatin results in increased expression of MMP1 mRNA Simvastatin results in decreased secretion of MMP1 mRNA; Simvastatin results in decreased secretion of MMP1 protein |
CTD |
PMID:17303772 PMID:17428261 PMID:18625914 PMID:31260663 |
|
NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160
|
|
G |
MMP10 |
matrix metallopeptidase 10 |
increases expression |
EXP |
Simvastatin results in increased expression of MMP10 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:102,770,502...102,780,628
Ensembl chr11:102,770,502...102,780,628
|
|
G |
MMP12 |
matrix metallopeptidase 12 |
increases expression |
EXP |
Simvastatin results in increased expression of MMP12 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:102,862,736...102,874,982
Ensembl chr11:102,862,736...102,874,982
|
|
G |
MMP13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of MMP13 mRNA Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA] |
CTD |
PMID:16274305 PMID:17428261 PMID:31260663 |
|
NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
decreases activity increases activity decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased activity of MMP2 protein Simvastatin results in increased activity of MMP2 protein Simvastatin results in decreased expression of MMP2 protein Simvastatin results in decreased expression of MMP2 mRNA Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein] Simvastatin inhibits the reaction [Monocrotaline results in increased expression of MMP2 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP2 protein |
CTD |
PMID:15210533 PMID:17038636 PMID:17158816 PMID:17169357 PMID:18309148 PMID:19360310 PMID:22022327 PMID:23831763 PMID:31260663 More...
|
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP28 |
matrix metallopeptidase 28 |
increases expression |
EXP |
Simvastatin results in increased expression of MMP28 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:35,756,249...35,795,641
Ensembl chr17:35,756,249...35,795,707
|
|
G |
MMP3 |
matrix metallopeptidase 3 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of MMP3 mRNA Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA] |
CTD |
PMID:16414398 PMID:31260663 |
|
NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609
|
|
G |
MMP8 |
matrix metallopeptidase 8 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP8 mRNA] |
CTD |
PMID:18625914 |
|
NCBI chr11:102,711,796...102,724,954
Ensembl chr11:102,711,796...102,727,050
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions increases activity decreases expression decreases activity |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA] Simvastatin results in increased activity of MMP9 protein Simvastatin results in decreased expression of MMP9 mRNA; Simvastatin results in decreased expression of MMP9 protein Simvastatin results in decreased activity of MMP9 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of MMP9 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP9 protein Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 protein] |
CTD |
PMID:15107580 PMID:15210533 PMID:15537504 PMID:15728660 PMID:16002570 PMID:16414398 PMID:17038636 PMID:17169357 PMID:17277159 PMID:17560598 PMID:18309148 PMID:18569431 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19505368 PMID:19589242 PMID:19820293 PMID:20835264 PMID:23831763 PMID:31260663 More...
|
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPO |
myeloperoxidase |
multiple interactions decreases activity decreases expression |
EXP ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein] Simvastatin results in decreased activity of MPO protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] Simvastatin results in decreased expression of MPO protein |
CTD |
PMID:15665042 PMID:17038636 PMID:21764683 PMID:33774062 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MRAS |
muscle RAS oncogene homolog |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Glucose results in increased activity of MRAS protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MRAS protein] |
CTD |
PMID:18569938 PMID:19299917 |
|
NCBI chr 3:138,347,648...138,405,535
Ensembl chr 3:138,347,648...138,405,534
|
|
G |
MRPS31 |
mitochondrial ribosomal protein S31 |
decreases response to substance |
EXP |
MRPS31 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr13:40,729,128...40,771,190
Ensembl chr13:40,729,128...40,771,190
|
|
G |
MSTN |
myostatin |
multiple interactions increases expression |
ISO |
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Simvastatin results in increased expression of and results in increased secretion of MSTN protein Simvastatin results in increased expression of MSTN mRNA; Simvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:190,055,700...190,062,729
Ensembl chr 2:190,055,700...190,062,729
|
|
G |
MT1A |
metallothionein 1A |
increases expression |
ISO |
Simvastatin results in increased expression of MT1A mRNA |
CTD |
PMID:19001041 |
|
NCBI chr16:56,638,666...56,640,087
Ensembl chr16:56,638,666...56,640,087
|
|
G |
MTHFR |
methylenetetrahydrofolate reductase |
multiple interactions increases expression affects response to substance |
EXP ISO |
Homocysteine inhibits the reaction [Simvastatin results in increased expression of MTHFR protein modified form]; Simvastatin promotes the reaction [Homocysteine results in increased expression of MTHFR protein] MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein] MTHFR affects the susceptibility to Simvastatin |
CTD |
PMID:18540024 |
|
NCBI chr 1:11,785,723...11,805,964
Ensembl chr 1:11,785,723...11,806,455
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
Simvastatin results in decreased phosphorylation of MTOR protein FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:22144680 PMID:33034787 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MUC5AC |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO EXP |
Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MUC5AC protein] Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein] |
CTD |
PMID:19024099 PMID:20359552 |
|
NCBI chr11:1,157,953...1,201,138
Ensembl chr11:1,157,953...1,201,138
|
|
G |
MVD |
mevalonate diphosphate decarboxylase |
increases expression |
ISO |
Simvastatin results in increased expression of MVD mRNA |
CTD |
PMID:25055962 |
|
NCBI chr16:88,651,940...88,663,091
Ensembl chr16:88,651,935...88,663,161
|
|
G |
MVK |
mevalonate kinase |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of MVK mRNA [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein] |
CTD |
PMID:12477733 PMID:25055962 |
|
NCBI chr12:109,573,272...109,598,125
Ensembl chr12:109,573,255...109,598,125
|
|
G |
MYBPH |
myosin binding protein H |
increases expression |
EXP |
Simvastatin results in increased expression of MYBPH mRNA |
CTD |
PMID:17183729 |
|
NCBI chr 1:203,167,811...203,179,214
Ensembl chr 1:203,167,811...203,175,826
|
|
G |
MYH10 |
myosin heavy chain 10 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MYH10 protein |
CTD |
PMID:16005304 |
|
NCBI chr17:8,474,212...8,630,725
Ensembl chr17:8,474,207...8,631,376
|
|
G |
MYH6 |
myosin heavy chain 6 |
increases expression |
ISO |
Simvastatin results in increased expression of MYH6 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr14:23,381,987...23,408,273
Ensembl chr14:23,381,982...23,408,273
|
|
G |
MYL5 |
myosin light chain 5 |
increases expression |
EXP |
Simvastatin results in increased expression of MYL5 mRNA |
CTD |
PMID:17183729 |
|
NCBI chr 4:674,542...682,028
Ensembl chr 4:673,580...682,028
|
|
G |
NDRG1 |
N-myc downstream regulated 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of NDRG1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022
|
|
G |
NEAT1 |
nuclear paraspeckle assembly transcript 1 |
increases expression |
EXP |
Simvastatin results in increased expression of NEAT1 mRNA; Simvastatin results in increased expression of NEAT1 mRNA alternative form |
CTD |
PMID:31311324 |
|
NCBI chr11:65,422,798...65,445,540
Ensembl chr11:65,422,774...65,445,540
|
|
G |
NFATC3 |
nuclear factor of activated T cells 3 |
multiple interactions increases localization decreases localization |
EXP |
Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in increased localization of NFATC3 protein Simvastatin results in decreased localization of NFATC3 protein alternative form |
CTD |
PMID:20369390 |
|
NCBI chr16:68,085,370...68,229,259
Ensembl chr16:68,084,751...68,229,259
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases localization increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased localization of NFE2L2 protein Simvastatin results in increased expression of NFE2L2 mRNA MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; Simvastatin results in increased expression of and affects the localization of NFE2L2 protein Mevalonic Acid affects the reaction [Simvastatin results in increased localization of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:17928392 PMID:18787804 PMID:30513525 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases expression decreases activity decreases localization increases localization |
EXP ISO |
artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of NFKB1 protein]; Simvastatin results in increased localization of and results in increased activity of NFKB1 protein Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]] Simvastatin results in decreased expression of NFKB1 mRNA Simvastatin results in decreased activity of NFKB1 protein Simvastatin results in decreased localization of NFKB1 protein |
CTD |
PMID:12753293 PMID:17038636 PMID:17277159 PMID:18463201 PMID:21465237 PMID:21925249 More...
|
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation |
EXP ISO |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of NFKBIA protein] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of NFKBIA protein] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]] |
CTD |
PMID:15705589 PMID:17075836 PMID:17178392 PMID:17277159 PMID:18073186 PMID:18463201 PMID:18826357 PMID:19299917 PMID:21925249 More...
|
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NLGN3 |
neuroligin 3 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr X:71,144,841...71,175,307
Ensembl chr X:71,144,821...71,175,255
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of NLRP3 mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] |
CTD |
PMID:30408459 PMID:35762198 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108
|
|
G |
NOG |
noggin |
multiple interactions |
ISO |
NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 |
|
NCBI chr17:56,593,699...56,595,611
Ensembl chr17:56,593,699...56,595,611
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
Simvastatin promotes the reaction [Doxorubicin results in increased expression of NOS2 protein] Simvastatin results in decreased expression of NOS2 mRNA; Simvastatin results in decreased expression of NOS2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]] Simvastatin results in increased expression of NOS2 mRNA; Simvastatin results in increased expression of NOS2 protein Homocysteine affects the reaction [Simvastatin results in increased expression of NOS2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; Simvastatin promotes the reaction [Homocysteine results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] |
CTD |
PMID:10188333 PMID:11470468 PMID:15705589 PMID:16414398 PMID:17729120 PMID:18047562 PMID:18309148 PMID:18463201 PMID:18540024 PMID:19505368 PMID:19729986 PMID:20452610 PMID:21844074 PMID:21925249 PMID:22022327 More...
|
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases expression decreases expression multiple interactions increases phosphorylation |
EXP ISO |
Simvastatin results in increased expression of NOS3; Simvastatin results in increased expression of NOS3 mRNA; Simvastatin results in increased expression of NOS3 protein Simvastatin results in decreased expression of NOS3 mRNA; Simvastatin results in decreased expression of NOS3 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of NOS3 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]] Simvastatin results in increased phosphorylation of NOS3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Smoke analog affects the expression of NOS3 mRNA]; Simvastatin results in increased expression of and results in increased phosphorylation of and results in increased activity of NOS3 protein |
CTD |
PMID:10188333 PMID:11470468 PMID:11947894 PMID:12379581 PMID:12406854 PMID:12963647 PMID:15572054 PMID:15711596 PMID:16002570 PMID:16375908 PMID:16414398 PMID:17335931 PMID:18221806 PMID:18309148 PMID:18826357 PMID:18981156 PMID:20493886 PMID:20562903 PMID:20659230 PMID:20737288 PMID:21968084 PMID:22022327 PMID:25517390 PMID:35762198 More...
|
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NOTCH1 |
notch receptor 1 |
increases cleavage increases expression |
ISO |
Simvastatin results in increased cleavage of NOTCH1 protein Simvastatin results in increased expression of NOTCH1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048
|
|
G |
NOTCH4 |
notch receptor 4 |
increases expression |
ISO |
Simvastatin results in increased expression of NOTCH4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 6:32,194,843...32,224,067
Ensembl chr 6:32,194,843...32,224,067
|
|
G |
NPC1L1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:17980884 |
|
NCBI chr 7:44,512,535...44,541,330
Ensembl chr 7:44,512,535...44,541,330
|
|
G |
NPHS1 |
NPHS1 adhesion molecule, nephrin |
increases expression |
EXP |
Simvastatin results in increased expression of NPHS1 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr19:35,825,372...35,852,504
Ensembl chr19:35,825,372...35,869,287
|
|
G |
NPHS2 |
NPHS2 stomatin family member, podocin |
increases expression |
EXP |
Simvastatin results in increased expression of NPHS2 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952
|
|
G |
NPPA |
natriuretic peptide A |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA] Simvastatin results in decreased expression of NPPA mRNA |
CTD |
PMID:16029635 PMID:16534557 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NPPB |
natriuretic peptide B |
decreases expression |
ISO |
Simvastatin results in decreased expression of NPPB; Simvastatin results in decreased expression of NPPB protein |
CTD |
PMID:16628357 PMID:21124329 |
|
NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of NQO1 mRNA; Simvastatin results in increased expression of NQO1 protein MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA] |
CTD |
PMID:30513525 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:30,304,206...30,309,390
Ensembl chr X:30,304,206...30,309,390
|
|
G |
NR1D1 |
nuclear receptor subfamily 1 group D member 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NR1D1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr17:40,092,793...40,100,589
Ensembl chr17:40,092,793...40,100,589
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of NR1H3 mRNA |
CTD |
PMID:22160096 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions |
ISO |
Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 protein] |
CTD |
PMID:33383043 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity multiple interactions |
EXP |
Simvastatin results in increased activity of NR1I2 protein [Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter] |
CTD |
PMID:15802384 PMID:17041008 PMID:24204015 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP ISO |
Simvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NR4A3 |
nuclear receptor subfamily 4 group A member 3 |
multiple interactions |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA] |
CTD |
PMID:16005304 |
|
NCBI chr 9:99,821,885...99,866,891
Ensembl chr 9:99,821,855...99,866,891
|
|
G |
NRP1 |
neuropilin 1 |
decreases response to substance |
EXP |
NRP1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr10:33,177,493...33,334,667
Ensembl chr10:33,177,492...33,336,262
|
|
G |
NSDHL |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
ISO |
Simvastatin results in decreased expression of NSDHL mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:152,831,063...152,869,729
Ensembl chr X:152,830,967...152,869,729
|
|
G |
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 1:156,815,750...156,881,850
Ensembl chr 1:156,815,636...156,881,850
|
|
G |
NTRK2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK2 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 9:84,668,522...85,027,054
Ensembl chr 9:84,668,375...85,095,751
|
|
G |
OCLN |
occludin |
increases expression |
ISO |
Simvastatin results in increased expression of OCLN |
CTD |
PMID:18544044 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
OLR1 |
oxidized low density lipoprotein receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of OLR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:10,158,301...10,176,266
Ensembl chr12:10,158,301...10,172,138
|
|
G |
OSBPL1A |
oxysterol binding protein like 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of OSBPL1A mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:24,162,045...24,397,824
Ensembl chr18:24,162,045...24,397,880
|
|
G |
OSM |
oncostatin M |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]; Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr22:30,262,829...30,266,851
Ensembl chr22:30,262,829...30,266,851
|
|
G |
P4HB |
prolyl 4-hydroxylase subunit beta |
decreases expression |
ISO |
Simvastatin results in decreased expression of P4HB mRNA |
CTD |
PMID:16414398 |
|
NCBI chr17:81,843,166...81,860,535
Ensembl chr17:81,843,159...81,860,856
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage decreases cleavage |
EXP ISO |
[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; pifithrin inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of PARP1 protein modified form]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein] IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein] Simvastatin inhibits the reaction [Glucose results in increased activity of PARP1 protein] Simvastatin results in decreased cleavage of PARP1 mRNA |
CTD |
PMID:16054375 PMID:18004065 PMID:20045437 PMID:20464445 PMID:21910007 PMID:26773838 PMID:27734117 More...
|
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PCNA |
proliferating cell nuclear antigen |
decreases expression |
EXP |
Simvastatin results in decreased expression of PCNA mRNA; Simvastatin results in decreased expression of PCNA protein |
CTD |
PMID:17428261 PMID:18824851 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PCSK9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
EXP |
[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA |
CTD |
PMID:17980884 |
|
NCBI chr 1:55,039,548...55,064,852
Ensembl chr 1:55,039,447...55,064,852
|
|
G |
PDE4B |
phosphodiesterase 4B |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDE4B mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 1:65,792,510...66,374,579
Ensembl chr 1:65,792,514...66,374,579
|
|
G |
PDGFA |
platelet derived growth factor subunit A |
decreases expression |
ISO |
Simvastatin results in decreased expression of PDGFA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 7:497,258...520,700
Ensembl chr 7:497,258...520,296
|
|
G |
PDGFB |
platelet derived growth factor subunit B |
decreases expression decreases activity multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of PDGFB protein Simvastatin results in decreased expression of PDGFB mRNA Simvastatin results in decreased activity of PDGFB protein Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDGFB mRNA] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of PDGFB protein]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] |
CTD |
PMID:8231022 PMID:10412745 PMID:10412775 PMID:15728660 PMID:16373842 |
|
NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982
|
|
G |
PDGFRA |
platelet derived growth factor receptor alpha |
decreases expression |
ISO |
Simvastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:54,229,293...54,298,245
Ensembl chr 4:54,229,280...54,298,245
|
|
G |
PDGFRB |
platelet derived growth factor receptor beta |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of PDGFRB mRNA [Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of PDGFRB mRNA |
CTD |
PMID:10412775 PMID:28263720 |
|
NCBI chr 5:150,113,839...150,155,845
Ensembl chr 5:150,113,839...150,155,872
|
|
G |
PDK2 |
pyruvate dehydrogenase kinase 2 |
increases expression |
ISO |
Simvastatin results in increased expression of PDK2 mRNA |
CTD |
PMID:19001041 |
|
NCBI chr17:50,094,737...50,112,152
Ensembl chr17:50,094,737...50,112,152
|
|
G |
PDK4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
ISO |
Simvastatin results in increased expression of PDK4 mRNA |
CTD |
PMID:19001041 PMID:19262002 |
|
NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
|
|
G |
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
ISO |
Simvastatin results in increased expression of PECAM1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr17:64,319,415...64,390,860
Ensembl chr17:64,319,415...64,413,776
|
|
G |
PHB2 |
prohibitin 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PHB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr12:6,965,327...6,970,753
Ensembl chr12:6,965,327...6,970,780
|
|
G |
PIGC |
phosphatidylinositol glycan anchor biosynthesis class C |
decreases expression |
ISO |
Simvastatin results in decreased expression of PIGC mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 1:172,441,457...172,444,069
Ensembl chr 1:172,370,189...172,444,086
|
|
G |
PITX2 |
paired like homeodomain 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PITX2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:110,617,423...110,642,123
Ensembl chr 4:110,617,423...110,642,123
|
|
G |
PKMYT1 |
protein kinase, membrane associated tyrosine/threonine 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of PKMYT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr16:2,972,808...2,980,446
Ensembl chr16:2,968,024...2,980,479
|
|
G |
PLA2G2A |
phospholipase A2 group IIA |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of PLA2G2A protein] |
CTD |
PMID:19237014 |
|
NCBI chr 1:19,975,431...19,980,434
Ensembl chr 1:19,975,431...19,980,416
|
|
G |
PLA2G7 |
phospholipase A2 group VII |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G7 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21176638 |
|
NCBI chr 6:46,704,201...46,735,721
Ensembl chr 6:46,704,201...46,735,693
|
|
G |
PLAT |
plasminogen activator, tissue type |
multiple interactions decreases expression increases activity increases expression |
EXP ISO |
geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT] Simvastatin results in decreased expression of PLAT mRNA Simvastatin results in increased activity of PLAT protein Simvastatin results in increased expression of PLAT; Simvastatin results in increased expression of PLAT mRNA; Simvastatin results in increased expression of PLAT protein |
CTD |
PMID:12371961 PMID:12753293 PMID:16414398 |
|
NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709
|
|
G |
PLAU |
plasminogen activator, urokinase |
decreases expression |
ISO |
Simvastatin results in decreased expression of PLAU mRNA |
CTD |
PMID:10412775 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
G |
PLCG2 |
phospholipase C gamma 2 |
increases expression |
EXP |
Simvastatin results in increased expression of PLCG2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr16:81,779,291...81,962,685
Ensembl chr16:81,779,279...81,962,685
|
|
G |
PLK2 |
polo like kinase 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PLK2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139
|
|
G |
PLOD3 |
procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PLOD3 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 7:101,205,984...101,217,581
Ensembl chr 7:101,205,977...101,218,420
|
|
G |
PLXND1 |
plexin D1 |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of PLXND1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 3:129,555,214...129,606,676
Ensembl chr 3:129,555,214...129,606,676
|
|
G |
PMAIP1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
affects localization increases expression multiple interactions |
EXP |
Simvastatin affects the localization of PMAIP1 protein Simvastatin results in increased expression of PMAIP1 mRNA; Simvastatin results in increased expression of PMAIP1 protein pifithrin inhibits the reaction [Simvastatin results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:20045437 |
|
NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305
|
|
G |
PMVK |
phosphomevalonate kinase |
increases expression |
ISO |
Simvastatin results in increased expression of PMVK mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:154,924,740...154,942,658
Ensembl chr 1:154,924,740...154,936,719
|
|
G |
POMT1 |
protein O-mannosyltransferase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of POMT1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 9:131,502,918...131,523,799
Ensembl chr 9:131,502,789...131,523,806
|
|
G |
PON1 |
paraoxonase 1 |
multiple interactions increases expression |
EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; PON1 gene polymorphism affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]; Simvastatin results in increased expression of and results in increased activity of PON1 protein; Squalene inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA] |
CTD |
PMID:14500290 PMID:15690306 PMID:16238680 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of PPARA mRNA Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA protein]; Simvastatin promotes the reaction [Zymosan results in increased expression of PPARA] PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA] |
CTD |
PMID:15234187 PMID:18981156 PMID:19001041 PMID:20835264 PMID:21323892 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression |
EXP ISO |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein] Simvastatin results in decreased expression of PPARG Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG protein] |
CTD |
PMID:15781755 PMID:19216230 PMID:20835264 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPP1R12A |
protein phosphatase 1 regulatory subunit 12A |
multiple interactions |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:24449418 |
|
NCBI chr12:79,773,563...79,935,460
Ensembl chr12:79,773,563...79,935,460
|
|
G |
PPP1R14A |
protein phosphatase 1 regulatory inhibitor subunit 14A |
multiple interactions |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein] |
CTD |
PMID:24449418 |
|
NCBI chr19:38,251,237...38,256,374
Ensembl chr19:38,251,237...38,256,532
|
|
G |
PRIM1 |
DNA primase subunit 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of PRIM1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr12:56,731,580...56,752,323
Ensembl chr12:56,730,438...56,752,374
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases expression |
ISO |
Simvastatin results in increased expression of PRKAA1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PSEN1 |
presenilin 1 |
increases expression |
ISO |
Simvastatin results in increased expression of PSEN1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr14:73,136,417...73,223,691
Ensembl chr14:73,136,418...73,223,691
|
|
G |
PTAFR |
platelet activating factor receptor |
decreases expression |
ISO |
Simvastatin results in decreased expression of PTAFR mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:28,147,166...28,193,856
Ensembl chr 1:28,147,166...28,193,936
|
|
G |
PTEN |
phosphatase and tensin homolog |
increases expression |
ISO |
Simvastatin results in increased expression of PTEN mRNA; Simvastatin results in increased expression of PTEN protein |
CTD |
PMID:20060890 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGES |
prostaglandin E synthase |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES protein] Simvastatin results in decreased expression of PTGES protein |
CTD |
PMID:17038636 |
|
NCBI chr 9:129,738,349...129,753,042
Ensembl chr 9:129,738,331...129,753,042
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
EXP ISO |
JTE 013 inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]] Simvastatin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] Simvastatin results in decreased expression of PTGS2 protein Simvastatin results in increased expression of PTGS2 mRNA Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] |
CTD |
PMID:17038636 PMID:17277159 PMID:17901590 PMID:18612546 PMID:19225232 PMID:19886038 PMID:20659230 PMID:21910007 PMID:30408459 More...
|
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTK2 |
protein tyrosine kinase 2 |
decreases activity |
EXP |
Simvastatin results in decreased activity of PTK2 protein |
CTD |
PMID:17428261 |
|
NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
|
|
G |
PXN |
paxillin |
multiple interactions decreases phosphorylation affects localization |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein] Simvastatin results in decreased phosphorylation of PXN protein Simvastatin affects the localization of PXN protein |
CTD |
PMID:22306966 |
|
NCBI chr12:120,210,447...120,265,730
Ensembl chr12:120,210,439...120,265,771
|
|
G |
RAC1 |
Rac family small GTPase 1 |
multiple interactions decreases activity increases activity decreases expression increases expression affects localization |
EXP ISO |
Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; Simvastatin affects the localization of and results in decreased activity of RAC1 protein; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of RAC1 protein] Simvastatin results in decreased activity of RAC1 protein Simvastatin results in increased activity of RAC1 protein Simvastatin results in decreased expression of RAC1 Simvastatin results in increased expression of RAC1 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of RAC1 protein] Simvastatin affects the localization of RAC1 protein |
CTD |
PMID:16698853 PMID:17169357 PMID:17303772 PMID:17513949 PMID:18625914 PMID:19332549 PMID:19360310 PMID:20045437 PMID:21334995 More...
|
|
NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
|
|
G |
RAC2 |
Rac family small GTPase 2 |
affects localization decreases activity |
EXP ISO |
Simvastatin affects the localization of RAC2 protein Simvastatin results in decreased activity of RAC2 protein |
CTD |
PMID:17169357 PMID:20045437 |
|
NCBI chr22:37,225,270...37,244,269
Ensembl chr22:37,225,270...37,259,594
|
|
G |
RAC3 |
Rac family small GTPase 3 |
affects localization |
EXP |
Simvastatin affects the localization of RAC3 protein |
CTD |
PMID:20045437 |
|
NCBI chr17:82,031,678...82,034,204
Ensembl chr17:82,031,678...82,034,204
|
|
G |
RACGAP1 |
Rac GTPase activating protein 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr12:49,989,162...50,033,440
Ensembl chr12:49,976,923...50,033,136
|
|
G |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases activity multiple interactions |
EXP ISO |
Simvastatin results in decreased activity of RAF1 protein Simvastatin inhibits the reaction [Streptozocin results in increased expression of RAF1 protein] |
CTD |
PMID:18569938 PMID:19360310 |
|
NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201
|
|
G |
RAP1A |
RAP1A, member of RAS oncogene family |
decreases prenylation decreases expression decreases geranoylation multiple interactions |
EXP ISO |
Simvastatin results in decreased prenylation of RAP1A protein Simvastatin results in decreased expression of RAP1A protein alternative form Simvastatin results in decreased geranoylation of RAP1A protein Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of RAP1A protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein |
CTD |
PMID:20018177 PMID:22120639 PMID:25578243 PMID:37956312 |
|
NCBI chr 1:111,542,009...111,716,691
Ensembl chr 1:111,542,218...111,716,691
|
|
G |
RASGRF1 |
Ras protein specific guanine nucleotide releasing factor 1 |
affects localization affects phosphorylation |
ISO |
Simvastatin affects the localization of RASGRF1 protein Simvastatin affects the phosphorylation of RASGRF1 protein |
CTD |
PMID:20417880 |
|
NCBI chr15:78,959,906...79,090,780
Ensembl chr15:78,959,906...79,090,780
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
EXP ISO |
Simvastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:17928568 PMID:18804536 |
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression decreases localization increases localization |
EXP ISO |
artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of RELA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of RELA protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of RELA protein]; Simvastatin results in increased localization of and results in increased activity of RELA protein Simvastatin results in decreased expression of RELA protein Simvastatin results in decreased expression of RELA mRNA; Simvastatin results in decreased expression of RELA protein Simvastatin results in decreased localization of RELA protein [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Homocysteine inhibits the reaction [Simvastatin results in decreased expression of RELA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of RELA protein] |
CTD |
PMID:12753293 PMID:15705589 PMID:16414398 PMID:17038636 PMID:17075836 PMID:17277159 PMID:17507688 PMID:18073186 PMID:18463201 PMID:18540024 PMID:18791746 PMID:19299917 PMID:21465237 PMID:21764683 PMID:21910007 PMID:21925249 More...
|
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
RET |
ret proto-oncogene |
multiple interactions |
EXP |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of RET mRNA |
CTD |
PMID:28263720 |
|
NCBI chr10:43,077,069...43,130,351
Ensembl chr10:43,077,064...43,130,351
|
|
G |
RETN |
resistin |
multiple interactions |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein] |
CTD |
PMID:18023360 |
|
NCBI chr19:7,669,049...7,670,455
Ensembl chr19:7,669,049...7,670,455
|
|
G |
RFC5 |
replication factor C subunit 5 |
decreases expression |
EXP |
Simvastatin results in decreased expression of RFC5 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr12:118,016,703...118,041,448
Ensembl chr12:118,013,588...118,033,130
|
|
G |
RGS2 |
regulator of G protein signaling 2 |
increases expression |
EXP |
Simvastatin results in increased expression of RGS2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:192,809,039...192,812,275
Ensembl chr 1:192,809,039...192,812,275
|
|
G |
RHOA |
ras homolog family member A |
multiple interactions decreases prenylation affects localization increases expression increases localization decreases expression decreases activity |
EXP ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin affects the localization of and results in decreased activity of RHOA protein; Simvastatin inhibits the reaction [geranylgeranyl pyrophosphate affects the localization of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin results in decreased localization of and results in decreased activity of RHOA protein; Simvastatin results in increased localization of and results in decreased prenylation of RHOA protein Simvastatin results in decreased prenylation of RHOA protein Simvastatin affects the localization of RHOA protein Simvastatin results in increased expression of RHOA protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein] Simvastatin results in increased expression of RHOA mRNA Simvastatin results in decreased expression of RHOA; Simvastatin results in decreased expression of RHOA protein geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of RHOA]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RHOA protein |
CTD |
PMID:12477733 PMID:14630613 PMID:15200425 PMID:16005304 PMID:16470222 PMID:16698853 PMID:16740276 PMID:17075836 PMID:17560598 PMID:18031796 PMID:18310456 PMID:18463201 PMID:18625202 PMID:18625914 PMID:18981156 PMID:19024099 PMID:19659652 PMID:20045437 PMID:21124329 PMID:21257924 PMID:24449418 More...
|
|
NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,139...49,412,998
|
|
G |
RHOC |
ras homolog family member C |
increases expression |
EXP |
Simvastatin results in increased expression of RHOC mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 1:112,701,131...112,707,408
Ensembl chr 1:112,701,127...112,707,434
|
|
G |
RIPK1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; [Simvastatin co-treated with Metformin] results in increased expression of RIPK1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]] |
CTD |
PMID:25412314 |
|
NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187
|
|
G |
RIPK3 |
receptor interacting serine/threonine kinase 3 |
multiple interactions |
EXP |
[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]] |
CTD |
PMID:25412314 |
|
NCBI chr14:24,336,025...24,339,991
Ensembl chr14:24,336,025...24,340,022
|
|
G |
RORC |
RAR related orphan receptor C |
multiple interactions decreases expression |
EXP |
IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RORC mRNA] |
CTD |
PMID:18453621 |
|
NCBI chr 1:151,806,071...151,831,802
Ensembl chr 1:151,806,071...151,831,845
|
|
G |
RPL39 |
ribosomal protein L39 |
increases expression |
ISO |
Simvastatin results in increased expression of RPL39 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr X:119,786,504...119,791,630
Ensembl chr X:119,786,504...119,791,630
|
|
G |
RPS10 |
ribosomal protein S10 |
increases expression |
ISO |
Simvastatin results in increased expression of RPS10 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 6:34,417,454...34,426,069
Ensembl chr 6:34,417,454...34,426,069
|
|
G |
RPS6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO |
Simvastatin results in decreased phosphorylation of RPS6KB1 protein FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:27734117 PMID:33034787 |
|
NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of RUNX2 Simvastatin results in increased expression of RUNX2 mRNA DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] |
CTD |
PMID:18310456 PMID:20381859 PMID:20417880 PMID:22058016 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
RYR2 |
ryanodine receptor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of RYR2 mRNA; Simvastatin results in increased expression of RYR2 protein |
CTD |
PMID:15916736 |
|
NCBI chr 1:237,042,184...237,833,988
Ensembl chr 1:237,042,184...237,833,988
|
|
G |
S100A6 |
S100 calcium binding protein A6 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of S100A6 mRNA Simvastatin results in increased expression of S100A6 mRNA; Simvastatin results in increased expression of S100A6 protein Simvastatin results in increased expression of and results in increased localization of S100A6 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr 1:153,534,599...153,535,991
Ensembl chr 1:153,534,599...153,536,244
|
|
G |
S100A8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
Simvastatin results in increased expression of S100A8 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
Simvastatin results in increased expression of S100A9 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
S1PR1 |
sphingosine-1-phosphate receptor 1 |
increases expression |
EXP |
Simvastatin results in increased expression of S1PR1 mRNA |
CTD |
PMID:18612546 |
|
NCBI chr 1:101,236,899...101,242,313
Ensembl chr 1:101,236,865...101,243,713
|
|
G |
S1PR3 |
sphingosine-1-phosphate receptor 3 |
increases expression decreases expression |
EXP |
Simvastatin results in increased expression of S1PR3 mRNA Simvastatin results in decreased expression of S1PR3 mRNA |
CTD |
PMID:18612546 PMID:18981156 |
|
NCBI chr 9:88,990,863...89,005,155
Ensembl chr 9:88,990,863...89,005,155
|
|
G |
SCAP |
SREBF chaperone |
affects response to substance |
EXP |
SCAP polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:16158080 |
|
NCBI chr 3:47,413,681...47,477,127
Ensembl chr 3:47,413,681...47,477,126
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
multiple interactions increases expression |
EXP ISO |
PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1] [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SCARB1 mRNA; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein] Simvastatin results in increased expression of SCARB1; Simvastatin results in increased expression of SCARB1 mRNA; Simvastatin results in increased expression of SCARB1 protein |
CTD |
PMID:18981156 PMID:20025956 PMID:21241519 PMID:25055962 PMID:33383043 |
|
NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
|
|
G |
SDC1 |
syndecan 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SDC1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:20,200,797...20,225,475
Ensembl chr 2:20,200,797...20,225,433
|
|
G |
SDC4 |
syndecan 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SDC4 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr20:45,325,288...45,348,424
Ensembl chr20:45,325,288...45,348,424
|
|
G |
SELE |
selectin E |
multiple interactions affects expression decreases expression |
EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of SELE protein modified form] Simvastatin affects the expression of SELE protein |
CTD |
PMID:10946302 PMID:14602771 PMID:16740276 PMID:21994025 |
|
NCBI chr 1:169,722,640...169,734,079
Ensembl chr 1:169,722,640...169,764,705
|
|
G |
SELP |
selectin P |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [staphylococcal alpha-toxin results in increased expression of SELP protein] Simvastatin results in decreased expression of SELP mRNA |
CTD |
PMID:12379581 PMID:16414398 |
|
NCBI chr 1:169,588,849...169,630,124
Ensembl chr 1:169,588,849...169,630,193
|
|
G |
SERPINE1 |
serpin family E member 1 |
decreases expression decreases secretion decreases activity multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of SERPINE1 mRNA; Simvastatin results in decreased expression of SERPINE1 protein Simvastatin results in decreased secretion of SERPINE1 protein Simvastatin results in decreased activity of SERPINE1 protein [Simvastatin co-treated with Dexamethasone] results in increased secretion of SERPINE1 protein |
CTD |
PMID:16375908 PMID:16414398 PMID:17513194 PMID:21524281 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SESN2 |
sestrin 2 |
increases expression |
ISO |
Simvastatin results in increased expression of SESN2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491
|
|
G |
SESN3 |
sestrin 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SESN3 mRNA |
CTD |
PMID:20883752 |
|
NCBI chr11:95,165,513...95,232,475
Ensembl chr11:95,165,513...95,232,541
|
|
G |
SGK2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
EXP |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter] |
CTD |
PMID:24204015 |
|
NCBI chr20:43,559,027...43,585,627
Ensembl chr20:43,558,968...43,588,237
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC38A4 |
solute carrier family 38 member 4 |
increases expression |
ISO |
Simvastatin results in increased expression of SLC38A4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr12:46,764,761...46,832,431
Ensembl chr12:46,764,761...46,832,408
|
|
G |
SLC6A4 |
solute carrier family 6 member 4 |
increases activity |
EXP |
Simvastatin results in increased activity of SLC6A4 protein |
CTD |
PMID:15740995 |
|
NCBI chr17:30,194,319...30,235,697
Ensembl chr17:30,194,319...30,236,002
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions increases response to substance affects response to substance decreases activity |
EXP |
[SLCO1B1 SNP results in increased abundance of Lithocholic Acid] which results in increased susceptibility to Simvastatin; [SLCO1B1 SNP results in increased abundance of Taurolithocholic Acid] which results in increased susceptibility to Simvastatin; Simvastatin inhibits the reaction [SLCO1B1 protein results in increased transport of estradiol-17 beta-glucuronide] SLCO1B1 gene SNP results in increased susceptibility to Simvastatin SLCO1B1 affects the susceptibility to Simvastatin; SLCO1B1 mutant form affects the susceptibility to Simvastatin; SLCO1B1 polymorphism affects the susceptibility to Simvastatin analog Simvastatin results in decreased activity of SLCO1B1 protein |
CTD |
PMID:15616150 PMID:17108811 PMID:18650507 PMID:19833260 PMID:21243006 PMID:22022402 PMID:31173123 More...
|
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SMAD1 |
SMAD family member 1 |
multiple interactions increases phosphorylation increases expression |
ISO |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]] Simvastatin results in increased phosphorylation of SMAD1 protein Simvastatin results in increased expression of SMAD1 mRNA |
CTD |
PMID:18310456 PMID:20417880 |
|
NCBI chr 4:145,480,770...145,559,176
Ensembl chr 4:145,481,194...145,559,176
|
|
G |
SMAD2 |
SMAD family member 2 |
decreases phosphorylation increases phosphorylation multiple interactions increases expression |
ISO |
Simvastatin results in decreased phosphorylation of SMAD2 protein Simvastatin results in increased phosphorylation of SMAD2 protein FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein] Simvastatin results in increased expression of SMAD2 mRNA |
CTD |
PMID:18310456 PMID:19659652 PMID:33034787 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SMAD3 |
SMAD family member 3 |
increases expression multiple interactions increases phosphorylation decreases phosphorylation |
ISO |
Simvastatin results in increased expression of SMAD3 mRNA FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein] Simvastatin results in decreased phosphorylation of SMAD3 protein |
CTD |
PMID:18310456 PMID:19659652 PMID:33034787 |
|
NCBI chr15:67,065,602...67,195,169
Ensembl chr15:67,063,763...67,195,173
|
|
G |
SMAD5 |
SMAD family member 5 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]] |
CTD |
PMID:18310456 |
|
NCBI chr 5:136,132,845...136,182,733
Ensembl chr 5:136,132,845...136,188,747
|
|
G |
SMAD9 |
SMAD family member 9 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]] |
CTD |
PMID:18310456 |
|
NCBI chr13:36,844,831...36,920,854
Ensembl chr13:36,844,831...36,920,887
|
|
G |
SNX17 |
sorting nexin 17 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of SNX17 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SNX17 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 2:27,370,616...27,377,535
Ensembl chr 2:27,370,496...27,377,535
|
|
G |
SOAT1 |
sterol O-acyltransferase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of SOAT1 mRNA |
CTD |
PMID:12056585 |
|
NCBI chr 1:179,293,797...179,358,680
Ensembl chr 1:179,293,714...179,358,680
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
Simvastatin results in increased expression of SOCS3 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077
|
|
G |
SOCS4 |
suppressor of cytokine signaling 4 |
increases expression |
ISO |
Simvastatin results in increased expression of SOCS4 mRNA; Simvastatin results in increased expression of SOCS4 protein |
CTD |
PMID:19262002 |
|
NCBI chr14:55,027,236...55,049,489
Ensembl chr14:55,027,230...55,049,489
|
|
G |
SOCS7 |
suppressor of cytokine signaling 7 |
increases expression |
EXP |
Simvastatin results in increased expression of SOCS7 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr17:38,351,844...38,405,593
Ensembl chr17:38,351,844...38,405,593
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SOD2 mRNA |
CTD |
PMID:16414398 PMID:20883752 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOD3 |
superoxide dismutase 3 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr 4:24,795,573...24,800,842
Ensembl chr 4:24,789,912...24,800,842
|
|
G |
SP1 |
Sp1 transcription factor |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr12:53,380,176...53,416,446
Ensembl chr12:53,380,176...53,416,446
|
|
G |
SP7 |
Sp7 transcription factor |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] Simvastatin results in increased expression of SP7; Simvastatin results in increased expression of SP7 mRNA; Simvastatin results in increased expression of SP7 protein |
CTD |
PMID:20564244 PMID:22058016 |
|
NCBI chr12:53,326,575...53,344,793
Ensembl chr12:53,326,575...53,345,315
|
|
G |
SPON2 |
spondin 2 |
increases expression |
EXP |
Simvastatin results in increased expression of SPON2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:1,166,932...1,208,844
Ensembl chr 4:1,166,932...1,208,962
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
decreases expression increases expression |
EXP ISO |
Simvastatin results in decreased expression of SPP1 mRNA Simvastatin results in increased expression of SPP1 protein |
CTD |
PMID:12914771 PMID:14601315 PMID:21076490 PMID:21109955 PMID:22058016 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:25412314 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
increases localization decreases expression |
EXP ISO |
Simvastatin results in increased localization of SREBF1 protein Simvastatin results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17655842 PMID:25055962 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter] Simvastatin results in increased expression of SREBF2 mRNA Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of SREBF2 mRNA]; Simvastatin results in increased activity of and results in increased localization of SREBF2 protein Simvastatin results in increased expression of SREBF2 protein modified form |
CTD |
PMID:12056585 PMID:14500290 PMID:20018177 |
|
NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306
|
|
G |
STAR |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of STAR mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions decreases activity decreases expression decreases phosphorylation |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT1 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA] Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein] Simvastatin results in decreased activity of STAT1 protein Simvastatin results in decreased expression of STAT1 mRNA; Simvastatin results in decreased expression of STAT1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:16534557 PMID:17507688 PMID:18453621 PMID:19886038 PMID:21268089 |
|
NCBI chr 2:190,969,149...191,014,171
Ensembl chr 2:190,908,460...191,020,960
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
decreases activity decreases phosphorylation multiple interactions affects expression |
EXP ISO |
Simvastatin results in decreased activity of STAT3 protein Simvastatin results in decreased phosphorylation of STAT3 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of STAT3 protein] Simvastatin affects the expression of STAT3 protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:17507688 PMID:18400235 PMID:18453621 PMID:19100119 PMID:19886038 PMID:20821229 PMID:21910007 More...
|
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
STAT5A |
signal transducer and activator of transcription 5A |
affects expression |
ISO |
Simvastatin affects the expression of STAT5A protein |
CTD |
PMID:17507688 |
|
NCBI chr17:42,287,439...42,311,943
Ensembl chr17:42,287,547...42,311,943
|
|
G |
STAT6 |
signal transducer and activator of transcription 6 |
affects expression |
ISO |
Simvastatin affects the expression of STAT6 protein |
CTD |
PMID:17507688 |
|
NCBI chr12:57,095,408...57,111,362
Ensembl chr12:57,095,408...57,132,139
|
|
G |
STK11 |
serine/threonine kinase 11 |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of STK11 protein |
CTD |
PMID:19332549 |
|
NCBI chr19:1,205,778...1,228,431
Ensembl chr19:1,177,558...1,228,431
|
|
G |
TAB1 |
TGF-beta activated kinase 1 (MAP3K7) binding protein 1 |
multiple interactions |
EXP |
Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein] |
CTD |
PMID:17277159 |
|
NCBI chr22:39,399,780...39,437,132
Ensembl chr22:39,399,778...39,437,060
|
|
G |
TANK |
TRAF family member associated NFKB activator |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of TANK mRNA |
CTD |
PMID:15665042 |
|
NCBI chr 2:161,136,963...161,236,230
Ensembl chr 2:161,136,908...161,236,230
|
|
G |
TBXAS1 |
thromboxane A synthase 1 |
decreases expression increases expression |
ISO |
Simvastatin results in decreased expression of TBXAS1 mRNA Simvastatin results in increased expression of TBXAS1 mRNA |
CTD |
PMID:16414398 PMID:20659230 |
|
NCBI chr 7:139,778,242...140,020,293
Ensembl chr 7:139,777,051...140,020,325
|
|
G |
TEK |
TEK receptor tyrosine kinase |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of TEK mRNA]; Simvastatin results in increased expression of and results in increased activity of TEK protein Simvastatin results in increased expression of TEK; Simvastatin results in increased expression of TEK mRNA |
CTD |
PMID:18544044 PMID:20821229 |
|
NCBI chr 9:27,109,141...27,230,178
Ensembl chr 9:27,109,141...27,230,174
|
|
G |
TF |
transferrin |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [TNF results in increased expression of TF] |
CTD |
PMID:12753293 |
|
NCBI chr 3:133,661,998...133,796,641
Ensembl chr 3:133,746,040...133,796,641
|
|
G |
TFRC |
transferrin receptor |
affects expression |
EXP |
Simvastatin affects the expression of TFRC protein |
CTD |
PMID:16387846 |
|
NCBI chr 3:196,049,284...196,082,090
Ensembl chr 3:196,012,511...196,082,153
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions decreases expression increases activity increases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin results in decreased expression of TGFB1 mRNA; Simvastatin results in decreased expression of TGFB1 protein Simvastatin results in increased activity of TGFB1 protein Simvastatin results in increased expression of TGFB1 mRNA Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein] |
CTD |
PMID:15298857 PMID:15677772 PMID:15855201 PMID:16320597 PMID:19080365 PMID:19262002 PMID:19659652 PMID:20024970 PMID:20687301 PMID:21844074 More...
|
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFBR2 |
transforming growth factor beta receptor 2 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TGFBR2 mRNA] Simvastatin results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:16320597 PMID:16373842 |
|
NCBI chr 3:30,606,356...30,694,142
Ensembl chr 3:30,606,601...30,694,142
|
|
G |
THBD |
thrombomodulin |
increases expression multiple interactions |
EXP |
Simvastatin results in increased expression of THBD mRNA; Simvastatin results in increased expression of THBD protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of THBD mRNA] |
CTD |
PMID:14630613 PMID:16375908 PMID:20493886 PMID:20737288 |
|
NCBI chr20:23,045,633...23,049,672
Ensembl chr20:23,045,633...23,049,672
|
|
G |
THBS1 |
thrombospondin 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of THBS1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:39,581,079...39,599,466
Ensembl chr15:39,581,079...39,599,466
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions decreases expression |
ISO |
Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16414398 PMID:20137537 PMID:22022327 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TIMP2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions decreases expression |
ISO |
Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP2 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:20137537 |
|
NCBI chr17:78,852,977...78,925,387
Ensembl chr17:78,852,977...78,925,387
|
|
G |
TLR2 |
toll like receptor 2 |
increases expression multiple interactions |
EXP |
Simvastatin results in increased expression of TLR2 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 protein] |
CTD |
PMID:16387846 PMID:16443229 |
|
NCBI chr 4:153,684,280...153,710,637
Ensembl chr 4:153,684,070...153,706,260
|
|
G |
TLR4 |
toll like receptor 4 |
increases expression multiple interactions decreases expression |
EXP ISO |
Simvastatin results in increased expression of TLR4 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein] Simvastatin results in decreased expression of TLR4 mRNA; Simvastatin results in decreased expression of TLR4 protein |
CTD |
PMID:16387846 PMID:16443229 PMID:19166837 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TM7SF2 |
transmembrane 7 superfamily member 2 |
increases expression |
ISO |
Simvastatin results in increased expression of TM7SF2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr11:65,111,872...65,116,230
Ensembl chr11:65,111,845...65,116,384
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Simvastatin results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNC |
tenascin C |
decreases expression |
ISO |
Simvastatin results in decreased expression of TNC mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:115,019,575...115,118,157
Ensembl chr 9:115,019,575...115,118,207
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions affects secretion decreases secretion decreases expression increases expression increases secretion decreases activity |
EXP ISO |
geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of TF]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA] Simvastatin affects the secretion of TNF protein Simvastatin results in decreased secretion of TNF protein Simvastatin results in decreased expression of TNF mRNA; Simvastatin results in decreased expression of TNF protein Simvastatin results in increased expression of TNF mRNA Simvastatin results in increased secretion of TNF protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Simvastatin results in decreased activity of TNF; Simvastatin results in decreased activity of TNF protein 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA] |
CTD |
PMID:10946302 PMID:12117737 PMID:12615677 PMID:12753293 PMID:12829860 PMID:12963647 PMID:15187114 PMID:15234187 PMID:15537504 PMID:15705589 PMID:15883752 PMID:16321392 PMID:16387846 PMID:16443229 PMID:16511915 PMID:16740276 PMID:17075836 PMID:17169357 PMID:17178392 PMID:17277159 PMID:17560598 PMID:17729120 PMID:17901590 PMID:18047562 PMID:18310456 PMID:18504409 PMID:19001041 PMID:19024099 PMID:19080365 PMID:19166837 PMID:20126887 PMID:20191585 PMID:20359552 PMID:20863785 PMID:21910007 PMID:21925249 PMID:21994025 PMID:22305382 PMID:30408459 PMID:33774062 PMID:35762198 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF11B |
TNF receptor superfamily member 11b |
increases expression |
EXP |
Simvastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:21431270 |
|
NCBI chr 8:118,923,557...118,951,885
Ensembl chr 8:118,923,557...118,951,885
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of TNFRSF1A mRNA |
CTD |
PMID:18310456 |
|
NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114
|
|
G |
TNFRSF1B |
TNF receptor superfamily member 1B |
decreases expression |
ISO |
Simvastatin results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:18310456 |
|
NCBI chr 1:12,166,991...12,209,220
Ensembl chr 1:12,166,991...12,209,228
|
|
G |
TNFRSF4 |
TNF receptor superfamily member 4 |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein] Simvastatin results in decreased expression of TNFRSF4 mRNA; Simvastatin results in decreased expression of TNFRSF4 protein |
CTD |
PMID:19589242 |
|
NCBI chr 1:1,211,340...1,214,153
Ensembl chr 1:1,211,326...1,214,153
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
multiple interactions increases response to substance |
EXP |
[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein] TNFSF10 protein results in increased susceptibility to Simvastatin |
CTD |
PMID:21910007 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TNFSF4 |
TNF superfamily member 4 |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein] Simvastatin results in decreased expression of TNFSF4 mRNA; Simvastatin results in decreased expression of TNFSF4 protein |
CTD |
PMID:19589242 |
|
NCBI chr 1:173,172,870...173,450,733
Ensembl chr 1:173,183,731...173,207,331
|
|
G |
TNNI3 |
troponin I3, cardiac type |
multiple interactions |
ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein] |
CTD |
PMID:35762198 |
|
NCBI chr19:55,151,767...55,157,732
Ensembl chr19:55,151,767...55,157,773
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions increases expression increases phosphorylation |
EXP ISO |
pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein]; Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]; Simvastatin results in increased expression of and results in increased phosphorylation of TP53 protein Simvastatin results in increased expression of TP53 mRNA; Simvastatin results in increased expression of TP53 mutant form; Simvastatin results in increased expression of TP53 protein Simvastatin results in increased phosphorylation of TP53 protein |
CTD |
PMID:15625077 PMID:18804536 PMID:20045437 PMID:21199873 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
|
|
G |
TPT1 |
tumor protein, translationally-controlled 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of TPT1 protein |
CTD |
PMID:20217863 |
|
NCBI chr13:45,333,471...45,341,183
Ensembl chr13:45,333,471...45,341,284
|
|
G |
TRA |
T cell receptor alpha locus |
decreases expression |
EXP |
Simvastatin results in decreased expression of TRA mRNA |
CTD |
PMID:18192897 |
|
NCBI chr14:21,621,904...22,552,132
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
decreases expression |
EXP |
Simvastatin results in decreased expression of TRADD mRNA |
CTD |
PMID:17277159 |
|
NCBI chr16:67,154,185...67,159,909
Ensembl chr16:67,154,185...67,159,909
|
|
G |
TRAF2 |
TNF receptor associated factor 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of TRAF2 mRNA |
CTD |
PMID:17277159 |
|
NCBI chr 9:136,881,958...136,926,607
Ensembl chr 9:136,881,912...136,926,607
|
|
G |
TRIM63 |
tripartite motif containing 63 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of TRIM63 mRNA FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA] Simvastatin results in increased expression of TRIM63 mRNA; Simvastatin results in increased expression of TRIM63 protein |
CTD |
PMID:19001041 PMID:27734117 PMID:33034787 |
|
NCBI chr 1:26,051,301...26,067,630
Ensembl chr 1:26,051,301...26,068,436
|
|
G |
TXNRD1 |
thioredoxin reductase 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
|
|
G |
TYMS |
thymidylate synthetase |
decreases expression |
EXP |
Simvastatin results in decreased expression of TYMS mRNA; Simvastatin results in decreased expression of TYMS protein |
CTD |
PMID:17428261 |
|
NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
|
|
G |
VASP |
vasodilator stimulated phosphoprotein |
decreases phosphorylation |
ISO |
Simvastatin results in decreased phosphorylation of VASP protein |
CTD |
PMID:19332549 |
|
NCBI chr19:45,507,479...45,526,983
Ensembl chr19:45,506,579...45,526,989
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of VCAM1 protein modified form] Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein; Simvastatin results in decreased expression of VCAM1 protein modified form |
CTD |
PMID:10946302 PMID:14602771 PMID:15234187 PMID:17105841 PMID:17169357 PMID:18269829 PMID:18309148 PMID:20863785 PMID:21874229 PMID:22245985 More...
|
|
NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
|
|
G |
VCL |
vinculin |
affects localization |
ISO |
Simvastatin affects the localization of VCL protein |
CTD |
PMID:22306966 |
|
NCBI chr10:73,998,116...74,121,363
Ensembl chr10:73,995,193...74,121,363
|
|
G |
VDAC1 |
voltage dependent anion channel 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of VDAC1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 5:133,971,871...134,114,540
Ensembl chr 5:133,971,871...134,004,975
|
|
G |
VDR |
vitamin D receptor |
increases expression |
ISO |
Simvastatin results in increased expression of VDR mRNA |
CTD |
PMID:19262002 |
|
NCBI chr12:47,841,537...47,904,994
Ensembl chr12:47,841,537...47,943,048
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions increases expression increases secretion decreases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein] Simvastatin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein] Simvastatin results in increased expression of VEGFA mRNA; Simvastatin results in increased expression of VEGFA protein Simvastatin results in increased secretion of VEGFA protein Simvastatin results in increased expression of VEGFA; Simvastatin results in increased expression of VEGFA mRNA Simvastatin results in decreased expression of VEGFA protein |
CTD |
PMID:15572054 PMID:16424782 PMID:17277159 PMID:18316203 PMID:18356691 PMID:18569938 PMID:20381859 PMID:20687301 PMID:20821229 PMID:21211366 More...
|
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VIM |
vimentin |
decreases expression |
ISO |
Simvastatin results in decreased expression of VIM protein |
CTD |
PMID:14973129 PMID:15855201 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
G |
VWF |
von Willebrand factor |
increases expression |
ISO |
Simvastatin results in increased expression of VWF mRNA; Simvastatin results in increased expression of VWF protein |
CTD |
PMID:19109527 |
|
NCBI chr12:5,948,877...6,124,670
Ensembl chr12:5,948,877...6,124,770
|
|
G |
WNT4 |
Wnt family member 4 |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT4 mRNA] Simvastatin results in increased expression of WNT4 protein |
CTD |
PMID:18004065 |
|
NCBI chr 1:22,117,313...22,143,097
Ensembl chr 1:22,117,313...22,143,969
|
|
G |
WNT5A |
Wnt family member 5A |
multiple interactions increases expression |
ISO |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA] Simvastatin results in increased expression of WNT5A mRNA; Simvastatin results in increased expression of WNT5A protein |
CTD |
PMID:18004065 PMID:19968183 |
|
NCBI chr 3:55,465,715...55,505,263
Ensembl chr 3:55,465,715...55,490,539
|
|
G |
XBP1 |
X-box binding protein 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of XBP1 protein |
CTD |
PMID:18807172 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
G |
XIAP |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
Simvastatin results in decreased expression of XIAP mRNA; Simvastatin results in decreased expression of XIAP protein |
CTD |
PMID:19262002 |
|
NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972
|
|
G |
ZNF700 |
zinc finger protein 700 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL5 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr19:11,925,107...11,950,763
Ensembl chr19:11,925,068...11,950,773
|
|
|
G |
ABCA8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr17:68,867,289...68,955,392
Ensembl chr17:68,867,289...68,955,392
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions decreases expression decreases activity increases activity increases transport affects response to substance increases expression |
EXP ISO |
[Endosulfan co-treated with Verapamil] inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]; [Endosulfan co-treated with Verapamil] results in decreased activity of ABCB1 protein; [phosalone co-treated with Verapamil] inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]; [phosalone co-treated with Verapamil] results in decreased activity of ABCB1 protein; [Verapamil binds to and results in decreased activity of ABCB1 protein] inhibits the reaction [sodium arsenite promotes the reaction [ABCB1 protein results in increased secretion of calcein AM]]; [Verapamil binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Verapamil binds to and results in decreased activity of ABCB1 protein] which results in decreased transport of N-cyano-1-((3,4-dimethoxyphenyl)methyl)-3,4-dihydro-6,7-dimethoxy-N'-octyl-2(1H)-isoquinoline-carboximidamide; [Verapamil co-treated with kaempferol] results in decreased expression of ABCB1 mRNA; [Verapamil co-treated with kaempferol] results in decreased expression of ABCB1 protein; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased export of calcein AM; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased export of Topotecan; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylhypaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of benzoylmesaconine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of Digoxin; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of hypaconitine; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of mesaconitine; [Verapamil results in decreased activity of ABCB1 protein] which results in increased susceptibility to Doxorubicin; [Verapamil results in decreased activity of ABCB1 protein] which results in increased susceptibility to Paclitaxel; [Verapamil results in decreased activity of ABCB1 protein] which results in increased uptake of fluorexon; Colchicine inhibits the reaction [Verapamil analog results in increased activity of ABCB1 protein mutant form]; Cyclosporine inhibits the reaction [Verapamil analog results in increased activity of ABCB1 protein mutant form]; Demecolcine inhibits the reaction [Verapamil analog results in increased activity of ABCB1 protein mutant form]; Diazinon promotes the reaction [Verapamil inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; Diazinon promotes the reaction [Verapamil results in decreased activity of ABCB1 protein]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein]; propiconazole promotes the reaction [Verapamil inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; propiconazole promotes the reaction [Verapamil results in decreased activity of ABCB1 protein]; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus]; Verapamil binds to and affects the activity of ABCB1 protein; Verapamil binds to and results in decreased activity of ABCB1 protein; Verapamil inhibits the reaction [5-Methoxypsoralen results in decreased activity of ABCB1 protein]; Verapamil inhibits the reaction [[5-Methoxypsoralen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [[Methoxsalen results in decreased activity of ABCB1 protein] which results in decreased export of and results in increased abundance of Daunorubicin]; Verapamil inhibits the reaction [ABCB1 protein affects the uptake of Vinblastine]; Verapamil inhibits the reaction [ABCB1 protein results in decreased abundance of Quercetin]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; Verapamil inhibits the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased export of calcein AM]; Verapamil inhibits the reaction [ABCB1 protein results in increased export of Doxorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased export of Fluorescent Dyes]; Verapamil inhibits the reaction [ABCB1 protein results in increased export of fluorexon]; Verapamil inhibits the reaction [ABCB1 protein results in increased export of Rhodamine 123]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of cyazofamid]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Doxorubicin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of huperzine A]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of N-cyano-1-((3,4-dimethoxyphenyl)methyl)-3,4-dihydro-6,7-dimethoxy-N'-octyl-2(1H)-isoquinoline-carboximidamide]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of quinidinium]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Sulpiride]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]; Verapamil inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Verapamil inhibits the reaction [Acetaminophen results in increased activity of ABCB1 protein]; Verapamil inhibits the reaction [Doxorubicin results in increased activity of ABCB1 protein]; Verapamil inhibits the reaction [Methoxsalen results in decreased activity of ABCB1 protein]; Verapamil inhibits the reaction [tangeretin results in increased activity of ABCB1 protein]; Verapamil inhibits the reaction [Verapamil analog results in increased activity of ABCB1 protein mutant form]; Verapamil promotes the reaction [ABCB1 protein mutant form binds to 8-azidoadenosine 5'-triphosphate]; Verapamil promotes the reaction [galangin results in increased activity of ABCB1 protein]; Verapamil promotes the reaction [kaempferol results in increased activity of ABCB1 protein]; Verapamil promotes the reaction [propiconazole inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]]; Verapamil promotes the reaction [propiconazole results in decreased activity of ABCB1 protein]; Verapamil promotes the reaction [Quercetin results in increased activity of ABCB1 protein]; Vinblastine inhibits the reaction [Verapamil analog results in increased activity of ABCB1 protein mutant form] Verapamil results in decreased expression of ABCB1A mRNA Verapamil results in decreased activity of ABCB1 protein; Verapamil results in decreased activity of ABCB1A protein [Verapamil results in decreased activity of ABCB1 protein] inhibits the reaction [P-glycoprotein inducer and activator TX5 results in increased export of Rhodamine 123]; Verapamil inhibits the reaction [ABCB1 results in decreased susceptibility to Cadmium Chloride] ABCB1 protein results in increased transport of Verapamil ABCB1A protein affects the susceptibility to Verapamil Verapamil results in decreased expression of ABCB1 protein Verapamil results in increased expression of ABCB1 mRNA Verapamil analog results in increased activity of ABCB1 protein mutant form; Verapamil results in increased activity of ABCB1 protein [Verapamil results in decreased expression of ABCB1] promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; [Verapamil results in decreased expression of ABCB1] promotes the reaction [Doxorubicin results in increased activity of CASP7 protein]; Verapamil promotes the reaction [Vanadates results in decreased activity of ABCB1A protein] |
CTD |
PMID:2900677 PMID:7083125 PMID:7476894 PMID:8917702 PMID:10527640 PMID:10571255 PMID:10636889 PMID:10997946 PMID:11027628 PMID:11836167 PMID:11895100 PMID:11920757 PMID:12202523 PMID:12387747 PMID:12670938 PMID:12708479 PMID:12711602 PMID:15112361 PMID:15276086 PMID:15451006 PMID:15502009 PMID:15627040 PMID:15640379 PMID:15725475 PMID:15861398 PMID:16033948 PMID:16049968 PMID:16121039 PMID:16442095 PMID:16904803 PMID:16930294 PMID:16959878 PMID:17134887 PMID:17526808 PMID:17947497 PMID:17973928 PMID:18204840 PMID:18408562 PMID:18673531 PMID:19070657 PMID:19505989 PMID:19528478 PMID:19944135 PMID:20457140 PMID:21783720 PMID:22079615 PMID:22233293 PMID:23200901 PMID:23273999 PMID:23976943 PMID:24321342 PMID:24380838 PMID:24446304 PMID:25058526 PMID:25268938 PMID:25625052 PMID:26995013 PMID:28587984 PMID:28597291 PMID:28669723 PMID:29079042 PMID:29174985 PMID:29625142 PMID:30102254 PMID:30391378 PMID:31348918 PMID:31756430 PMID:32003934 PMID:32497533 PMID:33321149 PMID:34217736 PMID:35063459 PMID:35550413 PMID:35753429 PMID:37259354 More...
|
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
decreases activity decreases expression |
ISO EXP |
Verapamil results in decreased activity of ABCB4 protein Verapamil results in decreased expression of ABCB4 mRNA |
CTD |
PMID:12202523 PMID:28437613 PMID:28552422 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 (ABCC1 blood group) |
affects activity multiple interactions decreases activity |
EXP ISO |
Verapamil affects the activity of ABCC1 protein Verapamil inhibits the reaction [ABCC1 protein affects the export of 5-carboxyfluorescein diacetate]; Verapamil inhibits the reaction [ABCC1 protein affects the export of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Verapamil inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]; Verapamil promotes the reaction [ABCC1 protein affects the export of Glutathione]; Verapamil promotes the reaction [ABCC1 protein affects the transport of Glutathione]; Verapamil promotes the reaction [ABCC1 protein results in increased uptake of Glutathione] Verapamil results in decreased activity of ABCC1 protein Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Daunorubicin]; Verapamil inhibits the reaction [ABCC1 protein results in decreased uptake of Etoposide] |
CTD |
PMID:7954421 PMID:9334814 PMID:10856430 PMID:11278867 PMID:12485947 PMID:15044619 PMID:15451006 PMID:15498506 PMID:16101123 PMID:16636798 More...
|
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [ABCC2 protein affects the export of 5-carboxyfluorescein diacetate] |
CTD |
PMID:16636798 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [ABCC3 protein affects the export of 5-carboxyfluorescein diacetate] |
CTD |
PMID:16636798 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCC6 |
ATP binding cassette subfamily C member 6 |
decreases activity |
EXP |
Verapamil results in decreased activity of ABCC6 protein |
CTD |
PMID:14667841 |
|
NCBI chr16:16,149,565...16,223,494
Ensembl chr16:16,149,565...16,223,522
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Verapamil inhibits the reaction [[Carbon Tetrachloride co-treated with lard co-treated with Ethanol] results in increased expression of ACTA2 protein] |
CTD |
PMID:17223571 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,935,074...88,991,339
|
|
G |
ADRA1A |
adrenoceptor alpha 1A |
multiple interactions affects binding |
EXP |
[Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Verapamil inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate] Verapamil binds to ADRA1A protein |
CTD |
PMID:9570190 |
|
NCBI chr 8:26,748,150...26,867,379
Ensembl chr 8:26,748,150...26,867,278
|
|
G |
ADRA1B |
adrenoceptor alpha 1B |
affects binding multiple interactions |
EXP |
Verapamil binds to ADRA1B protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Verapamil inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr 5:159,865,086...159,989,205
Ensembl chr 5:159,865,080...159,973,012
|
|
G |
ADRA1D |
adrenoceptor alpha 1D |
multiple interactions affects binding |
EXP |
[Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Verapamil inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate] Verapamil binds to ADRA1D protein |
CTD |
PMID:9570190 |
|
NCBI chr20:4,220,630...4,249,287
Ensembl chr20:4,220,630...4,249,287
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
affects response to substance |
EXP |
ADRB1 protein polymorphism affects the susceptibility to Verapamil |
CTD |
PMID:22192668 |
|
NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Thioacetamide results in decreased expression of AKT1 mRNA] |
CTD |
PMID:30526075 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
|
|
G |
AQP1 |
aquaporin 1 (Colton blood group) |
multiple interactions |
EXP |
Verapamil inhibits the reaction [cobaltous chloride results in increased expression of AQP1 protein] |
CTD |
PMID:22415096 |
|
NCBI chr 7:30,911,853...30,925,516
Ensembl chr 7:30,911,853...30,925,517
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
[Verapamil co-treated with Temozolomide] results in increased expression of BAX mRNA; Temozolomide promotes the reaction [Verapamil results in increased expression of BAX protein] |
CTD |
PMID:30003979 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression |
EXP |
[Temozolomide co-treated with Verapamil] results in decreased expression of BCL2 mRNA; [Temozolomide co-treated with Verapamil] results in decreased expression of BCL2 protein; [Verapamil co-treated with gambogic acid] results in decreased expression of BCL2 protein Verapamil results in decreased expression of BCL2 mRNA; Verapamil results in decreased expression of BCL2 protein |
CTD |
PMID:24373880 PMID:30003979 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
CACNA1C |
calcium voltage-gated channel subunit alpha1 C |
increases response to substance multiple interactions decreases expression |
EXP ISO |
CACNA1C gene polymorphism results in increased susceptibility to Verapamil Verapamil inhibits the reaction [Iron-Dextran Complex affects the expression of CACNA1C protein] Verapamil results in decreased expression of CACNA1C mRNA; Verapamil results in decreased expression of CACNA1C protein Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1C protein] |
CTD |
PMID:19791473 PMID:20031608 PMID:27095094 |
|
NCBI chr12:1,970,780...2,697,950
Ensembl chr12:1,970,772...2,697,950
|
|
G |
CACNA1F |
calcium voltage-gated channel subunit alpha1 F |
multiple interactions |
ISO |
Verapamil inhibits the reaction [CACNA1F protein results in increased transport of Barium] |
CTD |
PMID:14744918 |
|
NCBI chr X:49,205,063...49,233,340
Ensembl chr X:49,205,063...49,233,371
|
|
G |
CACNA1H |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Verapamil results in decreased expression of CACNA1H protein] Verapamil results in decreased expression of CACNA1H mRNA; Verapamil results in decreased expression of CACNA1H protein |
CTD |
PMID:19791473 |
|
NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169
|
|
G |
CALCA |
calcitonin related polypeptide alpha |
multiple interactions |
EXP |
Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein]; Verapamil inhibits the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA] |
CTD |
PMID:20682585 |
|
NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354
|
|
G |
CAMK2A |
calcium/calmodulin dependent protein kinase II alpha |
multiple interactions |
ISO |
Verapamil inhibits the reaction [LIF protein results in increased activity of CAMK2A protein]; Verapamil inhibits the reaction [LIF protein results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:11073891 |
|
NCBI chr 5:150,219,491...150,290,130
Ensembl chr 5:150,219,491...150,290,093
|
|
G |
CAMK4 |
calcium/calmodulin dependent protein kinase IV |
multiple interactions |
ISO |
Verapamil inhibits the reaction [LIF protein results in increased activity of CAMK4 protein] |
CTD |
PMID:11073891 |
|
NCBI chr 5:111,223,583...111,494,886
Ensembl chr 5:111,223,653...111,494,886
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] |
CTD |
PMID:28633109 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
multiple interactions |
EXP |
[Verapamil co-treated with Ruthenium Red co-treated with 2-aminoethoxydiphenyl borate] inhibits the reaction [Trichlorfon results in increased cleavage of and results in increased activity of CASP12 protein] |
CTD |
PMID:19631781 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases expression |
EXP ISO |
[Doxorubicin co-treated with Verapamil] results in increased activity of CASP3 protein; [Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP3 protein; [Verapamil co-treated with Ruthenium Red co-treated with 2-aminoethoxydiphenyl borate] inhibits the reaction [Trichlorfon results in increased cleavage of and results in increased activity of CASP3 protein]; Verapamil inhibits the reaction [Pilocarpine results in increased activity of CASP3 protein] Verapamil results in increased expression of CASP3 mRNA Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein] [Verapamil results in decreased expression of ABCB1] promotes the reaction [Doxorubicin results in increased activity of CASP3 protein] |
CTD |
PMID:14527821 PMID:15861398 PMID:18358092 PMID:19631781 PMID:19815060 PMID:19927300 PMID:24373880 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions |
ISO |
[Verapamil results in decreased expression of ABCB1] promotes the reaction [Doxorubicin results in increased activity of CASP7 protein] |
CTD |
PMID:15861398 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
[Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:24373880 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
[Verapamil co-treated with gambogic acid] results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:24373880 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
multiple interactions |
ISO EXP |
Verapamil inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CD44 protein binds to Hyaluronic Acid]]; Verapamil inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein] [Verapamil co-treated with kaempferol] results in decreased expression of CD44 mRNA; [Verapamil co-treated with kaempferol] results in decreased expression of CD44 protein |
CTD |
PMID:9929743 PMID:35063459 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CDH1 |
cadherin 1 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein] |
CTD |
PMID:34217686 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CIITA |
class II major histocompatibility complex transactivator |
affects expression |
EXP |
Verapamil affects the expression of CIITA mRNA |
CTD |
PMID:25811541 |
|
NCBI chr16:10,866,206...10,943,021
Ensembl chr16:10,866,222...10,943,021
|
|
G |
CLU |
clusterin |
affects expression |
EXP |
Verapamil affects the expression of CLU protein |
CTD |
PMID:12388792 |
|
NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO EXP |
Verapamil inhibits the reaction [Iron-Dextran Complex results in increased expression of COL1A1 protein] Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:27095094 PMID:34217686 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL3A1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein] |
CTD |
PMID:34217686 |
|
NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746
|
|
G |
CSRP3 |
cysteine and glycine rich protein 3 |
decreases localization |
ISO |
Verapamil results in decreased localization of CSRP3 protein |
CTD |
PMID:19376126 |
|
NCBI chr11:19,182,030...19,201,983
Ensembl chr11:19,182,030...19,210,571
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP1A2 protein |
CTD |
PMID:18420780 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2A7 |
cytochrome P450 family 2 subfamily A member 7 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr19:40,875,439...40,882,231
Ensembl chr19:40,875,439...40,882,752
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Cyclosporine results in increased expression of CYP2C11 protein] |
CTD |
PMID:28899749 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
multiple interactions decreases activity |
EXP ISO |
torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein] Verapamil results in decreased activity of CYP2C29 protein |
CTD |
PMID:15304522 PMID:18420780 |
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP2C9 protein |
CTD |
PMID:18420780 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
decreases activity |
ISO |
Verapamil results in decreased activity of CYP2D22 protein; Verapamil results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions affects metabolic processing decreases activity |
EXP |
[Verapamil results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; naringin inhibits the reaction [CYP3A4 protein affects the metabolism of Verapamil]; Verapamil inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Verapamil inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Verapamil inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Verapamil inhibits the reaction [CYP3A4 protein results in increased metabolism of Testosterone]; Verapamil inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] Verapamil results in decreased activity of CYP3A4 protein |
CTD |
PMID:15286053 PMID:15689501 PMID:15692829 PMID:15860655 PMID:16013069 PMID:19299527 PMID:21915887 PMID:25455453 More...
|
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A43 |
cytochrome P450 family 3 subfamily A member 43 |
decreases expression |
ISO |
Verapamil results in decreased expression of CYP3A18 mRNA |
CTD |
PMID:17973928 |
|
NCBI chr 7:99,828,013...99,866,093
Ensembl chr 7:99,828,013...99,866,093
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
decreases activity decreases expression |
EXP ISO |
Verapamil results in decreased activity of CYP3A5 protein Verapamil results in decreased expression of CYP3A9 mRNA |
CTD |
PMID:15689501 PMID:17973928 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
[Verapamil co-treated with gambogic acid] results in increased expression of DDIT3 protein |
CTD |
PMID:24373880 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DNM1L |
dynamin 1 like |
multiple interactions increases phosphorylation |
EXP |
Verapamil inhibits the reaction [bisphenol A affects the localization of DNM1L protein] Verapamil results in increased phosphorylation of DNM1L protein |
CTD |
PMID:31830493 PMID:34023961 |
|
NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650
|
|
G |
DRD1 |
dopamine receptor D1 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:9533112 |
|
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
|
|
G |
DRD2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Raclopride binds to DRD2 protein] |
CTD |
PMID:9533112 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [EDN1 protein results in increased expression of NPPB mRNA]; Verapamil inhibits the reaction [EDN1 protein results in increased expression of NPPB protein] |
CTD |
PMID:28942281 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
FN1 |
fibronectin 1 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] |
CTD |
PMID:34217686 |
|
NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Verapamil results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
|
|
G |
FTH1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Iron-Dextran Complex results in increased expression of FTH1 protein] |
CTD |
PMID:27095094 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
GAL |
galanin and GMAP prepropeptide |
affects expression |
EXP |
Verapamil affects the expression of GAL protein |
CTD |
PMID:12388792 |
|
NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175
|
|
G |
GAP43 |
growth associated protein 43 |
affects expression |
EXP |
Verapamil affects the expression of GAP43 protein |
CTD |
PMID:12388792 |
|
NCBI chr 3:115,623,510...115,721,483
Ensembl chr 3:115,623,510...115,721,490
|
|
G |
GC |
GC vitamin D binding protein |
affects expression |
ISO |
Verapamil affects the expression of GC protein |
CTD |
PMID:23533533 |
|
NCBI chr 4:71,741,693...71,805,520
Ensembl chr 4:71,741,696...71,804,041
|
|
G |
GFAP |
glial fibrillary acidic protein |
multiple interactions increases expression |
ISO |
Verapamil inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein]; Verapamil inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein] Verapamil results in increased expression of GFAP mRNA |
CTD |
PMID:21863293 PMID:21879721 PMID:22954530 |
|
NCBI chr17:44,903,159...44,915,500
Ensembl chr17:44,903,159...44,916,937
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Thioacetamide results in increased expression of GPT protein] |
CTD |
PMID:30526075 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GSN |
gelsolin |
affects expression |
ISO |
Verapamil affects the expression of GSN protein |
CTD |
PMID:23533533 |
|
NCBI chr 9:121,201,483...121,332,842
Ensembl chr 9:121,207,794...121,332,843
|
|
G |
HAMP |
hepcidin antimicrobial peptide |
multiple interactions |
ISO |
Verapamil promotes the reaction [Iron-Dextran Complex results in increased expression of HAMP mRNA] |
CTD |
PMID:27095094 |
|
NCBI chr19:35,282,528...35,285,143
Ensembl chr19:35,280,716...35,285,143
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
Verapamil results in increased expression of HMOX1 protein Verapamil inhibits the reaction [Thioacetamide results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:21525764 PMID:30526075 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
IAPP |
islet amyloid polypeptide |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Glucose results in increased expression of IAPP mRNA] |
CTD |
PMID:9142872 |
|
NCBI chr12:21,354,959...21,379,980
Ensembl chr12:21,354,959...21,379,980
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP |
Verapamil inhibits the reaction [Particulate Matter results in increased expression of IL1A mRNA] |
CTD |
PMID:15613243 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Verapamil inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] Verapamil inhibits the reaction [Diethylhexyl Phthalate results in increased secretion of IL6 protein] |
CTD |
PMID:20682585 PMID:35460826 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INSR |
insulin receptor |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INSR mRNA]; Verapamil inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INSR protein] |
CTD |
PMID:35460826 |
|
NCBI chr19:7,112,265...7,294,414
Ensembl chr19:7,112,255...7,294,414
|
|
G |
KCNA10 |
potassium voltage-gated channel subfamily A member 10 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [KCNA10 protein results in increased transport of Potassium] |
CTD |
PMID:10836990 |
|
NCBI chr 1:110,517,217...110,519,175
Ensembl chr 1:110,517,217...110,519,175
|
|
G |
KCNA3 |
potassium voltage-gated channel subfamily A member 3 |
decreases activity multiple interactions |
EXP |
Verapamil results in decreased activity of KCNA3 protein [Verapamil results in decreased activity of KCNA3 protein] which results in decreased import of Thallium |
CTD |
PMID:21362439 |
|
NCBI chr 1:110,653,560...110,674,940
Ensembl chr 1:110,653,560...110,674,940
|
|
G |
KCND3 |
potassium voltage-gated channel subfamily D member 3 |
decreases activity |
EXP |
Verapamil results in decreased activity of KCND3 protein |
CTD |
PMID:11181069 |
|
NCBI chr 1:111,770,662...111,989,668
Ensembl chr 1:111,770,662...111,989,668
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
EXP |
[Verapamil results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; Verapamil inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:15671647 PMID:19583963 PMID:21158687 PMID:21362439 PMID:24052561 PMID:30561737 More...
|
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNMB1 |
potassium calcium-activated channel subfamily M regulatory beta subunit 1 |
affects response to substance |
EXP |
KCNMB1 gene SNP affects the susceptibility to Verapamil |
CTD |
PMID:17700361 |
|
NCBI chr 5:170,374,671...170,389,367
Ensembl chr 5:170,374,671...170,389,634
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
multiple interactions |
ISO |
Verapamil inhibits the reaction [LIF protein results in increased activity of CAMK2A protein]; Verapamil inhibits the reaction [LIF protein results in increased activity of CAMK4 protein]; Verapamil inhibits the reaction [LIF protein results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:11073891 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [tetrabromobisphenol A results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15456914 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [tetrabromobisphenol A results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15456914 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Gentamicins results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:15936777 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MMP13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
Verapamil promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein] |
CTD |
PMID:27095094 |
|
NCBI chr11:102,942,995...102,955,732
Ensembl chr11:102,942,995...102,955,732
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Verapamil promotes the reaction [Paraquat results in increased activity of MPO protein] |
CTD |
PMID:17015168 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of MTOR mRNA]; Verapamil inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of MTOR protein] |
CTD |
PMID:35460826 |
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MYBPC3 |
myosin binding protein C3 |
affects response to substance |
ISO |
MYBPC3 protein affects the susceptibility to Verapamil |
CTD |
PMID:23896226 |
|
NCBI chr11:47,331,406...47,352,702
Ensembl chr11:47,331,406...47,352,702
|
|
G |
MYH7 |
myosin heavy chain 7 |
multiple interactions decreases expression |
ISO |
Dexamethasone inhibits the reaction [Verapamil results in decreased expression of MYH7 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Verapamil results in decreased expression of MYH7 mRNA]] |
CTD |
PMID:19596060 |
|
NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660
|
|
G |
MYL2 |
myosin light chain 2 |
multiple interactions decreases expression |
ISO |
[Verapamil co-treated with Doxorubicin] results in decreased expression of MYL2 mRNA; Dexamethasone inhibits the reaction [[Verapamil co-treated with Doxorubicin] results in decreased expression of MYL2 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [[Verapamil co-treated with Doxorubicin] results in decreased expression of MYL2 mRNA]] Verapamil results in decreased expression of MYL2 mRNA |
CTD |
PMID:19596060 |
|
NCBI chr12:110,910,845...110,921,449
Ensembl chr12:110,910,819...110,921,443
|
|
G |
NANOG |
Nanog homeobox |
multiple interactions |
EXP |
[Verapamil co-treated with kaempferol] results in decreased expression of NANOG mRNA; [Verapamil co-treated with kaempferol] results in decreased expression of NANOG protein |
CTD |
PMID:35063459 |
|
NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
|
|
G |
NEFL |
neurofilament light chain |
multiple interactions |
ISO |
Verapamil inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein]; Verapamil inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr 8:24,950,955...24,956,612
Ensembl chr 8:24,950,955...24,956,721
|
|
G |
NEFM |
neurofilament medium chain |
multiple interactions |
ISO |
Verapamil inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein]; Verapamil inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr 8:24,913,761...24,919,093
Ensembl chr 8:24,913,758...24,919,098
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
EXP ISO |
Verapamil affects the localization of NFE2L2 protein Verapamil inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 mRNA]; Verapamil inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 protein]; Verapamil promotes the reaction [Cilostazol inhibits the reaction [Thioacetamide results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:21525764 PMID:30295103 PMID:30526075 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Diethylhexyl Phthalate results in increased expression of NLRP3 mRNA]; Verapamil inhibits the reaction [Diethylhexyl Phthalate results in increased expression of NLRP3 protein] |
CTD |
PMID:35460826 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108
|
|
G |
NPPA |
natriuretic peptide A |
multiple interactions increases expression affects secretion |
EXP |
[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein Verapamil results in increased expression of NPPA protein Verapamil affects the secretion of NPPA protein |
CTD |
PMID:1457087 PMID:11996326 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NPPB |
natriuretic peptide B |
multiple interactions |
EXP |
Verapamil inhibits the reaction [EDN1 protein results in increased expression of NPPB mRNA]; Verapamil inhibits the reaction [EDN1 protein results in increased expression of NPPB protein] |
CTD |
PMID:28942281 |
|
NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
|
|
G |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Thioacetamide results in decreased expression of NQO1 protein]; Verapamil promotes the reaction [Cilostazol inhibits the reaction [Thioacetamide results in decreased expression of NQO1 protein]] |
CTD |
PMID:30295103 |
|
NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
|
|
G |
NR0B1 |
nuclear receptor subfamily 0 group B member 1 |
multiple interactions decreases expression |
ISO |
Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA] Verapamil results in decreased expression of NR0B1 mRNA |
CTD |
PMID:19822634 |
|
NCBI chr X:30,304,206...30,309,390
Ensembl chr X:30,304,206...30,309,390
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity multiple interactions |
EXP |
Verapamil results in increased activity of NR1I2 protein [Verapamil results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
multiple interactions |
ISO |
Verapamil promotes the reaction [Dexamethasone results in increased activity of NR3C1 protein] |
CTD |
PMID:12871829 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
ISO EXP |
Verapamil inhibits the reaction [PARP1 gene mutant form results in decreased uptake of Doxorubicin] [Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [[Verapamil co-treated with gambogic acid] results in increased cleavage of PARP1 protein] |
CTD |
PMID:15861398 PMID:24373880 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PF4 |
platelet factor 4 |
decreases expression |
EXP |
Verapamil results in decreased expression of PF4 protein |
CTD |
PMID:2962587 |
|
NCBI chr 4:73,980,811...73,982,124
Ensembl chr 4:73,980,811...73,982,027
|
|
G |
POLR1H |
RNA polymerase I subunit H |
multiple interactions |
EXP |
Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Doxorubicin]; Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Etoposide]; Verapamil inhibits the reaction [POLR1H protein results in decreased susceptibility to Vincristine]; Verapamil inhibits the reaction [POLR1H protein results in increased secretion of Doxorubicin] |
CTD |
PMID:14726695 |
|
NCBI chr 6:30,060,062...30,064,907
Ensembl chr 6:30,058,899...30,064,909
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
multiple interactions |
EXP |
[Verapamil co-treated with kaempferol] results in decreased expression of POU5F1 mRNA; [Verapamil co-treated with kaempferol] results in decreased expression of POU5F1 protein |
CTD |
PMID:35063459 |
|
NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
|
|
G |
PPBP |
pro-platelet basic protein |
decreases expression |
EXP |
Verapamil results in decreased expression of PPBP protein |
CTD |
PMID:2962587 |
|
NCBI chr 4:73,986,439...73,988,190
Ensembl chr 4:73,986,439...73,988,190
|
|
G |
PPP3CB |
protein phosphatase 3 catalytic subunit beta |
multiple interactions |
EXP |
Verapamil inhibits the reaction [bisphenol F results in increased expression of PPP3CB protein] |
CTD |
PMID:34023961 |
|
NCBI chr10:73,436,433...73,496,024
Ensembl chr10:73,436,433...73,496,024
|
|
G |
PRL |
prolactin |
multiple interactions increases secretion increases expression |
EXP |
Verapamil inhibits the reaction [Sulpiride results in increased secretion of PRL protein]; Verapamil promotes the reaction [TRH protein results in increased secretion of PRL protein] Verapamil results in increased secretion of PRL protein Verapamil results in increased expression of PRL protein |
CTD |
PMID:7851873 PMID:8845563 PMID:8977754 PMID:20595935 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
RET |
ret proto-oncogene |
affects expression |
EXP |
Verapamil affects the expression of RET protein |
CTD |
PMID:12388792 |
|
NCBI chr10:43,077,069...43,130,351
Ensembl chr10:43,077,064...43,130,351
|
|
G |
SLC11A2 |
solute carrier family 11 member 2 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Iron-Dextran Complex results in increased expression of SLC11A2 protein] |
CTD |
PMID:27095094 |
|
NCBI chr12:50,952,263...51,028,886
Ensembl chr12:50,979,401...51,028,566
|
|
G |
SLC19A3 |
solute carrier family 19 member 3 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Verapamil inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] |
CTD |
PMID:26528626 |
|
NCBI chr 2:227,683,763...227,718,028
Ensembl chr 2:227,683,763...227,718,028
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [SLC22A1 protein results in increased import of Tetraethylammonium]; Verapamil inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Verapamil inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Verapamil inhibits the reaction [SLC22A1 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:21641380 PMID:25466967 PMID:25862123 PMID:27450509 PMID:27989701 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP ISO |
Verapamil inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] Verapamil inhibits the reaction [SLC22A2 protein results in increased uptake of mepiquat] |
CTD |
PMID:21599003 PMID:33639197 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
G |
SLC22A3 |
solute carrier family 22 member 3 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Verapamil inhibits the reaction [SLC22A3 protein results in increased uptake of Metformin] |
CTD |
PMID:21641380 PMID:21697722 |
|
NCBI chr 6:160,348,378...160,452,577
Ensembl chr 6:160,348,378...160,452,577
|
|
G |
SLC22A4 |
solute carrier family 22 member 4 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [SLC22A4 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:21641380 |
|
NCBI chr 5:132,294,394...132,344,190
Ensembl chr 5:132,294,394...132,344,190
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
decreases activity |
EXP |
Verapamil results in decreased activity of SLC22A5 protein |
CTD |
PMID:15486076 |
|
NCBI chr 5:132,369,710...132,395,612
Ensembl chr 5:132,369,710...132,395,613
|
|
G |
SLC2A4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SLC2A4 mRNA]; Verapamil inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SLC2A4 protein] |
CTD |
PMID:35460826 |
|
NCBI chr17:7,281,718...7,288,257
Ensembl chr17:7,281,718...7,288,257
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
multiple interactions decreases activity |
EXP |
Verapamil inhibits the reaction [SLC47A1 protein results in increased import of Tetraethylammonium]; Verapamil inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Verapamil inhibits the reaction [SLC47A1 protein results in increased uptake of Tetraethylammonium] Verapamil results in decreased activity of SLC47A1 protein |
CTD |
PMID:22419765 PMID:27450509 PMID:27989701 PMID:31364238 |
|
NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
multiple interactions decreases activity |
EXP |
Verapamil inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Verapamil inhibits the reaction [SLC47A2 protein results in increased uptake of Tetraethylammonium] Verapamil results in decreased activity of SLC47A2 protein |
CTD |
PMID:22419765 PMID:27989701 PMID:28629854 PMID:31364238 |
|
NCBI chr17:19,678,317...19,718,979
Ensembl chr17:19,678,288...19,718,979
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [SLCO1A2 protein results in increased uptake of Quercetin] |
CTD |
PMID:24947867 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SMAD2 |
SMAD family member 2 |
multiple interactions |
EXP |
Verapamil inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:34217686 |
|
NCBI chr18:47,808,957...47,930,872
Ensembl chr18:47,808,957...47,931,146
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[Verapamil co-treated with Cilostazol] inhibits the reaction [Thioacetamide results in decreased activity of SOD1 protein]; Verapamil inhibits the reaction [Dexamethasone inhibits the reaction [Paraquat results in increased activity of SOD1 protein]]; Verapamil inhibits the reaction [Thioacetamide results in decreased activity of SOD1 protein] |
CTD |
PMID:17015168 PMID:30295103 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Dexamethasone inhibits the reaction [Paraquat results in increased activity of SOD2 protein]] |
CTD |
PMID:17015168 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOX2 |
SRY-box transcription factor 2 |
multiple interactions |
EXP |
[Verapamil co-treated with kaempferol] results in decreased expression of SOX2 mRNA |
CTD |
PMID:35063459 |
|
NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein] |
CTD |
PMID:19822634 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased expression of STAT3 protein]; Verapamil inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased expression of STAT3 protein] |
CTD |
PMID:19299911 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
ISO EXP |
Verapamil inhibits the reaction [[Carbon Tetrachloride co-treated with lard co-treated with Ethanol] results in increased expression of TGFB1 protein] Verapamil inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of FN1 mRNA]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Verapamil inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Verapamil inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:17223571 PMID:34217686 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
affects expression multiple interactions |
EXP ISO |
Verapamil affects the expression of TIMP1 protein Verapamil inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein] |
CTD |
PMID:12388792 PMID:27095094 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Verapamil affects the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Verapamil inhibits the reaction [Particulate Matter results in increased secretion of TNF protein] Verapamil inhibits the reaction [Diethylhexyl Phthalate results in increased secretion of TNF protein] Verapamil inhibits the reaction [tert-Butylhydroperoxide results in increased secretion of TNF protein] |
CTD |
PMID:15613243 PMID:17092623 PMID:17129690 PMID:17369293 PMID:35460826 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TRH |
thyrotropin releasing hormone |
multiple interactions |
EXP |
Verapamil inhibits the reaction [TRH protein results in increased secretion of TSHB protein]; Verapamil promotes the reaction [TRH protein results in increased secretion of PRL protein] |
CTD |
PMID:7851873 |
|
NCBI chr 3:129,974,720...129,977,935
Ensembl chr 3:129,974,688...129,977,935
|
|
G |
TSHB |
thyroid stimulating hormone subunit beta |
multiple interactions |
EXP |
Verapamil inhibits the reaction [TRH protein results in increased secretion of TSHB protein] |
CTD |
PMID:7851873 |
|
NCBI chr 1:115,029,826...115,034,309
Ensembl chr 1:115,029,826...115,034,302
|
|
G |
TXNIP |
thioredoxin interacting protein |
multiple interactions |
ISO |
Verapamil inhibits the reaction [Diethylhexyl Phthalate results in increased expression of TXNIP mRNA]; Verapamil inhibits the reaction [Diethylhexyl Phthalate results in increased expression of TXNIP protein] |
CTD |
PMID:35460826 |
|
NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579
|
|
G |
VIM |
vimentin |
multiple interactions |
ISO EXP |
Verapamil inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein]; Verapamil inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein] Verapamil inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:21863293 PMID:21879721 PMID:34217686 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|